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A B S T R A C T
Background
Liver transplantation is an established treatment option for end-stage liver failure. Now that newer, more potent immunosuppressants
have been developed, glucocorticosteroids may no longer be needed and their removal may prevent adverse effects.
Objectives
To assess the benefits and harms of glucocorticosteroid avoidance (excluding intra-operative use or treatment of acute rejection) or
withdrawal versus glucocorticosteroid-containing immunosuppression following liver transplantation.
Search methods
We searched the Cochrane Hepato-Biliary Group Controlled Trials Register, Cochrane Central Register of Controlled Trials (CEN-
TRAL), MEDLINE, Embase, Science Citation Index Expanded and Conference Proceedings Citation Index - Science, Literatura
Americano e do Caribe em Ciencias da Saude (LILACS), World Health Organization International Clinical Trials Registry Platform,
ClinicalTrials.gov, and The Transplant Library until May 2017.
Selection criteria
Randomised clinical trials assessing glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosup-
pression for liver transplanted people. Our inclusion criteria stated that participants should have received the same co-interventions. We
included trials that assessed complete glucocorticosteroid avoidance (excluding intra-operative use or treatment of acute rejection) versus
short-term glucocorticosteroids, as well as trials that assessed short-term glucocorticosteroids versus long-term glucocorticosteroids.
Data collection and analysis
We used RevMan to conduct meta-analyses, calculating risk ratio (RR) for dichotomous variables and mean difference (MD) for
continuous variables, both with 95% confidence intervals (CIs). We used a random-effects model and a fixed-effect model and reported
both results where a discrepancy existed; otherwise we reported only the results from the fixed-effect model. We assessed the risk of
systematic errors using ’Risk of bias’ domains. We controlled for random errors by performing Trial Sequential Analysis. We presented
our results in a ’Summary of findings’ table.
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Main results
We included 17 completed randomised clinical trials, but only 16 studies with 1347 participants provided data for the meta-analyses.
Ten of the 16 trials assessed complete postoperative glucocorticosteroid avoidance (excluding intra-operative use or treatment of acute
rejection) versus short-term glucocorticosteroids (782 participants) and six trials assessed short-term glucocorticosteroids versus long-
term glucocorticosteroids (565 participants). One additional study assessed complete post-operative glucocorticosteroid avoidance
but could only be incorporated into qualitative analysis of the results due to limited data published in an abstract. All trials were at
high risk of bias. Only eight trials reported on the type of donor used. Overall, we found no statistically significant difference for
mortality (RR 1.15, 95% CI 0.93 to 1.44; low-quality evidence), graft loss including death (RR 1.15, 95% CI 0.90 to 1.46; low-quality
evidence), or infection (RR 0.88, 95% CI 0.73 to 1.05; very low-quality evidence) when glucocorticosteroid avoidance or withdrawal
was compared with glucocorticosteroid-containing immunosuppression. Acute rejection and glucocorticosteroid-resistant rejection
were statistically significantly more frequent when glucocorticosteroid avoidance or withdrawal was compared with glucocorticosteroid-
containing immunosuppression (RR 1.33, 95% CI 1.08 to 1.64; low-quality evidence; and RR 2.14, 95% CI 1.13 to 4.02; very low-
quality evidence). Diabetes mellitus and hypertension were statistically significantly less frequent when glucocorticosteroid avoidance
or withdrawal was compared with glucocorticosteroid-containing immunosuppression (RR 0.81, 95% CI 0.66 to 0.99; low-quality
evidence; and RR 0.76, 95% CI 0.65 to 0.90; low-quality evidence). We performed Trial Sequential Analysis for all outcomes. None
of the outcomes crossed the monitoring boundaries or reached the required information size. Hence, we cannot exclude random errors
from the results of the conventional meta-analyses.
Authors’ conclusions
Many of the benefits and harms of glucocorticosteroid avoidance or withdrawal remain uncertain because of the limited number of
published randomised clinical trials, limitednumbers of participants andoutcomes, andhigh risk of bias in the trials.Glucocorticosteroid
avoidance or withdrawal appears to reduce diabetes mellitus and hypertension whilst increasing acute rejection, glucocorticosteroid-
resistant rejection, and renal impairment. We could identify no other benefits or harms of glucocorticosteroid avoidance or withdrawal.
Glucocorticosteroid avoidance or withdrawal may be of benefit in selected patients, especially those at low risk of rejection and high risk
of hypertension or diabetes mellitus. The optimal duration of glucocorticosteroid administration remains unclear. More randomised
clinical trials assessing glucocorticosteroid avoidance or withdrawal are needed. These should be large, high-quality trials that minimise
the risk of random and systematic error.
P L A I N L A N G U A G E S U M M A R Y
Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
Review question
We assessed whether avoiding or withdrawing glucocorticosteroids was better or worse than continuing to use glucocorticosteroids for
immunosuppression after liver transplantation.
Background
Glucocorticosteroids are used to prevent rejection of the liver after transplantation by suppressing the immune system. Some centres use
glucocorticosteroids indefinitely after liver transplantation whilst others slowly reduce them, and others do not use glucocorticosteroids
at all. Glucocorticosteroids have a number of important adverse effects, which may lead to illness and sometimes death in liver
transplantation. These adverse effects include diabetes mellitus, high blood pressure, and infection.
With recent developments in immunosuppression, glucocorticosteroids no longer feature as the main immunosuppressant used follow-
ing transplantation. The use of new immunosuppressant medication may mean that glucocorticosteroids may no longer be necessary
after transplantation. Rather than helping to prevent rejection of the liver graft theymight cause adverse effects. The benefits of avoiding
glucocorticosteroids or withdrawing them after a short while remain unclear.
Study characteristics
We searched for trials comparing glucocorticosteroid avoidance or withdrawal to continuing glucocorticosteroids. Seventeen randomised
clinical trials were included, of which 16 trials involving 1347 participants provided numeric data for the meta-analyses. All of the
studies assessed adults who had received a liver transplant. Of the 16 randomised clinical trials included in the meta-analyses, 10 trials
assessed avoidance of glucocorticosteroids compared with slowly reducing glucocorticosteroids (782 participants) and six trials assessed
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withdrawal of glucocorticosteroids following a slow reduction compared with a longer reduction or long-termuse of glucocorticosteroids
(565 participants). Only eight trials reported on the type of donor used. The evidence is current to May 2017.
Key results
Rejection, severe rejection, and kidney failure may be increased by avoiding or withdrawing glucocorticosteroids compared with contin-
uing glucocorticosteroids. Diabetes mellitus and high blood pressure may be reduced by avoiding or withdrawing glucocorticosteroids
compared with continuing glucocorticosteroids. We did not find any difference in survival of the patients, survival of the liver, other
adverse effects, or health-related quality of life.
Quality of the evidence
We assessed all of the trials we included as being at high risk of bias, which means that they may overestimate the benefits and
underestimate the harms of avoiding or withdrawing glucocorticosteroids. The evidence was either low quality or very low quality.
Conclusion
There is still some uncertainty about the benefits and harms of avoiding or withdrawing glucocorticosteroids after transplantation.
Avoiding or withdrawing glucocorticosteroids appears to increase rejection, severe rejection, and kidney failure but seems to reduce
diabetesmellitus and high blood pressure.We found no other obvious benefits or harms of avoiding or withdrawing glucocorticosteroids.
More randomised clinical trials are needed to assess avoidance and withdrawal of glucocorticosteroids for liver transplanted patients.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Glucocorticosteroid avoidance or withdrawal compared to glucocorticosteroid-based immunosuppression for liver transplanted patients
Patient or population: l iver transplanted pat ients
Setting: inpat ient and outpat ient
Intervention: glucocort icosteroid avoidance or withdrawal
Comparison: glucocort icosteroid-based immunosuppression
Outcomes* * Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(trials)
Quality of the evidence
(GRADE)
Comments
Risk with glucocor-
ticosteroid-based im-
munosuppression
Risk with glucocorti-
costeroid avoidance or
withdrawal
All-cause mortality Study populat ion RR 1.15
(0.93 to 1.44)
1323
(15 RCTs)
⊕⊕©©
LOW 1,2
The quality of the
evidence was consid-
ered low for both glu-
cocort icosteroid avoid-
ance and glucocort i-
costeroid withdrawal.
Trial Sequent ial Analy-
sis-adjusted CI 0.77-1.
66
166 per 1000 191 per 1000
(154 to 239)
Moderate
204 per 1000 234 per 1000
(189 to 293)
Graf t loss including
death
Study populat ion RR 1.15
(0.90 to 1.46)
1002
(11 RCTs)
⊕⊕©©
LOW 1,2
The quality of the
evidence was consid-
ered low for both glu-
cocort icosteroid avoid-
ance and glucocort i-
costeroid withdrawal.
Trial Sequent ial Analy-
sis-adjusted CI 0.75-2.
01
175 per 1000 203 per 1000
(159 to 259)
Moderate
218 per 1000 253 per 1000
(198 to 322)
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Acute reject ion Study populat ion RR 1.33
(1.08 to 1.64)
1347
(16 RCTs)
⊕⊕©©
LOW 1,2
The quality of the
evidence was consid-
ered low both glu-
cocort icosteroid avoid-
ance and glucocort i-
costeroid withdrawal.
Trial Sequent ial Analy-
sis-adjusted CI 0.92-1.
90
173 per 1000 230 per 1000
(187 to 283)
Moderate
194 per 1000 257 per 1000
(209 to 317)
Infect ion Study populat ion RR 0.88
(0.73 to 1.05)
778
(8 RCTs)
⊕©©©
VERY LOW 1,2,3
The quality of the evi-
dence was considered
very low for both glu-
cocort icosteroid avoid-
ance and glucocort i-
costeroid withdrawal.
Trial Sequent ial Analy-
sis-adjusted CI 0.49-1.
71
359 per 1000 316 per 1000
(262 to 377)
Moderate
402 per 1000 354 per 1000
(293 to 422)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
∗∗We assessed all outcomes at latest follow-up (range 13 months to 108 months)
CI: conf idence interval; RR: risk rat io; RCT: randomised clinical trial
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded one level due to risk of bias: all t rials were at high risk of bias.
2Downgraded one level due to imprecision ident if ied in the Trial Sequent ial Analysis; 95%CI includes both benef it and harm.
3Downgraded one level due to signif icant heterogeneity ident if ied between subgroups; avoidance versus withdrawal.
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B A C K G R O U N D
Liver transplantation is an established treatment option for end-
stage liver failure in selected patients and results in improved qual-
ity and quantity of life (Pillai 2009; Dienstag 2012). Currently,
liver transplant recipients have a one-year survival of over 90%
and a five-year survival of over 75% (Perera 2009).
Description of the condition
Over 1800 liver transplantations per year (whole liver or split liver)
were performed from post-mortem and living donors in the Eu-
rotransplant region from 2008 to 2012 (Eurotransplant 2012).
However, at the end of 2011 there were 2406 people in need
of liver transplantation (Eurotransplant 2012). In the UK, 784
liver transplantations were carried out in 2012 through 2013, but
494 patients remained on the waiting list as of 31 March 2013
(NHS Blood and Transplant 2013). In the USA, 6445 livers were
transplanted in 2013 including 252 living donor liver transplants
(OPTN 2014). In 2012, in the UK, the indications for liver trans-
plantation from deceased donors included alcoholic liver disease
(18.5%), hepatitis C virus (HCV) cirrhosis (8.1%), hepatocellular
carcinoma (17.1%), primary sclerosing cholangitis (8.2%), pri-
mary biliary cirrhosis (7.6%), and metabolic diseases (8.1%). Of
the deceased donor transplants, 88% were elective procedures and
12% for fulminant hepatic failure (Johnson 2014).
Description of the intervention
Liver transplant recipients have to take life-long immuno-
suppressive medication in order to achieve an effective pro-
phylaxis against allograft rejection. The most commonly used
immunosuppressive agents are calcineurin inhibitors (e.g. cy-
closporine, tacrolimus), antiproliferative agents (e.g. azathioprine,
mycophenolate mofetil), and glucocorticosteroids (e.g. methyl-
prednisolone). In addition, mammalian target of rapamycin in-
hibitors (e.g. sirolimus, everolimus) are used to prevent rejection.
Induction agents are often used to prevent rejection and facili-
tate calcineurin inhibitor and glucocorticosteroid minimisation
(Lupo 2008; Neumann 2012; Kim 2013; Herzer 2016). Gluco-
corticosteroids decrease interleukin 1, 2, and 6 activity and non-
specifically inhibit T-cell activation. Adverse effects due to glu-
cocorticosteroids such as hypertension, hyperglycaemia, hyperc-
holesterolaemia, and obesity are well known. In some cases, hy-
pertension is reported in over 50% of patients (Neal 2005; Llado
2006), but a glucocorticosteroid bolus is still given at the time of
transplantation and tapered after a while (Fernandez 1998; Hatz
1998; Renoult 2005; Hirose 2006). Cyclosporin A and tacrolimus
are both calcineurin inhibitors. Calcineurin normally activates nu-
clear factor of activated T cells, which leads to production of in-
terleukin 2 and 4 that stimulate growth and differentiation of the
T-cell response. Tacrolimus is used more widely than cyclosporin
due to reduced acute rejection and increased graft survival, but
tacrolimus carries a higher risk of new-onset diabetes after trans-
plant (NODAT) (Ho 1996; Ojo 2003; Haddad 2006). Despite
the favourable profile of tacrolimus compared with cyclosporine,
tacrolimus still carries a significant risk of renal failure and many
trials have investigated the replacement of tacrolimus with other
drugs, usually sirolimus or everolimus (Penninga 2012; Sterneck
2014). Mycophenolate mofetil (MMF; also known as mycophe-
nolic acid; MPA) inhibits inosine monophosphate dehydrogenase
(IMPDH). This enzyme is responsible for de novo synthesis of
guanosine nucleotides. The inhibition by MMF has cytostatic ef-
fects on T- and B-lymphocytes. MMF is still preferred to azathio-
prine (Allison 2000; Knight 2009).
How the intervention might work
Through the use of calcineurin inhibitors, liver transplantation
has become a standard procedure with good long-term results
(Haddad 2006). However, the burden of life-long immunosup-
pressive treatment in liver transplant recipients causes increased
morbidity and mortality. Optimal long-term immunosuppressive
treatment to reduce morbidity and mortality without leading to
graft loss has become of major importance. Treatment with gluco-
corticosteroids induces bone loss and may lead to cardiovascular
risk factors (e.g. hypertension, hyperlipidaemia, obesity, glucose
intolerance) (Hatz 1998). Avoidance of glucocorticosteroids may
reduce this excess morbidity without having an effect on graft loss
(Knight 2011). In addition, use of glucocorticosteroids after trans-
plantationmight reduce physical andmental health-related quality
of life, and increase symptoms of anxiety (Zaydfudim 2012). Fur-
thermore, glucocorticosteroids might increase the risk and severity
of hepatitis C recurrence in patients transplanted for hepatitis C.
Hence, glucocorticosteroid avoidance and reduction regimens for
liver transplant recipients have been developed and studied, but it
is still uncertain whether these regimens offer clear benefits (Segev
2008). These long-term adverse events and the development of
relatively new immunosuppressive medication (e.g. basiliximab)
may potentially enable the reduction or withdrawal of glucocor-
ticosteroids as an immunosuppressive treatment (Vanrenterghem
1999; Ganschow 2005; Penninga 2014).
There is some evidence that glucocorticosteroid avoidance or with-
drawal could be beneficial (Adams 2001; Kato 2005; Cintorino
2006; Llado 2006; Moench 2007; Penninga 2014a), but the over-
all effect still remains unclear. Five reviews with meta-analyses on
glucocorticosteroid avoidance or withdrawal for liver transplanted
people have been published, showing a possible advantage in car-
diovascular risk factors (e.g. diabetes mellitus, hypertension), a
possible benefit in cytomegalovirus (CMV) infection and a pos-
sible benefit for people transplanted for HCV-induced liver dis-
ease (Segev 2008; Sgourakis 2009; Knight 2011; Gu 2014; Lan
2014). One Cochrane network meta-analysis of maintenance im-
munosuppression for liver transplanted patients has been pub-
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lished showing a possible decrease in adverse events, but a possible
increase in retransplantation with glucocorticosteroid avoidance
or withdrawal (Rodríguez-Perálvarez 2017).
Why it is important to do this review
It is possible that glucocorticosteroids could be withdrawn follow-
ing liver transplantation or completely avoided without any nega-
tive effects whilst reducing the adverse effects associated with glu-
cocorticosteroids. However, people may face more adverse events
due to increased use of other immunosuppressants.
O B J E C T I V E S
To assess the benefits and harms of glucocorticosteroid avoid-
ance (excluding intra-operative use or treatment of acute rejection)
or withdrawal versus glucocorticosteroid-containing immunosup-
pression following liver transplantation.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised clinical trials evaluating the benefits and
harms of complete glucocorticosteroid avoidance (excluding intra-
operative use or treatment of acute rejection) or withdrawal ver-
sus glucocorticosteroid-containing immunosuppression for liver
transplanted people. We did not include non-randomised clini-
cal trials or trials that reported per-treatment analysis rather than
intention-to-treat analysis. For evaluation of harms, we included
quasi-randomised clinical trials and observational trials that we
identified during our searches for randomised clinical trials.
We did not apply any restrictions on date of publication, language,
or publication status (published or unpublished work).
Types of participants
We included people of any age, sex, and ethnic group during
and after liver transplantation, in any care setting, irrespective of
diagnosis and disease stage, type of graft (live donor, cadaveric,
split, whole, domino), and prescribed medication. We did not
include participants with other transplanted organs or those with
a previous liver transplant.
Types of interventions
We included randomised clinical trials that investigated weaning
off, versus not weaning off, glucocorticosteroids, as well as trials
that compared standard immunosuppression without glucocorti-
costeroids versus standard immunosuppression including gluco-
corticosteroids directly following transplantation.
We allowed co-interventions (e.g. induction with basiliximab,
co-administration of an antiproliferative such as mycophenolate
mofetil) if received equally by all intervention groups of the trial.
Types of outcome measures
Outcome measures did not form part of the eligibility criteria for
including trials in this review. We assessed all outcomes at latest
follow-up.
Primary outcomes
• All-cause mortality.
• Graft loss including death.
• Acute rejection. This is diagnosed by the combination of
abnormal liver biochemical variables (e.g. bilirubin, aspartate
transaminase, alanine transaminase, alkaline phosphatases,
gamma glutamyl transpeptidase), clinical signs such as fever, and
liver histological changes including mononuclear portal
inflammation, bile duct damage, and subendothelial
inflammation of portal or terminal hepatic veins (IWP 1995; IP
2000).
• Infection.
We have not included serious adverse events as an outcome as fol-
lowing organ transplantation the number of serious adverse events
is extremely high. As a result of this, very few trials in transplanta-
tion report serious adverse events as an outcome and instead report
outcomes individually (e.g. diabetes mellitus, infection, hyperten-
sion). As well as this, most transplant recipients experience one
or more serious adverse events following transplantation, meaning
that the number of adverse events may be 100% in both groups.
This means neither complete nor consistent serious adverse event
reporting can be guaranteed. Instead, we analysed selected out-
comes individually.
Secondary outcomes
• Other adverse events. Adverse events were defined as any
untoward medical occurrence not necessarily having a causal
relationship with the treatment but resulting in a dose reduction
or discontinuation of treatment (ICH-GCP 1997).
• Chronic rejection. Chronic rejection was characterised by
liver histological changes including the progressive loss of
interlobular bile ducts and arteriopathy characterised by foam
cell infiltration of the arterial intima.
• Glucocorticosteroid-resistant rejection.
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• Diabetes mellitus (de novo diabetes mellitus as described in
the study or total number of people with diabetes mellitus).
• Cytomegalovirus (CMV) infection (infection requiring
treatment).
• Hepatitis C virus (HCV) recurrence.
• Malignancy.
• Post-transplantation lymphoproliferative disorder (PTLD).
• Renal function (renal failure requiring dialysis, renal
insufficiency, estimated glomerular filtration rate, and serum
creatinine).
• De novo autoimmune hepatitis.
• Hypertension.
• Hyperlipidaemia.
• Cholesterol (serum cholesterol and hypercholesterolaemia).
• Health-related quality of life.
Search methods for identification of studies
We searched for eligible trials for the earliest entrance date possible
until the latest search date.
We managed all references with Refworks©.
Electronic searches
We searched the Cochrane Hepato-Biliary Group Controlled Tri-
als Register (Gluud 2018; May 2017), Cochrane Central Regis-
ter of Controlled Trials (CENTRAL; 2017, Issue 5), MEDLINE
Ovid (1946 to May 2017), Embase Ovid (1974 to May 2017),
Science Citation Index Expanded (Web of Science; 1900 to May
2017), Conference Proceedings Citation Index - Science (Web of
Science; 1990 to May 2017) (Royle 2003) and LILACS (Liter-
atura Americano e do Caribe em Ciencias da Saude; Clark 2002;
1982 to May 2017). Appendix 1 gives the search strategies with
the time spans of the searches. As the review progressed, we did
not need to improve the search strategies.
We also searched the World Health Organization International
Clinical Trials Registry Platform (apps.who.int/trialsearch/), Clin-
icalTrials.gov (clinicaltrials.gov/), and The Transplant Library
(Pengel 2011).
Searching other resources
Wecontacted experts in the field, such as scientific societies for liver
transplantation, and we asked whether they have been involved in
any further trials or are aware of recent or ongoing trials on the
effects of glucocorticosteroids for liver transplanted patients. We
tried to identify unpublished trials by contacting manufacturers of
glucocorticosteroids (i.e. Ratiopharm, Astellas, Aventis, Novartis,
Merck, Hexal, Pfizer, Roche).
We searched the reference lists of identified trials, non-randomised
trials, and other systematic reviews for additional publications of
interest.
Data collection and analysis
Selection of studies
Four review authors (CF, EH, JP, SW) independently assessed the
retrieved references for eligibility and resolved disagreements by
discussion with another author (LP). The excluded studies and the
reasons for their exclusion are listed in the table Characteristics of
excluded studies.
Data extraction and management
We extracted data on source, inclusion and exclusion criteria, de-
scription of participants and setting, interventions and co-inter-
ventions, outcomes, and sample size calculation using a data ex-
traction sheet. We did not identify any cross-over trials. We ex-
tracted data using the intention-to-treat principle. We translated
all trials reported in non-English language journals before assess-
ment. Where multiple publications of a trial exist, we grouped the
publications together and we extracted data from the most com-
plete publication and any relevant outcomes that are only reported
in one of the other publications. Where further information was
required, we contacted the original authors requesting this.
Assessment of risk of bias in included studies
Four review authors (CF, JP, EH, SW) independently assessed the
risk of bias of the trials, without masking them. We followed the
instructions given in the Cochrane Handbook for Systematic Re-
views of Interventions (Higgins 2011), and the Cochrane Hepato-
Biliary Group Module (Gluud 2018). Due to the risk of biased
overestimation of beneficial intervention effects (or underestimat-
ing of harmful effects) in randomised trials (Schulz 1995; Moher
1998;Kjaergard 2001;Wood 2008; Savovi 2012; Savovi 2012a;
Lundh 2017), we assessed the following bias risk domains with
definitions below. If information was not available in the pub-
lished trial, we contacted the authors in order to assess the trials
correctly.
Allocation sequence generation
• Low risk of bias: sequence generation was achieved using
computer random number generation or a random number
table. Drawing lots, tossing a coin, shuffling cards, and throwing
dice are adequate if performed by an independent person not
otherwise involved in the trial.
• Uncertain risk of bias: the method of sequence generation
was not specified.
• High risk of bias: the sequence generation method was not
random.
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Allocation concealment
• Low risk of bias: the participant allocations could not have
been foreseen in advance of, or during, enrolment. Allocation
was controlled by a central and independent randomisation unit.
The allocation sequence was unknown to the investigators (e.g. if
the allocation sequence was hidden in sequentially numbered,
opaque, and sealed envelopes).
• Uncertain risk of bias: the method used to conceal the
allocation was not described so that intervention allocations may
have been foreseen in advance of, or during, enrolment.
• High risk of bias: the allocation sequence was likely to be
known to the investigators who assigned the participants.
Blinding of participants and personnel
• Low risk of bias: it was mentioned that both participants
and personnel providing the interventions were blinded, and the
method of blinding was described, so that knowledge of
allocation was prevented during the trial.
• Unclear risk of bias: it was not mentioned if the trial was
blinded, or the trial was described as blinded, but the method or
extent of blinding was not described, so that knowledge of
allocation was possible during the trial.
• High risk of bias: the trial was not blinded, so that the
allocation was known during the trial.
Blinded outcome assessment
• Low risk of bias: it was mentioned that both participants
and personnel providing the interventions were blinded, and the
method of blinding was described, so that knowledge of
allocation was prevented during the trial.
• Unclear risk of bias: it was not mentioned if the trial was
blinded, or the trial was described as blinded, but the method or
extent of blinding was not described, so that knowledge of
allocation was possible during the trial.
• High risk of bias: the trial was not blinded, so that the
allocation was known during the trial.
Incomplete outcome data
• Low risk of bias: missing data were unlikely to make
treatment effects depart from plausible values. Sufficient
methods, such as multiple imputation, have been employed to
handle missing data.
• Uncertain risk of bias: there was insufficient information to
assess whether missing data in combination with the method
used to handle missing data were likely to induce bias in the
results.
• High risk of bias: the results were likely to be biased due to
missing data.
Selective outcome reporting
• Low risk: the trial reported the following pre-defined
outcomes: all-cause mortality, graft loss including death, acute
rejection, and infection. If the original trial protocol was
available, the outcomes should be those called for in that
protocol. If the trial protocol was obtained from a trial registry
(e.g. www.clinicaltrials.gov), the outcomes sought should have
been those enumerated in the original protocol if the trial
protocol was registered before or at the time that the trial was
begun. If the trial protocol was registered after the trial was
begun, we did not consider those outcomes to be reliable.
• Unclear risk: not all pre-defined outcomes were reported
fully, or it was unclear whether data on these outcomes were
recorded or not.
• High risk: one or more pre-defined outcomes were not
reported.
For-profit bias
• Low risk of bias: the trial appears to be free of industry
sponsorship or other type of for-profit support that may
manipulate the trial design, conduct, or results of the trial.
• Uncertain risk of bias: the trial may or may not be free of
for-profit bias as no information on clinical trial support or
sponsorship was provided.
• High risk of bias: the trial was sponsored by industry or
received another type of for-profit support.
Other risk of bias
• Low risk of bias: the trial appears to be free of other
components that could put it at risk of bias.
• Uncertain risk of bias: the trial may or may not be free of
other components that could put it at risk of bias.
• High risk of bias: there are other factors in the trial that
could put it at risk of bias.
We considered trials assessed as having ’low risk of bias’ in all of
the specified individual domains as trials with ’low risk of bias’. We
considered trials assessed as having ’uncertain risk of bias’ or ’high
risk of bias’ in one or more of the specified individual domains as
trials with ’high risk of bias’.
Measures of treatment effect
For dichotomous variables, we used risk ratio (RR) and 95% con-
fidence intervals (CI).
For continuous variables, we used the mean difference (MD) with
95% CI. If we had been able to identify different measures for
the health-related quality of life outcome, we would have used
standardised mean difference (SMD) with 95% CIs.
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Unit of analysis issues
In the case of trials using multiple treatment groups, we consid-
ered only the group in which glucocorticosteroids were adminis-
tered versus the group in which either placebo or no intervention
was administered. If we had been able to identify trials assessing
two or more groups with different glucocorticosteroid-containing
immunosuppression regimens compared to a control group, we
would have included data from all the groups and ensured that
participants were included only once per meta-analysis. If we had
been able to identify any cross-over trials, we would have extracted
data from the first period of treatment only.
Dealing with missing data
Where possible, we contacted the original authors of articles with
missing outcomes, missing summary data, or missing individual
data to request the missing data.
We included all participants irrespective of compliance or follow-
up. We analysed all available data and performed best-worst and
worst-best case scenario analyses in the event of missing data.
Assessment of heterogeneity
We explored heterogeneity by the Chi2 test with significance set
at P = 0.01, and we measured the quantity of heterogeneity with
the I2 statistic (Higgins 2002).
We assessed clinical heterogeneity by examining the included tri-
als for differences between the trials in types of participants (in-
cluding age, indication for transplantation, and presence of hep-
atitis C infection), quantity of glucocorticosteroid used (duration
of treatment and daily dose), and additional immunosuppression
(use of induction agents, use of antiproliferative agents, and use
of calcineurin inhibitors).
Assessment of reporting biases
We used a funnel plot to explore publication bias (Egger 1997;
Macaskill 2001), as we identified more than 10 randomised trials.
We used the linear regression approach described by Egger and
colleagues to determine the funnel plot asymmetry (Egger 1997).
Data synthesis
We performed the meta-analyses according to the recommenda-
tions of Cochrane (Higgins 2011), and the Cochrane Hepato-Bil-
iary Group Module (Gluud 2018). We used the software package
Review Manager 5.3 to conduct meta-analyses when there were
two or more eligible trials (RevMan 2014). For dichotomous vari-
ables, we calculated the risk ratio (RR) with 95% confidence in-
terval. For continuous variables, we calculated themean difference
(MD) with 95% confidence interval. We used a random-effects
model (DerSimonian 1986), and a fixed-effect model (DeMets
1987). In case of discrepancy between the twomodels, we reported
both results; otherwise, we reported only the results from the fixed-
effect model. We grouped trials investigating complete avoidance
of glucocorticosteroids together with trials investigating a rapid
taper of glucocorticosteroids as ’glucocorticosteroid avoidance and
withdrawal’ (Gluc avoid) protocols. We presented both avoidance
and rapid tapers as separate subtotals and where a discrepancy ex-
ists between the two protocols, we reported both results separately.
Trial Sequential Analysis
We applied Trial Sequential Analysis, as cumulative meta-analyses
are at risk of producing random errors because of sparse data and
repetitive testing on accumulating data (Thorlund 2011b; TSA
2011;Wetterslev2017). Tominimise randomerrors, we calculated
the diversity-adjusted required information size (DARIS) (i.e. the
number of participants needed in ameta-analysis to detect or reject
a certain intervention effect) (Wetterslev 2008; Wetterslev 2009).
The DARIS calculation accounts for the heterogeneity present in
the meta-analysis. In our meta-analysis, the DARIS was based on
the assumption of a plausible RR reduction of 20% (Wetterslev
2008). The underlying assumption of Trial Sequential Analysis is
that significance testing may be performed each time a new trial is
added to the meta-analysis. We added the trials according to the
year of publication, and if more than one trial was published in a
year, we added trials alphabetically according to the family name of
the first author. On the basis of the risk for type I (5%) and type II
(20%) errors, the chosen RR, the proportion with the outcome in
the control group, and the observed heterogeneity, we calculated
the DARIS and we constructed the trial sequential monitoring
boundaries for benefits and harms (Brok 2008; Wetterslev 2008;
Brok 2009; Thorlund 2009; Wetterslev 2009; Thorlund 2010;
Wetterslev 2017). These boundaries determine the statistical in-
ference one may draw regarding the cumulative meta-analysis that
has not reached the required information size. If the cumulative Z-
curve crosses the trial sequential monitoring boundary for benefit
or harm before the required information size is reached in a cu-
mulative meta-analysis, firm evidence may have been established
and further trials may be superfluous. On the other hand, if the
sequential monitoring boundaries are not surpassed and the trial
monitoring boundaries for futility are not crossed, it is most prob-
ably necessary to continue doing trials in order to detect or reject a
certain intervention effect.We used as default a type I error of 5%,
type II error of 20%, and a DARIS as found in the conventional
meta-analysis unless otherwise stated (Wetterslev 2008; Thorlund
2011a).
Subgroup analysis and investigation of heterogeneity
We performed the following pre-defined subgroup analyses.
• Different immunosuppressive agents.
• Co-interventions: comparing the intervention effect of
trials with one, two, or three co-interventions.
• Duration of treatment with glucocorticosteroids.
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• Trials before the year 2000 compared to trials in and after
the year 2000 (since immunosuppression protocols have changed
notably since 2000).
We were unable to perform the following pre-defined subgroup
analyses due to lack of evidence.
• Trials at low risk of bias compared to trials at high risk of
bias.
• Paediatric compared to adult liver transplantation.
• Time between transplantation and start of
glucocorticosteroid administration, determined by the median
time.
• Different indications for transplant.
Sensitivity analysis
We determined potential sensitivity analyses when we assessed our
results to examine the robustness of our findings.
Zero event trials
Review Manager 5 software is unable to handle trials with zero
events in both intervention groups when meta-analyses are per-
formed as risk ratios or odds ratios. It seems unjustified and unrea-
sonable to exclude zero event trials (Keus 2009), and potentially
create the risk of inflating the magnitude of the pooled treatment
effects. Therefore, we also performed a random-effects meta-anal-
ysis with empirical continuity correction of 0.01 in zero event tri-
als (Sweeting 2004; Keus 2009), using the R software (R 2017).
’Summary of findings’ tables
We constructed a ’Summary of findings’ table for the comparison
glucocorticoid-free versus glucocorticoid-containing immunosup-
pression following liver transplantation, presenting data on all pri-
mary outcomes and assessing the quality of the evidence based on
risk of bias, imprecision, indirectness, heterogeneity, and risk of
publication bias.We used the softwareGRADEpro© (GRADEpro
2008) to create Summary of findings for the main comparison.
R E S U L T S
Description of studies
Results of the search
Our electronic searches identified 4893 references (Figure 1).
Searching of bibliographies found 115 additional references. Ex-
clusion of duplicates and irrelevant references left 17 completed
randomised clinical trials published in a total of 70 publications
(32 peer-reviewed journal articles, 37 conference abstracts, and
one clinical trials registry listing) (see Characteristics of included
studies; Characteristics of excluded studies). One of the ran-
domised clinical trials was published in a conference abstract and
did not provide sufficient numeric data to allow incorporation of
these data into our meta-analysis (Zhong 2010). Of the 16 ran-
domised clinical trials included in our meta-analysis, four of the
trials were published only in peer-reviewed journals (Belli 1998;
Chen 2007; Hu 2008; Ju 2012), eleven of the trials were pub-
lished as both peer-reviewed journal articles and conference ab-
stracts (Tisone 1999; Belli 2001; Pageaux 2004; Margarit 2005;
Reggiani 2005; Llado 2006; Moench 2007; Vivarelli 2007; Lerut
2008; Pelletier 2013; Ramirez 2013), and one was published only
as a conference abstract (Studenik 2005).
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Figure 1. Flow chart to show studies included and excluded. RCT - randomised clinical trial; PP - per
protocol; ITT - intention-to-treat; HBG - Hepato-Biliary Group.
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Included studies
We included 16 randomised clinical trials in our meta-analysis, of
which 15 trials were two-armed trials and one was a three-armed
trial (Belli 2001). An additional trial, published in conference ab-
stracts, could not be included in the quantitative analysis as it did
not describe the number of participants allocated to each arm of
the trial (Zhong 2010). The abstract published data on 182 par-
ticipants and it is not clear from the abstract if the trial had been
completed at the time of the conference. The trial was anticipated
to include a total of 300 participants according to the study record
within the National Library of Medicine Clinical Trials Registry
(Zhong 2010). It is not possible to extract accurate numeric data
from the abstract. The abstract reports the percentage of partici-
pants in each group of the trial who develop each outcome, but
it does not report how many participants are randomised to each
arm. For this reason, for the remainder of our quantitative results,
we refer to the 16 completed trials which can be incorporated into
the quantitative analysis of this review.
The 16 trials included a total of 1347 participants in whom glu-
cocorticosteroids were compared as follows: complete glucocorti-
costeroid avoidance (excluding intra-operative use or treatment of
acute rejection) versus short-term glucocorticosteroids was com-
pared in 10 trials with a total of 782 participants (Tisone 1999;
Belli 2001; Margarit 2005; Reggiani 2005; Studenik 2005; Llado
2006; Lerut 2008; Ju 2012; Pelletier 2013; Ramirez 2013); and
short-term glucocorticosteroids versus long-term glucocorticos-
teroids were compared in six trials with a total of 565 participants
(Belli 1998; Pageaux 2004; Chen 2007; Moench 2007; Vivarelli
2007; Hu 2008). The additional trial compared complete gluco-
corticosteroid avoidance (excluding intra-operative use or treat-
ment of acute rejection) versus an unspecified duration of gluco-
corticosteroids (Zhong 2010).
As stated, complete glucocorticosteroid avoidance (excluding in-
tra-operative use or treatment of acute rejection) was used in the
experimental group in 10 trials (Tisone 1999; Belli 2001;Margarit
2005; Reggiani 2005; Studenik 2005; Llado 2006; Lerut 2008;
Ju 2012; Pelletier 2013; Ramirez 2013). These trials of complete
post-transplant glucocorticosteroid avoidance allowed glucocorti-
costeroids during the perioperative period and for treatment of
acute rejection. Seven trials used no glucocorticosteroids in the
perioperative period (Tisone 1999; Belli 2001; Margarit 2005;
Reggiani 2005; Llado 2006; Pelletier 2013; Ramirez 2013), two
trials used 500 mg glucocorticosteroids in the perioperative period
(Studenik 2005; Ju 2012), and one trial used 100 mg glucocorti-
costeroids in the perioperative period (Lerut 2008).
For the full details of glucocorticosteroid regimens (including
doses, frequencies, durations, and tapers) for each arm in all 16
trials included in the meta-analysis and the trial included in the
qualitative analysis see Characteristics of included studies.
Characteristics of the studies
Sixteen of the trials are published in English. One of the trials is
published only in Mandarin (Hu 2008). Two of the trials have
additional publications in languages other than English: one ab-
stract is published in German (Moench 2007), and one article in
Mandarin (Ju 2012).
Mean follow-up time was reported in 12 trials and varied from
13 months to 108 months (Belli 1998; Tisone 1999; Belli 2001;
Margarit 2005; Reggiani 2005; Studenik 2005; Moench 2007;
Vivarelli 2007; Lerut 2008; Ju 2012; Pelletier 2013; Ramirez
2013).
Four of the 17 trials were multicentre (Pageaux 2004; Llado 2006;
Vivarelli 2007; Zhong 2010), and the remaining 13 were sin-
gle centre (Belli 1998; Tisone 1999; Belli 2001; Margarit 2005;
Reggiani 2005; Studenik 2005; Chen 2007; Moench 2007; Hu
2008; Lerut 2008; Ju 2012; Pelletier 2013; Ramirez 2013).
All 17 of the trials consisted of exclusively adult populations.
Mean age of the intervention groups was reported in 14 trials
(Belli 1998; Tisone 1999; Pageaux 2004;Margarit 2005; Reggiani
2005; Llado 2006; Chen 2007; Moench 2007; Vivarelli 2007;
Hu 2008; Lerut 2008; Ju 2012; Pelletier 2013; Ramirez 2013).
Mean age of the participants ranged from 42 to 58 years. Sex ratio
of the participants was reported in 12 trials (Belli 1998; Tisone
1999; Pageaux 2004; Margarit 2005; Reggiani 2005; Llado 2006;
Chen 2007; Moench 2007; Lerut 2008; Ju 2012; Pelletier 2013;
Ramirez 2013). The total number of male participants in the 12
trials was 845 (73.0%) and the total number of female participants
was 312 (27.0%).
All of the trials report the primary indications for transplantation.
In 12 trials there were a variety of indications (Belli 1998; Tisone
1999; Pageaux 2004; Margarit 2005; Reggiani 2005; Studenik
2005; Llado 2006; Moench 2007; Lerut 2008; Ju 2012; Pelletier
2013; Ramirez 2013). Two trials exclusively included participants
with hepatitis C virus (HCV) cirrhosis as the primary indication
for transplantation, with a total of 71 participants (Belli 2001;
Vivarelli 2007). Three trials exclusively included participants with
hepatocellular carcinoma as the primary indication for transplan-
tation (Chen 2007; Hu 2008; Zhong 2010). A total of 258 partic-
ipants were reported as having HCV cirrhosis as the primary indi-
cation for transplantation, although there might have been more
participants who had an alternative primary indication but were
also HCV positive. Two trials published separate articles dealing
with a cohort of HCV-positive participants including a total of
124 participants (Llado 2006; Lerut 2008).One trial described the
outcomes ofHCV-positive participants as a separate cohort within
the main article, including a total of 35 participants (Margarit
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2005).
Eight trials reported on the type of donor used. In six of the tri-
als, the grafts were obtained exclusively from deceased (cadaveric)
donors (Pageaux 2004; Llado 2006; Vivarelli 2007; Hu 2008; Ju
2012; Ramirez 2013). In two of the trials, the grafts were obtained
from both deceased (cadaveric) and living donors (Moench 2007;
Lerut 2008), but in one of these trials the deceased donors were
exclusively donors after brain death (Moench 2007). The remain-
ing trials did not report on type of donor used (Belli 1998; Tisone
1999; Belli 2001; Margarit 2005; Reggiani 2005; Studenik 2005;
Chen 2007; Zhong 2010; Pelletier 2013).
Fifteen trials reported on the duration of glucocorticosteroid ad-
ministration in the glucocorticosteroid-containing arm. One trial
administered glucocorticosteroids for 64 days in the glucocor-
ticosteroid-containing arm (Lerut 2008). Seven trials adminis-
tered glucocorticosteroids for three months in the glucocorticos-
teroid-containing arm (Tisone 1999; Belli 2001; Margarit 2005;
Reggiani 2005; Llado 2006; Hu 2008; Ju 2012). One trial admin-
istered glucocorticosteroids for three to six months in the gluco-
corticosteroid-containing arm (Pelletier 2013). Two trials admin-
istered glucocorticosteroids for six months in the glucocorticos-
teroid-containing arm (Moench 2007; Ramirez 2013). One trial
administered glucocorticosteroids for nine months in the gluco-
corticosteroid-containing arm (Studenik 2005). One trial admin-
istered glucocorticosteroids for 25 months in the glucocorticos-
teroid-containing arm (Vivarelli 2007). Two trials administered
glucocorticosteroids indefinitely in the glucocorticosteroid-con-
taining arm (Belli 1998; Chen 2007). Two trials did not report the
duration of glucocorticosteroid administration in the glucocorti-
costeroid-containing arm (Pageaux 2004; Zhong 2010). For the
subgroup analyses on duration of glucocorticosteroid administra-
tion, we grouped the trials together as ’less than or equal to three
months’, ’greater than three and up to six months’, and ’greater
than six months’.
Five trials were commenced before 2000 (Belli 1998; Tisone 1999;
Belli 2001; Pageaux 2004; Margarit 2005), and the remaining
12 trials were commenced from 2000 onwards (Reggiani 2005;
Studenik 2005; Llado 2006; Chen 2007; Moench 2007; Vivarelli
2007;Hu2008; Lerut 2008; Zhong 2010; Ju 2012; Pelletier 2013;
Ramirez 2013).
Three trials reported no missing data at latest follow-up and pro-
vided adequate data to explain if any participants were not in-
cluded in the analysis so that these participants could be included
in the meta-analysis (Moench 2007; Lerut 2008; Ramirez 2013).
One of these trials reported 12/124 participants refusing biopsy
at five years (Lerut 2008). Nine trials did not report the number
of dropouts adequately (Tisone 1999; Belli 2001; Reggiani 2005;
Studenik 2005; Llado 2006; Chen 2007; Zhong 2010; Ju 2012;
Pelletier 2013). Five trials reported at least one participant lost
to follow-up, with a total of 25/642 participants in the glucocor-
ticosteroid avoidance or withdrawal group lost to follow-up and
21/651 participants in the glucocorticosteroid-containing group
lost to follow-up. One trial reported two dropouts in each group
(Belli 1998). One trial reported three dropouts in the glucocor-
ticosteroid withdrawal group and four dropouts in the glucocor-
ticosteroid-containing group (Hu 2008). One trial reported one
dropout in the glucocorticosteroidwithdrawal group and no drop-
outs in the glucocorticosteroid-containing group (Margarit 2005).
One trial reported 19 dropouts in the glucocorticosteroid with-
drawal group and 12 dropouts in the glucocorticosteroid-contain-
ing group (Pageaux 2004). One trial reported no dropouts in the
glucocorticosteroid withdrawal group and three dropouts in the
glucocorticosteroid-containing group (Vivarelli 2007). One trial
excluded 16 participants from the reported acute rejection rate due
to treatment failure (Belli 1998). Our protocol stated that all avail-
able data should be analysed using the intention-to-treat principle
(Fairfield 2014). Therefore, we included the three participants in
the glucocorticosteroid withdrawal group and 13 participants in
the long-term glucocorticosteroid group as ’lost to follow-up’ for
the outcome ’acute rejection’.
Concomitant immunosuppression
All trials reported on concomitant immunosuppression, but this
varied between trials. Of the 17 trials all used a calcineurin in-
hibitor with 11 using tacrolimus (Margarit 2005; Reggiani 2005;
Studenik 2005; Chen 2007; Moench 2007; Vivarelli 2007; Hu
2008; Lerut 2008; Ju 2012; Pelletier 2013; Ramirez 2013), and six
used cyclosporine A (Belli 1998; Tisone 1999; Belli 2001; Pageaux
2004; Llado 2006; Zhong 2010). One trial replaced tacrolimus
with sirolimus when clinically indicated (Ju 2012). Of the 11 tri-
als in which tacrolimus was used, five of the trials used no other
concomitant immunosuppression as described in the intervention
groups (Margarit 2005; Moench 2007; Vivarelli 2007; Hu 2008;
Lerut 2008) (see Characteristics of included studies).
Seven of the 17 trials used an antiproliferative agent, with six trials
using mycophenolate mofetil (Reggiani 2005; Studenik 2005;
Chen 2007; Ju 2012; Pelletier 2013; Ramirez 2013), and one
trial using azathioprine (Tisone 1999). All of the trials that used
mycophenolate mofetil also used tacrolimus and the one trial that
used azathioprine used cyclosporine A.
Induction therapy with a non-glucocorticosteroid agent was used
in nine of the trials. Two trials used rabbit antithymocyte glob-
ulin (RATG) (Belli 1998; Belli 2001); six trials used basiliximab
(Pageaux 2004; Llado 2006; Zhong 2010; Ju 2012; Pelletier 2013;
Ramirez 2013); and one trial used daclizumab (Studenik 2005).
Concomitant immunosuppression consisted of a calcineurin in-
hibitor used in combinationwith an antiproliferative agent in three
trials (Tisone 1999; Reggiani 2005; Chen 2007). Concomitant
immunosuppression consisted of a calcineurin inhibitor used in
combination with induction therapy in five trials (Belli 1998; Belli
2001; Pageaux 2004; Llado 2006; Zhong 2010). Concomitant
immunosuppression consisted of triple therapy with a calcineurin
inhibitor, an antiproliferative agent, and induction therapy in four
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trials (Studenik 2005; Ju 2012; Pelletier 2013; Ramirez 2013).
Excluded studies
Weexcluded27 trials after reading the full text of the articles. These
articles mostly related to randomised clinical trials but did not
assess glucocorticosteroid-containing versus glucocorticosteroid-
free immunosuppression. We explained the reasons for their ex-
clusion in Characteristics of excluded studies.
Risk of bias in included studies
Trial methodology was only adequately reported in two of the
trials (Moench 2007; Lerut 2008) (see Figure 2; Figure 3). We
considered all 17 of the trials to be at high risk of bias as we
considered one ormore of the bias components of each trial to be at
unclear risk of bias due to inadequately reported methodology or
at high risk of bias (Belli 1998; Tisone 1999; Belli 2001; Pageaux
2004;Margarit 2005; Reggiani 2005; Studenik 2005; Llado 2006;
Chen 2007;Moench 2007; Vivarelli 2007; Hu 2008; Lerut 2008;
Zhong 2010; Ju 2012; Pelletier 2013; Ramirez 2013).
Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Generation of the allocation sequence was adequately reported
in three trials (Tisone 1999; Ju 2012; Ramirez 2013), and in-
adequately reported in 14 trials (Belli 1998; Belli 2001; Pageaux
2004;Margarit 2005; Reggiani 2005; Studenik 2005; Llado 2006;
Chen 2007;Moench 2007; Vivarelli 2007; Hu 2008; Lerut 2008;
Zhong 2010; Pelletier 2013).
Allocation concealment was adequate in four trials (Margarit
2005; Moench 2007; Lerut 2008; Pelletier 2013), and inade-
quately reported in 13 trials (Belli 1998; Tisone 1999; Belli 2001;
Pageaux 2004; Reggiani 2005; Studenik 2005; Llado 2006; Chen
2007; Vivarelli 2007; Hu 2008; Zhong 2010; Ju 2012; Ramirez
2013).
Blinding
Three trials reported accurately and applied adequate methods
for blinding of participants (Pageaux 2004; Moench 2007; Lerut
2008). One of these trials blinded participants but not outcome
assessors (Moench 2007). Seven trials did not report on blinding
(Belli 1998; Belli 2001; Studenik 2005; Chen 2007; Hu 2008;
Zhong 2010; Ju 2012), and seven trials did not perform blinding (
Tisone 1999;Margarit 2005;Reggiani 2005; Llado 2006;Vivarelli
2007; Pelletier 2013; Ramirez 2013).
Incomplete outcome data
In four trials, either no data were missing or missing data were ad-
equately reported and unlikely to have influenced outcome results
(Moench 2007; Vivarelli 2007; Lerut 2008; Ramirez 2013). In
the remaining 13 trials missing data were inadequately addressed
(Belli 1998; Tisone 1999; Belli 2001; Pageaux 2004; Margarit
2005; Reggiani 2005; Studenik 2005; Llado 2006; Chen 2007;
Hu 2008; Zhong 2010; Ju 2012; Pelletier 2013). In one trial, a
participant was excluded following a re-transplant and death 10
days later (Ramirez 2013); as this occurred after randomisation,
we had to re-enter the participant into the analysis for inclusion
in the meta-analysis. In one trial, three participants were excluded
due to early death (two participants) and positive cross-match (one
participant) (Margarit 2005); as this occurred after randomisa-
tion, we had to re-enter the participants into the analysis for inclu-
sion in the meta-analysis: we added one case of mortality to each
group and one case of missing data to the glucocorticosteroid-
free group as well as we adjusted the totals accordingly. The trial
did not make comment on any other missing data. One trial ex-
cluded nine participants due to early death (five participants) and
ABO-blood group incompatibility (four participants) (Ju 2012),
reporting on the original allocated groups of the deaths but not the
ABO-blood group incompatibility; as this occurred after randomi-
sation, we had to re-enter the participants who suffered from early
mortality into the analysis for inclusion in the meta-analysis. One
trial excluded eight participants due to early death (three partici-
pants), graft loss (two participants), change to alternative primary
immunosuppressant (two participants), and de novo hepatitis B
virus (HBV) infection (one participant) (Vivarelli 2007); as this
occurred after randomisation, we had to re-enter the participants
into the analysis for inclusion in the meta-analysis: we added the
cases of mortality and graft loss to the intervention groups ac-
cordingly, and we counted the change in immunosuppressant and
HBV infection as loss to follow-up. As some of these participants
were randomised but excluded from the analysis, they might not
have been included in the demographic data except where authors
had provided relevant details. In the three-armed trial, six partici-
pants died and one developed portal vein thrombosis (Belli 2001).
The participants were split between the three arms (two in the
standard therapy arm; three in the glucocorticosteroid-free arm;
and two in the glucocorticosteroid-free and ribavirin arm), but
which group the participant with portal vein thrombosis was in
and which groups the deaths occurred in was not reported. We
could not include the outcome ofmortality in this trial in themain
analysis, but it was possible to include it in the best-worst, worst-
best analysis: the number of participants suffering from mortality
is either one or two in the standard therapy arm and either two or
three in the glucocorticosteroid-free arm, and we used these values
in the analysis.
Missing summary data
One trial reported mean arterial pressure, serum cholesterol, and
fasting blood glucose, but it did not provide a standard deviation
or range (Ramirez 2013). Furthermore, in this trial, no exact P
values were reported, but P values were described as “NS” (not
significant) (Ramirez 2013). These results are included in this
review.
Selective reporting
We had no access to the protocols for any of the trials other than
the trial only included in qualitative analysis (Zhong 2010). One
trial was published only in an abstract, so no comment on selective
reporting could be made (Studenik 2005). Of the 15 remaining
trials, 14 reported expected clinical outcomemeasures or outcomes
as specified in the methods section of the article (Belli 1998; Belli
2001; Pageaux 2004; Margarit 2005; Reggiani 2005; Llado 2006;
Chen 2007;Moench 2007; Vivarelli 2007; Hu 2008; Lerut 2008;
Ju 2012; Pelletier 2013; Ramirez 2013). One trial did not report
expected outcome of hypertension described in the introduction
and discussion section of the article (Tisone 1999).
17Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Other potential sources of bias
Seven trials reported part or full industry sponsorship (Pageaux
2004; Llado 2006; Moench 2007; Vivarelli 2007; Lerut 2008;
Pelletier 2013; Ramirez 2013). Four trials reported sponsorship
exclusively from other sources (Margarit 2005; Hu 2008; Zhong
2010; Ju 2012). The remaining six trials did not report on spon-
sorship (Belli 1998; Tisone 1999; Belli 2001; Reggiani 2005;
Studenik 2005; Chen 2007).
Three of the 17 trials reported a required sample size calculation
(Llado 2006;Moench 2007; Lerut 2008), whilst the remainder did
not (Belli 1998; Tisone 1999; Belli 2001; Pageaux 2004;Margarit
2005; Reggiani 2005; Studenik 2005; Chen 2007; Vivarelli 2007;
Hu 2008; Zhong 2010; Ju 2012; Pelletier 2013; Ramirez 2013).
Thirteen of the trials appeared to be free from early stopping. One
of the trials was stopped early following an interim analysis. The
stopping criteria were not described in the trial that was stopped
early (Reggiani 2005). Two trials did not report adequately on
early stopping (Studenik 2005, Chen 2007). One trial was pub-
lished only as a conference abstract and reported only preliminary
findings; the data are not included in this review due to inade-
quate reporting of participants in each intervention group (Zhong
2010).
Eleven of the 17 trials are free from baseline imbalance (Belli
1998; Tisone 1999; Pageaux 2004; Studenik 2005; Llado 2006;
Chen 2007; Moench 2007; Vivarelli 2007; Hu 2008; Pelletier
2013; Ramirez 2013). Three trials reported on significant baseline
imbalance (Margarit 2005; Reggiani 2005; Lerut 2008). In three
of the trials, the baseline characteristics were inadequately reported
to allow comparison (Belli 2001; Zhong 2010; Ju 2012).
Effects of interventions
See: Summary of findings for the main comparison
Glucocorticosteroid avoidance or withdrawal compared
to glucocorticosteroid-based immunosuppression for liver
transplanted patients
See Summary of findings for the main comparison for the effects
of glucocorticosteroid avoidance or withdrawal versus glucocor-
ticosteroid-containing immunosuppression for liver transplanted
patients.
Glucocorticosteroid avoidance or withdrawal versus
glucocorticosteroid-containing immunosuppression
All-cause mortality
Fifteen trials with 1323 participants reported adequately on mor-
tality, and overall we found no statistically significant difference
when glucocorticosteroid avoidance or withdrawal was compared
with glucocorticosteroid-containing immunosuppression (128/
659 (19%) versus 110/664 (17%); risk ratio (RR) 1.15, 95% con-
fidence interval (CI) 0.93 to 1.44; low-quality evidence; Analysis
1.1). One trial reported the total number of deaths and a portal
vein thrombosis as a composite outcome for the entire trial but did
not adequately describe to which group the portal vein thrombosis
and the deaths belonged (Belli 2001). As a result of this, the trial
could not be included for this outcome except in the best-worst
and worst-best analyses (Analysis 8.1; Analysis 9.1). Trial Sequen-
tial Analysis showed that trial sequential monitoring boundaries
were not broken by the cumulative Z-curve and the required in-
formation size of 3520 participants was not obtained (Figure 4).
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Figure 4. Mortality: glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid containing
immunosuppression. Trial Sequential Analysis of the effect of glucocorticosteroid avoidance or withdrawal
versus glucocorticosteroid-containing immunosuppression on mortality based on 15 trials with 1323
participants. The diversity-adjusted required information size (DARIS) of 3520 participants was calculated on
the basis of type I error of 5%, type II error of 20% and risk reduction of 20%, and information size was adjusted
for diversity (0%). The cumulative Z-curve does not cross trial sequential monitoring boundaries, and the
required information size was not reached.
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Graft loss including death
Eleven trials with 1002 participants reported on graft loss includ-
ing death, and overall we found no statistically significant dif-
ference when glucocorticosteroid avoidance or withdrawal was
compared with glucocorticosteroid-containing immunosuppres-
sion (118/631 (19%) versus 97/638 (15%); RR 1.15, 95% CI
0.90 to 1.46; low-quality evidence; Analysis 1.2). Trial Sequential
Analysis showed that trial sequential monitoring boundaries were
not broken by the cumulative Z-curve and the required informa-
tion size of 2423 participants was not obtained (Figure 5).
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Figure 5. Graft loss including death: glucocorticosteroid avoidance or withdrawal versus
glucocorticosteroid containing immunosuppression. Trial Sequential Analysis of the effect of
glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosuppression on
graft loss including death based on 11 trials with 1002 participants. The diversity-adjusted required
information size (DARIS) was calculated on the basis of type I error of 5%, type II error of 20% and risk
reduction of 20%, and information size was adjusted for diversity (0%). The cumulative Z-curve does not cross
trial sequential monitoring boundaries, and the required information size was not reached.
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Acute rejection
Acute rejection was defined as the total number of participants
who experienced one ormore rejection episodes. Sixteen trials with
1347 participants reported on acute rejection, and acute rejection
was statistically significantly more frequent when glucocorticos-
teroid avoidance or withdrawal was compared with glucocorti-
costeroid-containing immunosuppression (150/670 (22%) versus
117/677 (17%); RR 1.33, 95% CI 1.08 to 1.64; low-quality ev-
idence; Analysis 1.3). However, Trial Sequential Analysis showed
that trial sequential monitoring boundaries were not broken by
the cumulative Z-curve and the required information size of 3520
participants was not obtained (Figure 6).
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Figure 6. Acute rejection: glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid
containing immunosuppression. Trial Sequential Analysis of the effect of glucocorticosteroid avoidance or
withdrawal versus glucocorticosteroid-containing immunosuppression on acute rejection based on 16 trials
with 1347 participants. The diversity-adjusted required information size (DARIS) was calculated on the basis of
type I error of 5%, type II error of 20% and risk reduction of 20%, and information size was adjusted for
diversity (0%). The cumulative Z-curve does not cross trial sequential monitoring boundaries, and the required
information size was not reached.
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Infection
Eight trials with 778 participants reported adequately on infec-
tion, and overall we found no statistically significant difference
when glucocorticosteroid avoidance or withdrawal was compared
with glucocorticosteroid-containing immunosuppression (120/
382 (31%) versus 142/396 (36%); RR 0.88, 95% CI 0.73 to
1.05; very low-quality evidence; Analysis 1.4). Infection was de-
fined in each of the eight trials as the number of participants who
experienced one or more infection. Two other trials reported the
total number of cases of infection including those with multiple
episodes of infection (Margarit 2005; Lerut 2008). Trial Sequen-
tial Analysis showed that trial sequential monitoring boundaries
were not broken by the cumulative Z-curve and the required in-
formation size of 3222 participants was not obtained.
Other adverse events
No trials reported on adverse events. A number of trials reported
“deaths due to an adverse event” or separate adverse events such
as the development of de novo diabetes mellitus but none of the
trials reported the total number of adverse events.
Chronic rejection
Nine trials with 974 participants reported on chronic rejec-
tion, and overall we found no statistically significant difference
when glucocorticosteroid avoidance or withdrawal was compared
with glucocorticosteroid containing immunosuppression (16/482
(3%) versus 15/492 (3%); RR 1.08, 95% CI 0.56 to 2.10;
very low-quality evidence; Analysis 1.5). Trial Sequential Analysis
showed that trial sequential monitoring boundaries were not bro-
ken by the cumulative Z-curve and the required information size
of 26,534 participants was not obtained.
Glucocorticosteroid-resistant rejection
Glucocorticosteroid-resistant rejection was defined as the total
number of participants who experienced one or more glucocor-
ticosteroid-resistant rejections. Ten trials with 1020 participants
reported on glucocorticosteroid-resistant rejection, and glucocor-
ticosteroid-resistant rejection was statistically significantly more
frequent when glucocorticosteroid avoidance or withdrawal was
compared with glucocorticosteroid-containing immunosuppres-
sion (27/505 (5%) versus 13/515 (3%); RR 2.14, 95% CI 1.13
to 4.02; very low-quality evidence; Analysis 1.6). Trial Sequential
Analysis showed that trial sequential monitoring boundaries were
not broken by the cumulative Z-curve and the required informa-
tion size of 2190 participants was not obtained.
Diabetes mellitus
Twelve trials with 1185 participants reported on diabetes mellitus,
and diabetes mellitus was not significantly different when gluco-
corticosteroid avoidance or withdrawal was compared with gluco-
corticosteroid-containing immunosuppression (125/588 (21%)
versus 156/597 (26%); RR 0.82, 95% CI 0.64 to 1.07; low-qual-
ity evidence) when we applied the random-effects model. How-
ever, when we applied the fixed-effect model, diabetes mellitus
was statistically significantly less frequent when glucocorticos-
teroid avoidance or withdrawal was compared with glucocorticos-
teroid-containing immunosuppression (RR 0.81, 95% CI 0.66 to
0.99; low-quality evidence; Analysis 1.7). Trial Sequential Anal-
ysis showed that trial sequential monitoring boundaries were not
broken by the cumulative Z-curve and the required information
size of 3348 participants was not obtained.
Cytomegalovirus (CMV) infection
CMV infection was defined as the development of CMV disease
requiring treatment. Seven trials with 786 participants reported
on CMV infection, and overall we found no statistically signifi-
cant difference when glucocorticosteroid avoidance or withdrawal
was compared with glucocorticosteroid-containing immunosup-
pression (28/387 (7%) versus 38/399 (10%); RR 0.74, 95% CI
0.48 to 1.16; low-quality evidence; Analysis 1.8). Trial Sequential
Analysis showed that trial sequential monitoring boundaries were
not broken by the cumulative Z-curve and the required informa-
tion size of 6429 participants was not obtained.
Hepatitis C virus (HCV) recurrence
Ten trials with 477 participants reported on HCV recurrence, and
overall we found no statistically significant difference when gluco-
corticosteroid avoidance or withdrawal was compared with gluco-
corticosteroid-containing immunosuppression (159/232 (69%)
versus 162/245 (66%); RR 1.03, 95% CI 0.92 to 1.15; very low-
quality evidence; Analysis 1.9). Trial Sequential Analysis showed
that trial sequential monitoring boundaries were not broken by
the cumulative Z-curve but the required information size of 435
participants was obtained, meaning that we can exclude a relative
risk reduction of 20% or more.
Malignancy
Three trials with 528 participants reported on de novomalignancy,
and overall we found no statistically significant difference when
glucocorticosteroid avoidance or withdrawal was compared with
glucocorticosteroid-containing immunosuppression (3/258 (1%)
versus 7/270 (3%); RR 0.52, 95% CI 0.16 to 1.74; very low-
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quality evidence; Analysis 1.10). Trial Sequential Analysis showed
that trial sequential monitoring boundaries were not broken by the
cumulative Z-curve and the required information size of 22,911
participants was not obtained.
Post-transplant lymphoproliferative disorder
Two trials with 330 participants reported on post-transplant lym-
phoproliferative disorder, and overall we found no statistically sig-
nificant difference when glucocorticosteroid avoidance or with-
drawal was compared with glucocorticosteroid-containing im-
munosuppression (3/162 (2%) versus 1/168 (1%); RR 2.39,
95% CI 0.36 to 15.95; very low-quality evidence; Analysis 1.11).
Trial Sequential Analysis showed that trial sequential monitoring
boundaries were not broken by the cumulative Z-curve and the
required information size of 70,005 participants was not obtained.
Renal function
No trials reported on renal failure requiring dialysis.
Four trials with 447 participants reported on renal insufficiency,
and overall we found no statistically significant difference when
glucocorticosteroid avoidance was compared with glucocorticos-
teroid-containing immunosuppression (67/216 (31%) versus 77/
231 (33%); RR 0.93, 95% CI 0.73 to 1.19; very low-quality evi-
dence; Analysis 1.12). Trial Sequential Analysis showed that trial
sequential monitoring boundaries were not broken by the cumu-
lative Z-curve and the required information size of 3735 partici-
pants was not obtained.
No trials reported on estimated glomerular filtration rate.
Four trials with 309 participants reported on creatinine (mg/dL),
and creatinine was not significantly different when glucocorticos-
teroid avoidance or withdrawal was compared with glucocorticos-
teroid-containing immunosuppression (MD 0.01 mg/dL, 95%
CI -0.21 to 0.23; very low-quality evidence) when we applied the
random-effects model. However, when we applied the fixed-effect
model, creatinine was statistically significantly raised when gluco-
corticosteroid avoidance or withdrawal was compared with gluco-
corticosteroid-containing immunosuppression (MD 0.11 mg/dL,
95% CI 0.07 to 0.16; very low-quality evidence; Analysis 1.13).
De novo autoimmune hepatitis
No trials reported on de novo autoimmune hepatitis.
Hypertension
Ten trials with 1098 participants reported on hypertension,
and hypertension was statistically significantly less frequent
when glucocorticosteroid avoidance or withdrawal was compared
with glucocorticosteroid-containing immunosuppression (157/
543 (29%) versus 210/555 (38%); RR 0.76, 95% CI 0.65 to
0.90; low-quality evidence; Analysis 1.14). Trial Sequential Anal-
ysis showed that trial sequential monitoring boundaries were not
broken by the cumulative Z-curve and the required information
size of 3409 participants was not obtained.
Hyperlipidaemia
Four trials with 400 participants reported on hyperlipidaemia,
and overall we found no statistically significant difference when
glucocorticosteroid avoidance was compared with glucocorticos-
teroid-containing immunosuppression (13/197 (7%) versus 18/
203 (9%); RR 0.75, 95% CI 0.38 to 1.48; very low-quality evi-
dence; Analysis 1.15). Trial Sequential Analysis showed that trial
sequential monitoring boundaries were not broken by the cumu-
lative Z-curve and the required information size of 7214 partici-
pants was not obtained.
Cholesterol
Five trials with 556 participants reported on serum cholesterol
(mg/dL), and serum cholesterol was statistically significantly re-
duced when glucocorticosteroid avoidance or withdrawal was
compared with glucocorticosteroid-containing immunosuppres-
sion (mean difference (MD) -18.49 mg/dL, 95% CI -22.02 to -
14.96; very low-quality evidence; Analysis 1.16).
Two trials with 266 participants reported on hypercholestero-
laemia, and hypercholesterolaemia was not significantly different
when glucocorticosteroid avoidance or withdrawal was compared
with glucocorticosteroid-containing immunosuppression (16/134
(12%) versus 28/132 (21%); RR 0.56, 95% CI 0.32 to 1.00;
very low-quality evidence; Analysis 1.17). Trial Sequential Anal-
ysis showed that trial sequential monitoring boundaries were not
broken by the cumulative Z-curve and the required information
size of 20,334 participants was not obtained.
Health-related quality of life
No trials reported on health-related quality of life.
Zero event trial correction
Trials with zero events in both intervention groups were found in
several of the analyses. For all of these analyses, we applied a ran-
dom-effects meta-analysis with empirical continuity correction of
0.01 using the R software (R 2017). This correction of zero event
trials resulted in none of the analyses yielding statistically signif-
icantly different results (i.e. all statistically significant differences
in results between the groups remained statistically significantly
different after zero event trial correction, and all non-statistically
significant differences in results between the groups remained non-
statistically significantly different after zero event trial correction).
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Subgroup analyses
We were not able to perform our predefined subgroup analysis on
trials at low risk of bias compared to trials at high risk of bias, as
we considered none of the trials included in the review to be at
low risk of bias.
We were not able to perform our predefined subgroup analysis
on trials with paediatric participants compared to trials with adult
participants, as all of the trials included in the review recruited
exclusively adult participants.
We were not able to perform our predefined subgroup analysis
on the median time between transplantation and the commence-
ment of glucocorticosteroid administration, as none of the trials
included in the review reported this in their methodology.
We performed subgroup analyses on glucocorticosteroid avoid-
ance compared to glucocorticosteroid withdrawal (Analysis 1.1
through Analysis 1.17). Tests for subgroup differences between
glucocorticosteroid avoidance and glucocorticosteroid withdrawal
were not statistically significantly different for most outcomes,
except for the outcomes ’Infection’, ’Creatinine’ and ’Hyperc-
holesterolaemia’. We found a statistically significant interaction
for infection (P = 0.04). This difference between glucocorticos-
teroid avoidance and glucocorticosteroid withdrawal is caused by
one trial using glucocorticosteroid withdrawal that caused signif-
icantly fewer infections in the glucocorticosteroid avoidance or
withdrawal group compared to trials in which glucocorticosteroid
avoidance was used (RR 0.12, 95% CI 0.02 to 0.89). We found
a statistically significant interaction for creatinine (P = 0.0004).
This difference between glucocorticosteroid avoidance and gluco-
corticosteroid withdrawal is caused by two trials using glucocorti-
costeroid withdrawal that caused significantly lower creatinine in
the glucocorticosteroid avoidance or withdrawal group compared
to trials in which glucocorticosteroid avoidance was used (MD -
0.06 mg/dL, 95% CI -0.16 to 0.05). We found a statistically sig-
nificant interaction for hypercholesterolaemia (P = 0.008). This
difference is caused by one trial reporting no statistically significant
difference and one trial reporting statistically significantly lower
rates of hypercholesterolaemia in the glucocorticosteroid avoid-
ance andwithdrawal arm. There are only a small number of studies
reporting on infection, creatinine, and hypercholesterolaemia.The
difference observed between subgroups for these outcomes may
therefore be due to a factor other than glucocorticosteroid use.
We performed subgroup analyses on type of calcineurin inhibitor
used (tacrolimus or cyclosporine A) (Analysis 2.1 through Analysis
2.16). Tests for subgroup differences between type of calcineurin
inhibitor used as a co-intervention were not statistically signifi-
cantly different for most outcomes, except for the outcome ’Crea-
tinine’ for which we found a statistically significant interaction (P
< 0.00001). This difference between type of calcineurin inhibitor
used as co-intervention is caused by one trial using the calcineurin
inhibitor tacrolimus, which caused significantly higher serum cre-
atinine levels in the glucocorticosteroid avoidance or withdrawal
group compared to trials in which cyclosporine A was used (MD
0.25 mg/dL, 95% CI 0.19 to 0.31).
We performed subgroup analyses on type of antiproliferative agent
(azathioprine or mycophenolate mofetil) compared to no antipro-
liferative agent (Analysis 3.1 through Analysis 3.14). Tests for sub-
group differences between the type of antiproliferative agent used
as a co-intervention when compared to no antiproliferative agent
were not statistically significantly different for most outcomes, ex-
cept for the outcome ’Creatinine’, for which we found a statis-
tically significant interaction (P < 0.00001). This difference be-
tween the type of antiproliferative agent used as a co-intervention
is caused by one trial using the antiproliferative agent mycopheno-
late mofetil, which caused significantly higher serum creatinine in
the glucocorticosteroid avoidance or withdrawal group compared
to trials in which azathioprine or no antiproliferative agent were
used (MD 0.25 mg/dL, 95% CI 0.19 to 0.31).
Weperformed subgroup analyses on type of induction agent (basil-
iximab, daclizumab, or rabbit antithymocyte globulin) compared
to no induction agent (Analysis 4.1 through Analysis 4.16). Tests
for subgroup differences between the type of induction therapy
used as a co-intervention when compared to no induction agent
were not statistically significantly different for most outcomes,
except for the outcomes ’Infection’, ’Creatinine’, ’Hypertension’
and ’Cholesterol’. We found a statistically significant difference
for infection (P = 0.04). This difference between the type of in-
duction therapy used as a co-intervention is caused by the in-
duction agent rabbit antithymocyte globulin, which caused sig-
nificantly fewer infections in the glucocorticosteroid avoidance or
withdrawal group compared to trials in which basiliximab or no
induction agents were used (RR 0.12, 95% CI 0.02 to 0.89). We
found a statistically significant interaction for serum creatinine (P
< 0.00001). This difference between the type of induction therapy
used as a co-intervention is caused by the induction agent basil-
iximab, which caused significantly higher serum creatinine in the
glucocorticosteroid avoidance or withdrawal group compared to
trials in which no induction agent was used (MD 0.25 mg/dL,
95% CI 0.19 to 0.31). We found a statistically significant inter-
action for hypertension (P = 0.03). This difference between the
type of induction therapy used as a co-intervention is caused by
the induction agent rabbit antithymocyte globulin, which caused
significantly lower rates of hypertension in the glucocorticosteroid
avoidance or withdrawal group compared to trials in which basil-
iximab or no induction agent were used (RR 0.30, 95% CI 0.16
to 0.57). We found a statistically significant interaction for serum
cholesterol (P = 0.0001). This difference between the type of in-
duction therapy used as a co-intervention is caused in part by the
induction agent rabbit antithymocyte globulin, which caused sig-
nificantly lower serumcholesterol in the glucocorticosteroid avoid-
ance or withdrawal group compared to trials in which basiliximab
was used (MD -70.00 mg/dL, 95% CI -101.17 to -39.83) and
in part by one trial that did not use an induction agent, which
caused significantly lower serum cholesterol in the glucocorticos-
teroid avoidance or withdrawal group compared to trials in which
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basiliximab was used (MD -146.00 mg/dL, 95% CI -192.16 to -
99.84).
We performed subgroup analyses on the number of co-interven-
tions given (monotherapy, dual therapy, or triple therapy) (Analy-
sis 5.1 through Analysis 5.16). Tests for subgroup differences be-
tween the number of co-interventions given were not statistically
significantly different for most outcomes, except for the outcomes
’Creatinine’ and ’Cholesterol’. We found a statistically significant
interaction for serum creatinine (P < 0.00001). This difference
between the number of co-interventions given is caused by the
use of triple therapy in one trial, which caused significantly higher
serum creatinine in the glucocorticosteroid avoidance or with-
drawal group compared to monotherapy or triple therapy (MD
0.25 mg/dL, 95% CI 0.19 to 0.31). We found a statistically sig-
nificant difference for serum cholesterol (P < 0.00001). This dif-
ference between the number of co-interventions given is caused
by the use of monotherapy in one trial, which caused significantly
higher serum cholesterol in the glucocorticosteroid avoidance or
withdrawal group compared to dual therapy or triple therapy (MD
35.00 mg/dL, 95% CI 12.31 to 57.69).
We performed subgroup analyses on the duration of glucocorti-
costeroid use in the longer glucocorticosteroid taper arm or the
long-term glucocorticosteroid arm (up to three months of gluco-
corticosteroids; greater than three months and up to six months
of glucocorticosteroids; or greater than six months of glucocorti-
costeroids) (Analysis 6.1 through Analysis 6.13). One trial did not
report on the duration of glucocorticosteroid use in the glucocor-
ticosteroid-containing arm and was not included in this sub-anal-
ysis (Pageaux 2004). Tests for subgroup differences between du-
ration of glucocorticosteroid use in the glucocorticosteroid-con-
taining arm were not statistically significantly different for most
outcomes, except for the outcomes ’Creatinine’, ’Hypertension’,
’Cholesterol’ and ’Hypercholesterolaemia’.We found a statistically
significant difference for serum creatinine (P = 0.00001). This dif-
ference between the duration of glucocorticosteroid use is caused
by one trial using three to six months of glucocorticosteroids in
the glucocorticosteroid-containing group, which caused signifi-
cantly higher serum creatinine in the glucocorticosteroid avoid-
ance or withdrawal group compared to trials using two to three
months of glucocorticosteroids and more than six months of glu-
cocorticosteroids in the glucocorticosteroid-containing arm (MD
0.25 mg/dL, 95% CI 0.19 to 0.31). We found a statistically sig-
nificant difference for hypertension (P = 0.001). This difference
between duration of glucocorticosteroid use in the glucocorticos-
teroid-containing arm is caused, in part, by one trial which used
long-term glucocorticosteroid in the glucocorticosteroid-contain-
ing arm, which caused significantly lower rates of hypertension in
the glucocorticosteroid avoidance or withdrawal group compared
to trials using two to three months or three to six months of glu-
cocorticosteroids in the glucocorticosteroid-containing arm (RR
0.30, 95% CI 0.16 to 0.57). We found a statistically significant
difference for cholesterol (P = 0.002). This difference between du-
ration of glucocorticosteroid use in the glucocorticosteroid-con-
taining arm is caused by two trials using long-term glucocorticos-
teroids in the glucocorticosteroid-containing arm, which caused
significantly lower serum cholesterol in the glucocorticosteroid
avoidance or withdrawal group compared to trials using two to
three months or three to six months of glucocorticosteroids in the
glucocorticosteroid-containing arm (MD -92.75 mg/dL, 95% CI
-118.01 to -67.50). We found a statistically significant interac-
tion for hypercholesterolaemia (P = 0.008). This difference be-
tween duration of glucocorticosteroid use in the glucocorticos-
teroid-containing is due to the small number of trials reporting
on hypercholesterolaemia, with one trial reporting no statistically
significant difference and one trial reporting statistically signifi-
cantly lower rates of hypercholesterolaemia in the glucocorticos-
teroid avoidance and withdrawal arm. The difference observed be-
tween subgroups for hypercholesterolaemia may therefore be due
to a factor other than duration of glucocorticosteroid use.
We performed subgroup analyses on trials commenced before the
year 2000 and trials commenced from 2000 onwards (Analysis
7.1 through Analysis 7.16). Tests for subgroup differences be-
tween trials commenced before 2000 and trials commenced from
2000 onwards were not statistically significantly different for most
outcomes, except for the outcomes ’Creatinine’, ’Hypertension’,
and ’Cholesterol’. We found a statistically significant interaction
for creatinine (P < 0.00001). This difference between trials com-
menced before 2000 and trials commenced from 2000 onwards is
caused by one trial started after 2000, which caused significantly
higher serum creatinine in the glucocorticosteroid avoidance or
withdrawal group compared to a trial started before 2000 (MD
0.25 mg/dL, 95% CI 0.19 to 0.31). We found a statistically sig-
nificant difference for hypertension (P = 0.03). This difference be-
tween trials commenced before 2000 and trials commenced from
2000 onwards is caused by one trial started before 2000, which
caused significantly lower rates of hypertension in the glucocorti-
costeroid avoidance or withdrawal group compared to trials started
after 2000 (RR 0.30, 95% CI 0.16 to 0.57). We found a statis-
tically significant difference for cholesterol (P = 0.03). This dif-
ference between trials commenced before 2000 and trials com-
menced from 2000 onwards is caused by one trial started before
2000, which caused significantly lower serum cholesterol in the
glucocorticosteroid avoidance or withdrawal group compared to
trials started after 2000 (MD -70.00 mg/dL, 95% CI -101.17 to
-39.83).
The statistically significant interactions in serum creatinine and
serum cholesterol between many of the subgroups are unlikely to
reflect actual differences between the subgroups. Instead they are
likely to reflect the relatively small number of trials that report
on these outcomes and the considerable heterogeneity influencing
these outcomes.
Best-worst and worst-best analyses
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We found trials with missing data in several of the analyses. For
each of these analyses, we applied a best-worst analysis and a worst-
best analysis.
Best-worst analyses
The best-worst analyses (best results possible for glucocorticos-
teroid avoidance or withdrawal) did not yield statistically signifi-
cantly different results from the conventional meta-analysis except
for acute rejection, infection, glucocorticosteroid-resistant rejec-
tion, CMV infection, malignancy, post-transplant lymphoprolif-
erative disorder, and hyperlipidaemia (Analysis 8.1 through Anal-
ysis 8.12). We observed no statistically significant difference in the
best-worst analyses for acute rejection (RR 1.04, 95% CI 0.85 to
1.26) or glucocorticosteroid-resistant rejection (RR 1.00, 95% CI
0.61 to 1.65) when glucocorticosteroid avoidance or withdrawal
was compared with glucocorticosteroid-containing immunosup-
pression. We found statistically significant reductions in the best-
worst analyses for infection (RR0.80, 95%CI0.67 to 0.96),CMV
infection (RR 0.57, 95% CI 0.37 to 0.87), malignancy (RR 0.21,
95% CI 0.07 to 0.61), post-transplant lymphoproliferative disor-
der (RR 0.24, 95% CI 0.07 to 0.85), and hyperlipidaemia (RR
0.40, 95% CI 0.21 to 0.73) when glucocorticosteroid avoidance
or withdrawal was compared with glucocorticosteroid-containing
immunosuppression. However, it is unlikely that all 12 partici-
pants lost to follow-up in the glucocorticosteroid-containing im-
munosuppression arm of Pageaux 2004 suffered from malignancy
and post-transplant lymphoproliferative disorder. We found no
statistically significant differences between the best-worst analyses
and the conventional meta-analysis for mortality, graft loss includ-
ing death, chronic rejection, diabetes mellitus, or hypertension
when glucocorticosteroid avoidance or withdrawal was compared
with glucocorticosteroid-containing immunosuppression.
Worst-best analyses
The worst-best analyses (worst results possible for glucocorticos-
teroid avoidance or withdrawal) did not yield statistically signif-
icantly different results from the conventional meta-analysis ex-
cept for mortality, graft loss including death, chronic rejection, di-
abetes mellitus, malignancy, post-transplant lymphoproliferative
disorder, hypertension, and hyperlipidaemia (Analysis 9.1 through
Analysis 9.13). We observed no statistically significant difference
in the worst-best analyses for diabetes mellitus (RR 0.95, 95%
CI 0.79 to 1.15) or hypertension (RR 0.87, 95% CI 0.75 to
1.02) when glucocorticosteroid avoidance or withdrawal was com-
pared with glucocorticosteroid-containing immunosuppression.
We found statistically significant increases in the worst-best anal-
yses for mortality (RR 1.35, 95% CI 1.10 to 1.67), graft loss in-
cluding death (RR 1.38, 95% CI 1.08 to 1.74), chronic rejection
(RR 2.45, 95% CI 1.40 to 4.31), malignancy (RR 3.05, 95% CI
1.38 to 6.73), post-transplant lymphoproliferative disorder (RR
15.64, 95% CI 3.08 to 79.56), and hyperlipidaemia (RR 1.92,
95% CI 1.12 to 3.28) when the glucocorticosteroid avoidance
or withdrawal was compared with glucocorticosteroid-containing
immunosuppression. However, it is unlikely that all 19 partici-
pants lost to follow-up in the glucocorticosteroid withdrawal arm
of Pageaux 2004 suffered from malignancy and post-transplant
lymphoproliferative disorder. We found no statistically significant
differences between the best-worst analyses and the conventional
meta-analysis for acute rejection, infection, glucocorticosteroid-
resistant rejection, CMV infection, or renal insufficiency when
glucocorticosteroid avoidance or withdrawal was compared with
glucocorticosteroid-containing immunosuppression.
Adverse events reported in non-randomised studies
Our search was primarily to identify randomised clinical trials and
systematic reviews. However, the search returned multiple cita-
tions from quasi-randomised or non-randomised studies. In these
studies, we searched for adverse events that were different to those
reported in the randomised clinical studies in terms of number or
type of adverse event. We were unable to find any unique adverse
events in the non-randomised studies and we found no signifi-
cant discrepancy in the rates of the adverse events reported in the
randomised trials of this systematic review. We did not find any
unique adverse events reported in the completed study that we
were not able to incorporate to the meta-analysis (Zhong 2010).
Publication bias
We performed a linear regression test to explore funnel plot asym-
metry for any outcomes reported in 10 ormore trials (Egger 1997).
We found no asymmetry for mortality, graft loss including death,
acute rejection, glucocorticosteroid-resistant rejection, or hepatitis
C virus recurrence. We identified tendencies towards significant
asymmetry for diabetes mellitus (P = 0.06) and hypertension (P
= 0.07). This asymmetry may be due to heterogeneity introduced
by one study (Belli 1998); when this study was removed, no asym-
metry was detected.
D I S C U S S I O N
Summary of main results
We identified 16 completed randomised clinical trials including
1347 participants and one other trial for which limited data were
available. Eleven of these completed trials compared glucocor-
ticosteroid avoidance with short-term glucocorticosteroids and
the remaining six compared rapid glucocorticosteroid tapers with
longer tapers or long-term glucocorticosteroids. All but one trial
were two-armed parallel-group trials with one three-armed par-
allel group trial for which only the control arm and the relevant
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intervention arm were included in our review. We aimed to as-
sess mortality, graft loss including death, acute rejection, infec-
tion, adverse events, chronic rejection, glucocorticosteroid-resis-
tant rejection, diabetes mellitus, cytomegalovirus (CMV) infec-
tion, hepatitis C virus (HCV) recurrence, malignancy, post-trans-
plant lymphoproliferative disorder, renal failure requiring dialysis,
renal insufficiency, estimated glomerular filtration rate (eGFR),
serum creatinine, de novo autoimmune hepatitis, hypertension,
hyperlipidaemia, serum cholesterol, hypercholesterolaemia, and
health-related quality of life. Adverse events, renal failure requiring
dialysis, eGFR, de novo autoimmune hepatitis, and health-related
quality of life were not reported in any of the trials. We assessed
all other outcomes in the meta-analysis.
Acute rejection appeared to be increased when glucocorticosteroid
avoidance or withdrawal were compared with glucocorticosteroid-
containing immunosuppression. Glucocorticosteroid-resistant re-
jection appeared to be increased when glucocorticosteroid avoid-
ance or withdrawal were compared with glucocorticosteroid-con-
taining immunosuppression. Diabetes mellitus appeared to be in-
creased when glucocorticosteroid avoidance or withdrawal were
compared with glucocorticosteroid-containing immunosuppres-
sion, when we applied the fixed-effect, but not the random-effects
model. Serum creatinine appeared to be increased when glucocor-
ticosteroid avoidance or withdrawal were compared with gluco-
corticosteroid-containing immunosuppression, when we applied
the fixed-effect, but not the random-effects model. Hypertension
appeared to be reduced when glucocorticosteroid avoidance or
withdrawal were compared with glucocorticosteroid-containing
immunosuppression. Serum cholesterol appeared to be reduced
when glucocorticosteroid avoidance or withdrawal were compared
with glucocorticosteroid-containing immunosuppression.
We found no evidence for an increase or decrease in mortality,
graft loss including death, infection, chronic rejection, CMV in-
fection, HCV recurrence, malignancy, post-transplant lympho-
proliferative disorder, renal insufficiency, hyperlipidaemia, or hy-
percholesterolaemia when comparing glucocorticosteroid avoid-
ance or withdrawal with glucocorticosteroid-containing immuno-
suppression. We performed Trial Sequential Analysis for all out-
comes, and for none of the outcomes were the monitoring bound-
aries crossed or the required information size reached. Hence, we
cannot exclude random errors for the results of the conventional
meta-analyses.
We identified five trials exclusively composed of or reporting co-
horts of hepatitis C virus-infected participants, including 231 par-
ticipants.
Overall completeness and applicability of
evidence
We included 16 completed trials in our meta-analysis, which com-
pared glucocorticosteroid avoidance or withdrawal with gluco-
corticosteroid-containing immunosuppression. We could not per-
form meta-analyses on each of our predefined outcomes as the
trials we identified did not report on all of them. We were unable
to include one completed trial due to inadequate data published
for this trial.
All of the trials reported on acute rejection. Almost all of the tri-
als reported on mortality, graft loss including death, and diabetes
mellitus. Most trials reported on infection, chronic rejection, glu-
cocorticosteroid-resistant rejection, HCV recurrence, and hyper-
tension. Few trials report on CMV infection, malignancy, post-
transplant lymphoproliferative disorder, renal insufficiency, serum
creatinine, hyperlipidaemia, serum cholesterol, and hypercholes-
terolaemia. None of the trials reported on adverse events, renal
failure requiring dialysis, eGFR, de novo autoimmune hepatitis, or
health-related quality of life. Of the outcomes for which few trials
reported results, many had conflicting results, as demonstrated by
the moderate or significant level of heterogeneity identified in the
analyses.
Our meta-analyses include a variety of immunosuppressive regi-
mens including different combinations and types of calcineurin
inhibitor, antiproliferative agent, and induction agent and include
the majority of the agents in common use. One induction agent
in common use, alemtuzumab, was not used in any of the trials.
Follow-up in the included trials ranged from six months to 10
years. Our review has very limited evidence for long-term out-
comes for glucocorticosteroid avoidance or withdrawal versus glu-
cocorticosteroid-containing immunosuppression. Long-term ef-
fects are particularly relevant for mortality, graft loss, malignancy,
and post-transplant lymphoproliferative disorder.
The participants included in each of the trials do not fully reflect
the characteristics of the general liver transplant population. None
of the trials included in our review included paediatric participants
and only a limited number included living donors. Only eight of
the trials reported on type of donor. There is, however, a variety of
concomitant immunosuppressants reflecting the majority of im-
munosuppressants in current use as well as a variety of indications
for transplantation.
Quality of the evidence
The quality of our review findings and interpretations are limited
by the number of trials included in the review and the low quality
of certain aspects within the trials. For several of the comparisons
only a very small number of trials could be included, with limited
reporting on the rarer outcomes of interest. These factors are re-
sponsible for the broad confidence intervals representing impreci-
sion in many of our analyses.
Our review is limited by indirectness as it does not include paedi-
atric participants or multiple organ transplant recipients. As well
as this, many of the included trials listed living donors in their
exclusion criteria. For this reason our results cannot be directly
related to these patients.
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We explored statistical heterogeneity with the Chi2 test and quan-
tified heterogeneity using the I2 statistic (Higgins 2002). The Chi
2 test is not as effective for situations where few trials with few
participants are included in a meta-analysis, such as is the case for
our review. This means that many of the outcomes for which we
found a statistically significant difference indicate a moderate or
significant level of heterogeneity. It also means that in situations in
which a non-statistically significant result was shown, it could still
have been influenced by heterogeneity. To overcome this uncer-
tainty, we applied both fixed-effect and random-effects meta-anal-
ysis models, and reported both models whenwe found differences.
In our review, the fixed-effect model identified several statistically
significant differences, which were not identified by the random-
effects model. We considered six outcomes (infection, chronic re-
jection, diabetes mellitus, malignancy, renal insufficiency, and hy-
pertension) to have moderate levels of heterogeneity. We consid-
ered three outcomes (creatinine, cholesterol, and hypercholestero-
laemia) to have significant levels of heterogeneity. The outcomes
with the highest levels of heterogeneity were reported in only a
small number of the included trials. Two of these outcomes were
also continuous outcomes and demonstrated considerable incon-
sistency between the small number of studies in which they were
reported. The heterogeneity identified in the outcomes ’Diabetes
mellitus’ and ’Hypertension’ is due to one trial in the glucocor-
ticosteroid withdrawal sub-analysis (Belli 2001). This trial, with
over 100 participants, which used rabbit antithymocyte globulin,
also used the highest cumulative glucocorticosteroid dose in the
glucocorticosteroid-containing group. As glucocorticosteroids are
known to increase the rates of hypertension and diabetes mellitus
(Hatz 1998), we believe that this comparatively high glucocorti-
costeroid dose may be responsible for the inconsistency in these
outcomes. Following the sensitivity analyses, we found that this
trial is also responsible for several of the identified subgroup dif-
ferences.
We detected possible publication bias for hypertension and dia-
betes mellitus. This, however, may be due to the heterogeneity
introduced by one study and when this study is removed from the
analysis, no possibility of publication bias is detected.
Risk of bias is known to be responsible for overestimation of in-
tervention benefits and underestimation of intervention harms in
randomised trials with inadequate methodological quality (Schulz
1995; Moher 1998; Kjaergard 2001; Wood 2008; Savovi 2012;
Savovi 2012a; Lundh 2017). Of the 17 included trials, three
trials (18%) reported adequate generation of the randomisation
sequence, four (24%) reported adequate allocation concealment,
three (18%) reported adequate blinding of participants, two (12%)
reported adequate blinding of outcome assessors, four (24%) ap-
pear to be uninfluenced by incomplete outcome data, 14 (82%)
appear to be free from selective reporting, and we could consider
none to be free from ’other bias’, with reasons being industry spon-
sorship and lack of reporting of required sample size calculation.
Thirteen (76%) appear to be free from early stopping, and 11
(65%) appear to be free from baseline imbalance. We considered
all trials to be at high risk of bias.
Potential biases in the review process
Weperformed a systematic review andmeta-analysis in accordance
with the methodology described in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011).
We followed our peer-reviewed and prepublished protocol with
predefined participants, interventions, comparisons, and out-
comes to avoid biases in the review preparation (Fairfield 2014).
We performed a comprehensive and extensive literature search for
both published and unpublished data from a variety of sources
that met our predefined inclusion criteria. We extracted all avail-
able data and based our meta-analysis on the intention-to-treat
principle. We performed several sub-analyses and sensitivity anal-
yses when appropriate to assess the robustness of our data. We
performed empirical continuity correction for zero event trials.
Our meta-analysis includes larger numbers of randomised clinical
trials on glucocorticosteroid avoidance or withdrawal than other
meta-analyses published on this topic (Segev 2008; Sgourakis
2009; Knight 2011; Gu 2014; Lan 2014), improving the quality
and comprehensiveness, and reducing the risks of imprecision.
Althoughwe contacted various experts in the field and pharmaceu-
tical companies, our search might have missed unpublished data
including trials with negative results. This bias remains difficult to
avoid. We performed linear regression tests to identify asymmetry
in funnel plots in order to identify any possible publication bias.
We also contacted the authors of any trials with incomplete data
to obtain any unpublished or missing data.
In addition, we conducted Trial Sequential Analyses for all out-
comes (Wetterslev 2008; Thorlund 2011b; TSA 2011; Wetterslev
2017) in order to test the robustness of our results. We calculated
theDARIS on the basis of type I error of 5%, type II error of 20%,
and risk reduction of 20%, and adjusted the information size for
diversity (Wetterslev 2009). For all the Trial Sequential Analyses,
the cumulative Z-curve did not cross trial sequential monitoring
boundaries, and the DARIS was not reached; hence, we cannot
exclude random errors regarding our results (play of chance). Ex-
cept for the outcome HCV recurrence, trial sequential monitor-
ing boundaries were not broken by the cumulative Z-curve, but
the required information size of 435 participants was obtained,
meaning that we can exclude a relative risk reduction of 20% or
more regarding HCV recurrence.
Our searchwas conducted inMay 2017 and it is possible thatmore
recent studies may have been published, which are not considered
in our review.
Agreements and disagreements with other
studies or reviews
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Five non-Cochrane meta-analyses on glucocorticosteroid avoid-
ance or withdrawal for liver transplanted patients have been pub-
lished (Segev 2008; Sgourakis 2009; Knight 2011; Gu 2014; Lan
2014), as well as one Cochrane network meta-analysis assessing
maintenance immunosuppression for liver transplanted patients
(Rodríguez-Perálvarez 2017). Three of thesemeta-analyses also in-
clude trials inwhich glucocorticosteroids have been comparedwith
another agent (Segev 2008; Sgourakis 2009; Gu 2014), but have
reported these as sub-analyses allowing for comparisons with our
review. One review focuses on comparison of monotherapy with
glucocorticosteroid-containing combinations although included
studies where monotherapy was compared with three immuno-
suppressive agents of which one was a glucocorticosteroid (Lan
2014). Our review deals more extensively with risk of bias (sys-
tematic errors) and risk of random errors (play of chance) in the
randomised clinical trials we identified. We have also performed
a much larger number of sub-analyses, and performed Trial Se-
quential Analyses for all outcomes.
Overall, the meta-analysis in Segev 2008 found a decrease in
cholesterol, CMV infection, and HCV recurrence but an increase
in acute rejection with glucocorticosteroid avoidance or with-
drawal, although no difference in mortality, graft loss, hyperten-
sion, diabetes mellitus, glucocorticosteroid-resistant rejection, or
infection was observed. Segev 2008 reports statistically signifi-
cantly decreased rates of acute rejection, glucocorticosteroid-resis-
tant rejection, and diabetes mellitus when glucocorticosteroids are
replaced with an alternative immunosuppressive agent. This also
means that overall the rates of acute rejection are decreased when
these trials are assessed in combination with trials where gluco-
corticosteroids are not replaced. One possible reason behind the
comparatively lower rates of diabetes mellitus when glucocorticos-
teroids were replaced rather than withdrawn or avoided is that the
majority of the trials in the review treated acute rejection with glu-
cocorticosteroids and the higher rates of acute rejection in the trials
where glucocorticosteroids were avoided or withdrawn results in
glucocorticosteroids being administered for rejection treatment.
These pulses of glucocorticosteroids may have increased the rates
of diabetes mellitus, masking any benefit gained from not using
them (Hatz 1998). This may also explain why Segev 2008 iden-
tified statistically significant reductions in HCV recurrence with
glucocorticosteroid avoidance or withdrawal whilst our review did
not. This is because glucocorticosteroid pulses are known to pro-
mote HCV recurrence and the higher rates of acute rejection iden-
tified in our review resulted in higher rates of glucocorticosteroid
pulses (Sheiner 1995; Singh 1996).
Overall, the meta-analysis in Sgourakis 2009 found a decrease
in diabetes mellitus, CMV infection, and cholesterol and an in-
crease in acute rejection with glucocorticosteroid avoidance or
withdrawal, although no difference in mortality, graft loss, glu-
cocorticosteroid-resistant rejection, chronic rejection, infection,
hypertension, renal insufficiency, and mortality in HCV-infected
participants was observed. Sgourakis 2009 also found a decrease in
acute rejection for trials where glucocorticosteroids were replaced
by an alternative immunosuppressive agent.
Overall the meta-analysis in Knight 2011 found a decrease in
diabetes mellitus and no significant increases or decreases in any
other outcomes includingmortality, graft loss, hypertension, acute
rejection, and cholesterol with glucocorticosteroid avoidance or
withdrawal. Knight 2011 contains only seven trials and many
of the analyses have significant levels of heterogeneity. A non-
significant trend was identified in many of the outcomes, but the
low number of trials is likely to have caused wider confidence
intervals, preventing genuine effects from being identified.
Overall, the meta-analysis in Gu 2014 found a decrease in dia-
betes mellitus and CMV infection and no significant increases or
decreases in any other outcomes including mortality, graft loss,
acute rejection, chronic rejection, HCV recurrence, infection, and
hypertension with glucocorticosteroid avoidance or withdrawal.
The meta-analysis in Lan 2014 claims to have found a total
of 14 randomised clinical trials assessing immunosuppression
monotherapy (using tacrolimus, cyclosporine, or mycophenolate
mofetil) versus glucocorticosteroid-containing immunosuppres-
sion. A total of seven of the “randomised studies” included in Lan
2014 appear to relate to only three studies (Belli 1998; Moench
2007; Manousou 2009), which have been subject to duplicate
publication. The authors of Lan 2014 have included the results
of each report as a separate study in each relevant meta-analysis
meaning that the same participants have been included multiple
times. As a consequence of the probability of duplicate publica-
tion bias in the meta-analysis by Lan and colleagues. (Lan 2014),
we have therefore decided not to make any comparisons with the
results of our review. A letter has been sent to the editor of the
relevant journal highlighting the inclusion of duplicate studies in
Lan 2014 (Fairfield 2017).
Overall, the network meta-analysis in Rodríguez-Perálvarez 2017
found a reduction in adverse events but no change in mortal-
ity or graft rejection with glucocorticosteroid avoidance or with-
drawal in cyclosporine-based regimens when making direct com-
parison. Rodríguez-Perálvarez 2017 found a reduction in adverse
events with no change in mortality, graft rejection, or retrans-
plantation with glucocorticosteroid avoidance or withdrawal in
cyclosporine-based regimens when making indirect comparison.
Overall, the network meta-analysis in Rodríguez-Perálvarez 2017
found an increase in retransplantation but no change in chronic
kidney disease with glucocorticosteroid avoidance or withdrawal
in tacrolimus-based regimens when making direct comparison.
Rodríguez-Perálvarez 2017 found no change in mortality, graft
loss, renal impairment, or retransplantation with glucocorticos-
teroid avoidance or withdrawal in tacrolimus-based monotherapy
regimes when making indirect comparison. Rodríguez-Perálvarez
2017 found an increase in retransplantation with glucocorticos-
teroid avoidance or withdrawal in tacrolimus- and mycopheno-
late mofetil-based regimens when making indirect comparison.
The network meta-analysis in Rodríguez-Perálvarez 2017 includes
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only three individual studies assessing glucocorticosteroid avoid-
ance and withdrawal.
In accordance with these meta-analyses, we found statistically sig-
nificant decreases in diabetes mellitus and cholesterol as well as a
statistically significant increase in acute rejection with glucocor-
ticosteroid avoidance or withdrawal when applying conventional
meta-analyses. Similar to the othermeta-analyses, we found no sta-
tistically significant changes in mortality, graft loss, chronic rejec-
tion, and infection.We also found a statistically significant increase
in glucocorticosteroid-resistant rejection and a statistically signifi-
cant decrease in hypertension with glucocorticosteroid avoidance
or withdrawal.
Reduction in CMV infection, HCV recurrence and adverse events
with an increase in retransplantationwere not shown in our review.
The differences between the findings of our review and those of
other publishedmeta-analyses may be due to our review excluding
studies comparing glucocorticosteroids with alternative immuno-
suppressive agents.
A similar meta-analysis has been performed for kidney transplan-
tation (Knight 2010). The review contained 34 trials with a total
of 5637 participants and assessed the benefits and harms of glu-
cocorticosteroid avoidance or withdrawal in kidney transplant re-
cipients. Knight 2010 found statistically significant reductions in
hypertension (risk ratio (RR) 0.90, 95% confidence interval (CI)
0.85 to 0.94), hypercholesterolaemia (RR 0.76, 95% CI 0.67 to
0.87), diabetes mellitus (RR 0.64, 95% CI 0.50 to 0.83), and cre-
atinine clearance (weighted mean difference (WMD) -3.06 mL/
min, 95% CI -4.66 to -1.45), as well as statistically significant in-
creases in acute rejection (RR 1.56, 95%CI 1.31 to 1.87) and cre-
atinine (WMD 4.24 µmol/L, 95% CI 2.08 to 6.40) with gluco-
corticosteroid avoidance or withdrawal. Knight 2010 observed no
statistically significant differences in mortality, graft loss, or gluco-
corticosteroid-resistant rejection. These findings are very similar
to the findings of our review. The differences observed in Knight
2010 in creatinine in kidney transplant recipients were not found
in our review for liver transplant recipients; this may be due to the
small number of trials included in our review that reported serum
creatinine.
Knight 2011 also reports the outcomes with glucocorticosteroid
avoidance or withdrawal for heart and pancreas transplantation
although only one trial was identified in each. Esmore 1989 re-
ports statistically significant reductions in the number of antihy-
pertensives required (0.8 ± 0.6 antihypertensives versus 1.3 ± 0.7
antihypertensives) and serum cholesterol (5.4 ± 1.2 mmol/L ver-
sus 6.2 ± 0.9 mmol/L), as well as statistically significant increases
in rejection rates within the first three months from transplanta-
tion (2.3 ± 0.23 episodes per 100 patient days versus 1.5 ± 0.18
episodes per 100 patient days) and glucocorticosteroid-resistant
rejection (26.4% versus 10.2%) with glucocorticosteroid avoid-
ance or withdrawal for heart transplant recipients. Esmore 1989
reports no statistically significant differences in mortality or graft
loss with glucocorticosteroid avoidance or withdrawal. Gruessner
2001 reports a statistically significant reduction in cholesterol and
triglyceride levels in simultaneous pancreas and kidney transplant
recipients with glucocorticosteroid avoidance or withdrawal (rates
not given). Gruessner 2001 reports no statistically significant dif-
ferences in mortality or graft loss with glucocorticosteroid avoid-
ance or withdrawal.
Possible benefits of glucocorticosteroid avoidance and withdrawal,
including reductions in cardiovascular risk factors, were identified
in this review. However, possible increases in acute rejection and
glucocorticosteroid-resistant rejection were also identified. These
findings are similar to reviews of glucocorticosteroid avoidance
and withdrawal for heart and kidney transplant recipients. Unfor-
tunately the benefits and harms found in the conventional meta-
analysis could not be confirmedbyTrial Sequential Analysesmean-
ing that we cannot exclude random errors.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Our review has a low to moderate quality of evidence for the ef-
fects of glucocorticosteroid avoidance or withdrawal. The effects
of glucocorticosteroid avoidance or withdrawal remain uncertain.
Our review showed no clear benefits or harms for mortality, graft
loss including death, infection, chronic rejection, cytomegalovirus
(CMV) infection, hepatitis C virus (HCV) recurrence, malig-
nancy, post-transplant lymphoproliferative disorder, renal insuf-
ficiency, creatinine, hyperlipidaemia, cholesterol, or hypercholes-
terolaemia. Hypertension and diabetes mellitus may be reduced,
but acute rejection and glucocorticosteroid-resistant rejectionmay
be increased with glucocorticosteroid avoidance or withdrawal.
Glucocorticosteroid-free immunosuppression may provide a safe
alternative for liver transplanted patients who are intolerant of glu-
cocorticosteroids. Although we found no statistically significant
difference for mortality or graft loss, these findings should be in-
terpreted with caution.
Implications for research
Given the results of our analysis, it appears that appropriately sized
randomised clinical trials comparing glucocorticosteroid avoid-
ance or withdrawal with glucocorticosteroid-containing immuno-
suppression in liver transplant participants using contemporar-
ily adjunctive immunosuppression are warranted. As episodes of
acute rejection following liver transplantation tend to occur more
frequently in the initial weeks following transplantation (Wiesner
1998), trials investigatingwhether short-termglucocorticosteroids
(first few weeks) reduce the rates of acute rejection without ex-
posing liver transplant recipients to cardiovascular risk factors for
long periods of time appear to be warranted. We feel it may be
of benefit to construct a high-quality three-arm trial comparing
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complete postoperative glucocorticosteroid avoidance, short-term
glucocorticosteroids, and long-term glucocorticosteroids.
Our review did not identify any statistically significant increase
or decrease in HCV recurrence with glucocorticosteroid-free im-
munosuppression despite reports that glucocorticosteroids in-
crease the severity of HCV hepatitis (Sheiner 1995; Singh 1996;
Segev 2008; Sgourakis 2009). One possible reason for this is the
higher rate of acute rejection in the glucocorticosteroid-free arm,
which was treated with glucocorticosteroid pulses. It is possible
that with the use of alternative immunosuppression strategies to
prevent rejection that glucocorticosteroid-free immunosuppres-
sion may lead to lower rates of HCV recurrence (Hibi 2015). Our
review identified a number of studies published between 2009 and
2017 in which glucocorticosteroids were replaced with an alterna-
tive immunosuppressant. An updated systematic review andmeta-
analysis of these studies is merited.
These trials should be conducted with low risk of systematic error
(bias) and low risk of random error (play of chance), and should
follow the ’SPIRIT’ guidelines (SPIRIT 2013a; SPIRIT 2013b)
and ’CONSORT’ guidelines (www.consort-statement.org).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Belli 1998
Methods Trial design: randomised, single-centre clinical trial
Mean follow-up: total: 41 ± 16 months, range 4 to 68 months
Study duration: date of randomisation to last follow-up before 28 February 1997, or
patient death or re-transplantation
Language: English
Type of information: journal article
Judgement on quality: unclear risk of bias
Participants Setting: Ospedale Niguarda Ca’ Granda, Milan, Italy
Allocation of participants: 104 participants, 50 allocated to long-term glucocorticos-
teroids, 54 allocated to short-term glucocorticosteroids
Sex ratio: total: 74 (71%) males, 30 (29%) females
Intervention A: 37 (74%) males, 13 (26%) females
Intervention B: 37 (68.5%) males, 17 (31.5%) females
Mean age: total: not reported
Intervention A: 45 ± 14
Intervention B: 42 ± 16
Indication (no. (%)): (indications reported for whole study population but not inter-
vention groups)
HCV: 42 (40.4%)
HBV: 24 (23.1%)
HBV and HCV: 8 (7.7%)
Alcoholic cirrhosis: 9 (8.7%)
Primary biliary cirrhosis: 6 (5.8%)
Cryptogenic cirrhosis: 8 (7.7%)
Others: 7 (6.7%)
Type of donor: not reported
Inclusion criteria: adult liver transplant recipients
Exclusion criteria: previous liver transplant, previous other organ transplant, multiorgan
transplant
Other: rejection before randomisation (n (%)):
Intervention A: 15 (30%)
Intervention B: 22 (41%)
Interventions Intervention A: methylprednisolone: from day 90, 20 mg per day with 5 mg reductions
every 2 weeks until stopped
Intervention B: methylprednisolone: from day 90, 20 mg per day with 5 mg reductions
every 2 weeks until maintenance dose of 0.1 mg/kg/day continued for duration of study
Concomitant immunosuppression:
Rabbit antithymocyte globulins: 2 mg/kg/day for 5 to 7 days from day 0
Cyclosporine A: 200 to 300 ng/mL (from day 90 for “first months”) and 150 ng/mL to
250 ng/mL thereafter
Methylprednisolone: 1000 mg intraoperatively; 200 mg at day 1; 160 mg at day 2; 120
mg at day 3; 80 mg at day 4; 40 mg at day 5; 20 mg at day 6; then continued at the
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Belli 1998 (Continued)
same dose until day 90
Outcomes Patient survival, acute rejection, chronic rejection, hypertension, diabetes, severe bone
complications, infections, serum cholesterol, recurrent hepatitis B, recurrent hepatitis C
and treatment failure
Notes Cross-over between intervention arms: no
Sample size calculation: not reported
Sources of funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote from the publication: “One hun-
dred four first orthotopic liver transplan-
tations performed between May 1991 and
June 1995 at the Niguarda Hospital in Mi-
lan and surviving long enough to reach the
randomization time point were prospec-
tively assigned to one of the two mainte-
nance immunosuppressive regimens. Fifty
patients were randomized to receive cy-
closporine plus long-term corticosteroids
(Group I) and 54 patients were randomized
to cyclosporine monotherapy (Group II).”
Comment: Generation of randomisation
sequence not described
Allocation concealment (selection bias) Unclear risk Comment: Allocation concealment not de-
scribed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: Blinding of participants and
medical staff not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: Blinding of outcome assessors
not described
Incomplete outcome data (attrition bias) Unclear risk Comment: Number of withdrawals and
reasons for withdrawal not reported
Selective reporting (reporting bias) Low risk Comment: All predefined outcomes and
clinically relevant outcomes appear to be
reported
Other bias Unclear risk Comment: No sample size calculation re-
ported
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Free of early stopping? Low risk Comment: Study not stopped early
Free of baseline imbalance? Low risk Comment: No evidence of baseline imbal-
ance reported in “Table 3”
Belli 2001
Methods Trial design: randomised, single-centre clinical trial
Mean follow-up: not reported
Intervention A: 22 months
Intervention B: 21 months
Study duration: randomisation fromNovember 1997 toNovember 1999, duration from
randomisation not reported
Language: English
Type of information: journal article
Judgement on quality: high risk of bias
Participants Setting: Ospedale Niguarda Ca’ Granda, Milan, Italy
Allocation of participants: 24 participants, 13 allocated to glucocorticosteroids, 11 allo-
cated to no intervention
Sex ratio: total: not reported
Intervention A: not reported
Intervention B: not reported
Mean age: total: not reported
Intervention A: not reported
Intervention B: not reported
Indication (no. (%)):
HCV cirrhosis: total: 24 (100%), Intervention A: 13 (100%), Intervention B: 11 (100%)
Type of donor: not reported
Inclusion criteria: adult liver transplant recipients with HCV cirrhosis
Exclusion criteria: not reported
Interventions Intervention A: no intervention
Intervention B: glucocorticosteroids for 3 months, doses not reported
Concomitant immunosuppression:
Rabbit antithymocyte globulin: dose not reported, given for 5 days
Azathioprine: dose not reported, given for 1 month
Cyclosporine A: dose not reported
Outcomes Acute rejection, chronic rejection, recurrent hepatitis C, severe cholestasis, ALT, mortal-
ity, portal vein thrombosis
Notes Cross-over between intervention arms: no
Sample size calculation: not reported
Sources of funding: not reported
One intervention group was excluded from the meta-analysis as differences between
hepatitis C virus prophylaxis (ribavirin) were noted
Although the overall data for mortality and portal vein thrombosis have been reported,
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Belli 2001 (Continued)
the exact number of participants in each group with these outcomes is not reported,
therefore these results are not included in the meta-analysis but are included in the best-
worst worst-best analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote from the publication: “Between
November 1997 and November 1999 37
patients (pts) were randomized to one of
three groups: ...”
Comment: Generation of randomisation
sequence not described
Allocation concealment (selection bias) Unclear risk Comment: Allocation concealment not de-
scribed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: Blinding of participants and
medical staff not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment:Blinding of outcome assessors
not described
Incomplete outcome data (attrition bias) High risk Quote from the publication: “Of these 37
pts, only 30were considered in the analysis.
Seven pts were excluded because of early
death after transplant (6 pts) or because of
concurrent confounding clinical problems
(1 pt with portal vein thrombosis).”
Comment: Mortality and portal vein
thrombosis not reported fully. As this is a
three-arm trial it is not possible to accu-
rately record data on mortality within each
group as the trial does not report which
arm of the trial the portal vein thrombo-
sis occurred in and which arms of the trial
each mortality occurred in. Therefore, the
outcomes have not been included in the
meta-analysis but have been included in
the best-worst worst-best analyses. Other-
wise, number of withdrawals and reasons
for withdrawal not reported
Selective reporting (reporting bias) Low risk Comment: All outcomes appear to be fully
reported
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Other bias Unclear risk Comment: No sample size calculation re-
ported
Free of early stopping? Low risk Comment: Study not stopped early
Free of baseline imbalance? Unclear risk Comment: Baseline characteristics not re-
ported
Chen 2007
Methods Trial design: randomised, single-centre clinical trial
Mean follow-up: not reported
Intervention A: not reported
Intervention B: not reported
Study duration: not reported
Language: English
Type of information: journal article
Judgement on quality: unclear risk of bias
Participants Setting: Tongji Hospital, Wuha, Hubei Province, China
Allocation of participants: 54 participants, 28 allocated to Intervention A, 26 allocated
to Intervention B
Sex ratio: total: 53 (98%) males, 1 (2%) female
Intervention A: 27 (96%) males, 1 (4%) female
Intervention B: 26 (100%) males, 0 (0%) female
Mean age: total: not reported
Intervention A: 45.7 ± 3.5
Intervention B: 47.4 ± 6.3
Indication (no. (%)):
Hepatocellular carcinoma: total: 54 (100%), Intervention A: 28 (100%), Intervention
B: 26 (100%)
Type of donor: not reported
Inclusion criteria: not reported
Exclusion criteria: not reported
Other:
Cold ischaemia time (minutes): total: not reported, Intervention A: 486.1 ± 97.0, Inter-
vention B: 462.1 ± 88.0
Warm ischaemia time (minutes): total: not reported. Intervention A: 51.5 ± 3.4, Inter-
vention B: 50.8 ± 3.1
Interventions Intervention A: glucocorticosteroids: 3 months rapid taper to stop at 3 months, type of
glucocorticosteroid and doses not reported
Intervention B: glucocorticosteroids: 3 months slow taper with 10 mg/day maintenance
long-term, type of glucocorticosteroid and doses during taper not reported
Concomitant immunosuppression:
Methylprednisolone: 500 mg/day for 3 days
Tacrolimus: aiming for trough doses of 6 to 8 micrograms/mL for 1 year and then 4 to
6 micrograms/mL thereafter
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Chen 2007 (Continued)
Mycophenolate mofetil: 0.5 to 1 g/day for 1 year and then stopped at 1 year
Outcomes Mortality, acute rejection, creatinine, HCC recurrence, ALT, cholesterol, fasting blood
sugar
Notes Cross-over between intervention arms: no
Sample size calculation: not reported
Sources of funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote from the publication: “Fifty-four
patients suffering from advanced-stage
hepatoma (all exceeding the Milan crite-
rion) underwent liver transplantation be-
tween April 2003 and June 2005. There
were two immunosuppressive protocols: 28
patients (group A) were given an early
steroid-withdrawal protocol and 26 pa-
tients (group B) were given a steroid-main-
tenance protocol.”
Quote from the publication: “This ran-
domized clinical study was focused on a
particular group of recipients who suffered
from advanced-stage hepatocellular carci-
noma before liver transplantation.”
Quote from the “Comments” section of the
publication: “The present study was a ran-
domized clinical trial of steroid withdrawal
after liver transplantation in patients with
advanced-stage hepatocellular carcinoma.
We have cited several articles from other
investigators that report research on steroid
withdrawal after liver transplantation.”
Comment: Generation of randomisation
sequence not described
Allocation concealment (selection bias) Unclear risk Comment: Allocation concealment not de-
scribed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: Blinding of participants and
medical staff not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: Blinding of outcome assessors
not described
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Incomplete outcome data (attrition bias) Unclear risk Comment: Number of withdrawals and
reasons for withdrawal not reported
Selective reporting (reporting bias) Low risk Comment: All outcomes appear to be fully
reported
Other bias Unclear risk Comment: No sample size calculation re-
ported
Free of early stopping? Unclear risk Comment: Study does not appear to be
stopped early
Free of baseline imbalance? Low risk Quote from the publication: “Factors such
as age at transplantation, stage of carci-
noma, Child-Pugh score, graft cold is-
chemic time, anhepatic phase, operation
time, and mean level of liver function be-
fore operation were noted, and these pa-
rameters were well matched in both groups
(Table 1).”
Comment: Study appears to be free from
baseline imbalance
Hu 2008
Methods Trial design: randomised, single-centre clinical trial
Mean follow-up: not reported
Study duration: 6 months from randomisation, randomisation from September 2006 to
March 2008
Language: Mandarin
Type of information: journal article
Judgement on quality: unclear risk of bias
Participants Setting: Organ Transplantation Center, the First Affiliated Hospital of Sun Yat-Sen
University, Guangzhou, China
Allocation of participants: 76 participants, 36 allocated to Intervention A, 40 allocated
to Intervention B
Sex ratio: total: not reported
Intervention A: 5:1 (numbers and % not reported)
Intervention B: 4:1 (numbers and % not reported)
Mean age: total: not reported
Intervention A: 47.6+/-5.8
Intervention B: 45.2+/-6.5
Indication (no. (%)): not reported
Type of donor: deceased donor
Inclusion criteria: first liver transplantation, hepatocellular carcinoma, aged 18 to 65,
deceased donor transplantation and informed consent given
Exclusion criteria: previous liver transplant, multi-organ transplantation, living donor
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transplantation, ABO-incompatible transplantation. Primary disease: primary sclerosing
cholangitis or autoimmune hepatitis. Preoperative psychiatric symptoms, gastric ulcer,
use of hormones, diabetes mellitus, hypertension, hyperlipidaemia or malignancy other
than primary hepatocellular carcinoma. Participation in other trials
Interventions Intervention A: no intervention
Intervention B: prednisone from day 8, commencing at 48 mg reduced by 8 mg every 3
days to a maintenance dose of 4 mg by day 26, stopped after 3 months
Concomitant immunosuppression:
Tacrolimus: 3 mg intraoperatively then adjusted postoperatively to 8 to 12 micrograms/
mL
Methylprednisolone: 1000 mg intraoperatively, then 500 mg on day 1, 240 mg on day
2, 200 mg on day 3, 160 mg on day 4, 80 mg on day 5, 40 mg on day 6 and 20 mg on
day 7
Outcomes Mortality, infection, hepatic artery thrombosis, hypertension, diabetes mellitus, hyper-
lipidaemia, neurotoxicity, gastrointestinal complications, other adverse events
Notes Cross-over between intervention arms: no
Sample size calculation: not reported
Sources of funding: National Nature foundation, China Medical Board in New York,
Nature foundation of Guangzhou province
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: Generation of randomisation
sequence not described
Allocation concealment (selection bias) Unclear risk Comment: Allocation concealment not de-
scribed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: Blinding of participants and
medical staff not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: Blinding of outcome assessors
not described
Incomplete outcome data (attrition bias) Unclear risk Comment: Number of withdrawals and
reasons for withdrawal not reported
Selective reporting (reporting bias) Low risk Comment: All outcomes appear to be fully
reported
Other bias Unclear risk Comment: No sample size calculation re-
ported
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Free of early stopping? Low risk Comment: Study not stopped early
Free of baseline imbalance? Low risk Comment: Study appears to be free from
baseline imbalance
Ju 2012
Methods Trial design: randomised, single-centre clinical trial
Mean follow-up: total: not reported; InterventionA: 23months (range: 12 to 36months)
; Intervention B: 21 months (range: 12 to 36 months)
Study duration: 3 years from randomisation, randomisation from September 2006 to
September 2008
Language: English
Type of information: journal article
Judgement on quality: unclear risk of bias
Participants Setting: Organ Transplantation Center, the First Affiliated Hospital of Sun Yat-Sen
University, Guangzhou, China
Allocation of participants: 87 participants, 44 allocated to Intervention A, 43 allocated
to Intervention B
Sex ratio: total: 64 (78.0%) males, 18 (22.0%) females
Intervention A: not reported
Intervention B: not reported
Mean age: total: 45.7 (range: 26 to 68)
Intervention A: not reported
Intervention B: not reported
Indication (no. (%)): (indications reported for whole study population but not inter-
vention groups)
Hepatocellular carcinoma: total: 36 (43.9%)
HBV cirrhosis: total: 33 (40.2%)
HCV cirrhosis: total: 3 (3.7%)
Alcoholic cirrhosis: total: 3 (3.7%)
Severe hepatitis: total: 6 (7.3%)
Polycystic liver: total: 1 (1.2%)
Type of donor: deceased donor
Inclusion criteria: adult liver transplant recipients
Exclusion criteria: pretransplant infection (except HBV, HCV), marginal grafts (donors
with moderate to severe NAFLD, HBV infection, age > 60, cold ischaemia > 14 hours),
multiorgan transplants, retransplant, partial liver transplant including living donor, lack
of consent, ABO incompatibility
Interventions Intervention A: no intervention
Intervention B: methylprednisolone at 240 mg on day 1 tapered by 10 mg/day for 8
days. Prednisone at 48 mg on day 9 with 8 mg tapered until 4 mg/day by day 26 before
stopping at 3 months
Concomitant immunosuppression:
Methylprednisolone: 500 mg intraoperatively
Basiliximab: 20 mg perioperatively
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Tacrolimus: commenced on day 4 at 0.04 mg/kg/day aiming for trough levels of 8 to 12
ng/mL, tapered to 6 to 10 ng/mL by 3 months and 5 to 8 ng/mL by 6 months
Mycophenolate mofetil: as required
Sirolimus: as required
Outcomes Mortality, acute rejection, CMV infection, hypertension, hyperlipidaemia, hypergly-
caemia, infection
Notes Cross-over between intervention arms: no
Sample size calculation: not reported
Sources of funding: National High Technology Research and Development Program of
China, the Key Clinical Project from the Ministry of Health, National Natural Science
Foundation of China, special fund for science research by Ministry of Health, the China
Medical Board in New York, the Key Projects in the National Science & Technology
Pillar Program during the Eleventh Five-Year Plan Period of China and Science and
Technology Planning Project of Guangdong Province
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote from the publication: “After screen-
ing, 91 patients were randomized to re-
ceive standard immunosuppressive proto-
col (SP group) or 24-hour steroid avoid-
ance protocol (24-h SA group) according to
random sequence generated by SPSS soft-
ware (SPSS: An IBMCompany, version 13.
0, IBM Corporation, Armonk, New York,
USA).”
Comment: Randomisation achieve by
computer-generated random sequence
Allocation concealment (selection bias) Unclear risk Comment: Allocation concealment not de-
scribed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: Blinding of participants and
medical staff not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: Blinding of outcome assessors
not described
Incomplete outcome data (attrition bias) Unclear risk Quote from the publication: “Nine pa-
tients were excluded from the analysis ow-
ing to ABO blood type incompatibility (4/
9) and perioperative death (5/9). Among
the patients who died perioperatively, 3 pa-
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tients in the SP group died of acute heart
failure (1/5), renal failure (1/5), and mas-
sive intraperitoneal bleeding (1/5), and 2
patients in the 24-h SA group died of re-
nal failure (1/5) and primary allograft non-
function (1/5).”
Comment: The publication provides suffi-
cient information to allow participants ex-
cluded due to perioperative mortality to be
re-entered into the meta-analysis. Other-
wise, the number of withdrawals and rea-
sons for withdrawal not reported
Selective reporting (reporting bias) Low risk Comment: All outcomes appear to be fully
reported
Other bias Unclear risk Comment: No sample size calculation re-
ported
Free of early stopping? Low risk Comment: Study not stopped early
Free of baseline imbalance? Unclear risk Quote from the publication: “There was no
significant difference between the groups
when comparing the number of cases and
duration of MMF or sirolimus use postop-
eratively (Table 1).”
Comment: The publication reports that
there is no significant difference between
mycophenolate mofetil or sirolimus use be-
tween the groups both other baseline char-
acteristics are not reported
Lerut 2008
Methods Trial design: randomised, double-blinded, placebo-controlled, single-centre clinical trial
Mean follow-up: total: 48 months (range: 12 to 84 months)
Study duration: 5 years from randomisation
Language: English
Type of information: journal article
Judgement on quality: high risk of bias
Participants Setting: Université Catholique de Louvain Cliniques, Universitaires Saint-Luc, Brussels,
Belgium
Allocation of participants: 156 participants, 78 allocated to Intervention A, 78 allocated
to Intervention B
Sex ratio: total: 98 (62.8%) males, 58 (37.2%) females
Intervention A: 50 (64.1%) males, 28 (35.9%) females
Intervention B: 48 (61.5%) males, 30 (38.5%) females
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Mean age: total: not reported
Intervention A: 52.1 ± 13.0
Intervention B: 49.0 ± 12.7
Indication (no. (%)):
HCV cirrhosis: total: 35 (22.4%), Intervention A: 21 (26.9%), Intervention B: 14 (17.
9%)
Cholestatic disease: total: 18 (11.5%), Intervention A: 10 (12.8%), Intervention B: 8
(10.3%)
Vascular disease: total: 3 (1.9%), Intervention A: 3 (3.8%), Intervention B: 0 (0%)
Metabolic disease: total: 9 (5.8%), Intervention A: 2 (2.6%), Intervention B: 7 (9.0%)
Benign tumour: total: 9 (5.8%), Intervention A: 4 (5.1%), Intervention B: 5 (6.4%)
Hepatocellular carcinoma: total: 37 (23.7%), Intervention A: 19 (24.4%), Intervention
B: 18 (23.1%)
Fulminant failure: total: 22 (14.1%), Intervention A: 9 (11.5%), Intervention B: 13 (16.
7%)
Type of donor: living and deceased donors
Inclusion criteria: adult liver transplant recipient
Exclusion criteria: unfavourable oncological diagnosis, already included in another RCT
Other:
Ischaemia time: Intervention A: 603+/-231 minutes, Intervention B: 682+/-204 minutes
Artificial organ support: total: 11 (7.1%), Intervention A: 10 (12.8%), Intervention B:
1 (1.3%)
Right liver living liver transplantation: total: 9 (5.8%), Intervention A: 0 (0%), Inter-
vention B: 9 (11.5%)
Baseline imbalance: the intervention groups differ significantly in relation to ischaemia
time, living donor liver transplantation and artificial organ support
Interventions Intervention A: matched placebo
Intervention B: methylprednisolone started at 16 mg then tapered every 14 days by 4
mg from day 21 to stop at day 64
Concomitant immunosuppression:
Tacrolimus: aiming for trough level of 5 to 8 ng/mL
Hydrocortisone: 1000 mg intraoperatively
Outcomes Mortality, graft loss, acute rejection, glucocorticosteroid-resistant rejection, chronic re-
jection, infection, bacterial infection, viral infection, fungal infection, CMV infection,
bilirubin, ALT, GGT, post-transplant lymphoproliferative disorder (PTLD), renal insuf-
ficiency, diabetes mellitus, new-onset diabetes after transplantation (NODAT), hyper-
uricaemia, hypercholesterolaemia, hypertension, de novo hypertension, osseo-muscular
pain or fractures, cataract, Karnofsky index, recurrent hepatitis C, intrahepatic biliary
problems
Notes Cross-over between intervention arms: no
Sample size calculation: yes
Sources of funding: the Belgian FRSM, Astellas Pharma, Munchen, Germany
Risk of bias
Bias Authors’ judgement Support for judgement
56Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Lerut 2008 (Continued)
Random sequence generation (selection
bias)
Unclear risk Quote from the publication: “The patients
were randomized, 1:1 into our previously
used IS scheme consisting of TAC-lowdose
and short-term steroids (TAC-ST; n 78) or
into TAC-placebo (TAC-PL; n 78).”
Comment: Generation of randomisation
sequence not described
Allocation concealment (selection bias) Low risk Quote from the publication: “The random-
ization was done at the end of surgery us-
ing serially numbered, sealed, and opaque
envelopes.”
Comment: Adequate allocation conceal-
ment using sealed, opaque envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote from the publication: “Steroids
and placebos were administered in iden-
tical plastic containers containing a simi-
lar number of identical, opaque capsules.
Their number, corresponding to a reduc-
ing dose that covered a post-LT period of
64 days, was prepared by an independent
pharmacist.”
Quote from the publication: “All patients,
health care providers, and outcome asses-
sor teams were blinded until the 12-month
analysis was complete.”
Comment: Double-blinded trial, both par-
ticipants and medical staff blinded to treat-
ment. Adequate placebo using identical
opaque capsules
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote from the publication: “All patients,
health care providers, and outcome asses-
sor teams were blinded until the 12-month
analysis was complete.”
Comment: All outcome assessors including
pathologists blinded
Incomplete outcome data (attrition bias) Low risk Quote from the publication: “There were
no dropouts or withdrawals in either inter-
vention group.”
Quote from the 2014 publication: “Five-
year biopsy was done in 112 (89.6%) pa-
tients (Table 2). Twelve (9.6%) patients
with stable, normal liver tests refused a
biopsy (n = 11); once (0.8%) tissue mate-
rial was insufficient for analysis.”
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Nomissing outcome data, no withdrawals.
Data missing from participants refusing
liver biopsy in the five-year follow-up un-
likely to affect outcome results
Selective reporting (reporting bias) Low risk Comment: All outcomes appear to be fully
reported
Other bias High risk Quote from the publication: “This work
was supported by a grant from the Bel-
gian FRSM (3.4548.02). Astellas Pharma,
Munchen, Germany provided the random-
ization envelopes and an unrestricted grant,
which will be used to cover pharmacody-
namic and viral (HCV) monitoring, which
are not included in this report.”
Comment: Study is industry sponsored
Free of early stopping? Low risk Comment: Study not stopped early
Free of baseline imbalance? High risk Quote from the publication: “Technical
variants were not taken into account when
randomizing the patients because in our
center, results of elective living LT and split
LT are similar to those obtained after whole
LT. The need for artificial organ support
also was not considered for randomization,
as the placebo groupwould have a lower de-
gree of IS anyway. The randomization was
also independent of the presence of pos-
itive lymphocytotoxic cross-match and of
viral HBV or HCV infection. The charac-
teristics of the study population are sum-
marized inTable 1. The groups differed sig-
nificantly in relation to total ischemia time,
frequency of living donor LT, need for arti-
ficial (renal, hepatic, andpulmonary) organ
support, andmean creatinine values during
the first 14 post-LT days.”
Comment: Study not free from baseline
imbalance
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Methods Trial design: randomised, multicentre, open-label clinical trial
Mean follow-up: not reported
Study duration: randomisation between April 2001 and September 2004, 6 months
from randomisation (longer for HCV-positive patients)
Language: English
Type of information: journal article
Judgement on quality: high risk
Participants Setting: 7 transplantation centres in Spain
Allocation of participants: 198 participants, 102 allocated to Intervention A, 96 allocated
to Intervention B
Sex ratio: total: 155 (78.3%) males, 43 (21.7%) females
Intervention A: 80 (78.4%) males, 22 (21.6%) females
Intervention B: 75 (78.1%) males, 21 (21.9%) females
Mean age: total: not reported
Intervention A: 55.4 ± 8.9
Intervention B: 52.9 ± 9.5
Indication (no. (%)):
HCC: total: 63 (31.8%), Intervention A: 34 (33.3%), Intervention B: 29 (30.2%)
HCV cirrhosis: total: 46 (23.2%), Intervention A: 20 (19.6%), Intervention B: 26 (27.
1%)
HBV cirrhosis: total: 14 (7.1%), Intervention A: 8 (7.8%), Intervention B: 6 (6.3%)
Alcoholic cirrhosis: total: 55 (27.8%), Intervention A: 29 (28.4%), Intervention B: 26
(27.1%)
Other: total: 20 (10.1%), Intervention A: 11 (10.8%), Intervention B: 9 (9.4%)
Type of donor: deceased donor
Inclusion criteria: liver transplant recipients from cadaveric donors aged > 18
Exclusion criteria: exclusion criteria: transplant for fulminant liver disease, retransplant,
previous or concurrent other organ transplant, autoimmune hepatitis, primary biliary
cirrhosis, HIV infection, likely poor compliance
Other:
Disease status:
HCV-positive recipient: total: 88 (44.4%), Intervention A: 45 (44.1%), Intervention B:
43 (44.8%)
CMV-positive recipient: total: 165 (83.3%), Intervention A: 83 (81.3%), Intervention
B: 82 (85.4%)
Diabetes mellitus pretransplant: total: 49 (24.7%), Intervention A: 28 (27.5%), Inter-
vention B: 21 (21.9%)
Glycated haemoglobin pretransplant: total: not reported, Intervention A: 4.9 ± 1.5,
Intervention B: 4.6 ± 0.9
Hypertension pretransplant: total: 17 (8.6%), Intervention A: 11 (10.8%), Intervention
B: 6 (6.3%)
Serum cholesterol pretransplant: total: not reported, Intervention A: 3.8 ± 1.2, Inter-
vention B: 4.0 ± 1.3 (%)
Interventions Intervention A: no intervention
Intervention B: hydrocortisone: 500 mg intraoperatively, then 0.5 mg/kg/day for days 1
to 5, 0.25 mg/kg/day for days 6 to 30, 0.15 mg/kg/day for days 31 to 90, no intervention
from day 91
Concomitant immunosuppression:
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Basiliximab: 20 mg intraoperatively
Cyclosporine A: started at 10 mg/kg/day aiming for trough levels of 800 ng/mL to 1200
ng/mL
Outcomes Mortality, graft loss, acute rejection, glucocorticosteroid-resistant rejection, chronic re-
jection, adverse events, infections, bacterial infection, viral infection, fungal infection,
CMV infection, HSV infection, metabolic decompensations, diabetes mellitus, hyper-
tension, recurrent hepatitis C, treatment failure, renal failure, neurological deficit, gin-
gival hypertrophy, de novo malignancy, cholesterol, triglyceride, days until rejection
Notes Cross-over between intervention arms: no
Sample size calculation: yes
Sources of funding: Novartis Pharma, TV3 Marathon Foundation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: Generation of randomisation
sequence not described
Allocation concealment (selection bias) Unclear risk Comment: Allocation concealment not de-
scribed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote from the publication: “The trial
was an open-label, not-blinded, prospec-
tive, randomized study.”
Comment: Blinding of participants and
medical staff not performed
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote from the publication: “The trial
was an open-label, not-blinded, prospec-
tive, randomized study.”
Comment: Blinding of outcome assessors
not performed
Incomplete outcome data (attrition bias) Unclear risk Quote from the publication: “Two patients
were exclude from the study after random-
ization because of protocol violations.”
Comment: The protocol violations are not
described and the groups to which these
patients were randomised is not described.
Otherwise, the number of withdrawals and
reasons for withdrawal not reported
Selective reporting (reporting bias) Low risk Comment: All outcomes appear to be fully
reported
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Other bias High risk Quote from the publication: “The authors
who have taken part in this study have de-
clared a relationship with the manufactur-
ers of the drugs involved and they received
funding from the drug companies involved
to carry out their research.”
Quote from the publication: “We are
grateful to Infociencia Clinical Research
for monitoring the study, and especially
thankCati Bonet for the statistical analysis.
This research was supported by Novartis
Pharma, and by the TV3 Marathon Foun-
dation.”
Comment: Study is partly industry spon-
sored
Free of early stopping? Low risk Comment: Study not stopped early
Free of baseline imbalance? Low risk Quote from the publication: “Patient de-
mographics and baseline characteristics
were similar between groups (Table 1). It
should be noted that 45% of patients were
HCV-positive. Main operative and initial
post-operative evolution was also similar
between groups (Table 2)”
Comment: Study free from baseline imbal-
ance
Margarit 2005
Methods Trial design: randomised, single-centre clinical trial
Mean follow-up: 44 months (range: 3 to 60)
Study duration: randomisation from October 1998 to September 2000, 5 years from
randomisation
Language: English
Type of information: journal article
Judgement on quality: high risk
Participants Setting: Liver Transplantation Unit, Hospital General Vall Hebron, Barcelona, Spain
Allocation of participants: 63 participants, 33 allocated to Intervention A, 30 allocated
to Intervention B
Sex ratio: total: 43 (71.7%) males, 17 (28.3%) females
Intervention A: 25 (78.1%) males, 7 (21.9%) females
Intervention B: 18 (64.3%) males, 10 (35.7%) females
Mean age: total: not reported
Intervention A: 56 ± 8
Intervention B: 57 ± 7
Indication (no. (%)):
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HCV cirrhosis: total: 35 (58.3%), Intervention A: 15 (46.9%), Intervention B: 20 (71.
4%)
Alcoholic cirrhosis: total: 16 (26.7%), Intervention A: 11 (34.4%), Intervention B: 5
(17.9%)
HBV cirrhosis: total: 5 (8.3%), Intervention A: 2 (6.3%), Intervention B: 3 (10.7%)
Cryptogenic cirrhosis: total: 2 (3.3%), Intervention A: 2 (6.3%), Intervention B: 0 (0%)
Haemochromatosis: total: 2 (3.3%), Intervention A: 2 (6.3%), Intervention B: 0 (0%)
Type of donor: not reported
Inclusion criteria: first elective liver transplant, informed consent
Exclusion criteria: renal failure, preoperative steroid consumption
Interventions Intervention A: no intervention
Intervention B: methylprednisolone: 100 mg twice daily tapered to 20 mg/day by day 6
and tapered to complete stop at 3 months if possible
Concomitant immunosuppression:
Tacrolimus: 0.05 mg/kg twice daily aiming for trough levels of 10 to 15 ng/mL for “a
few weeks” and 8 to 12 ng/mL thereafter
Outcomes Mortality, infection, bacterial infection, viral infection, fungal infection, toxicity, HCV
recurrence, severity of recurrent hepatitis C, renal insufficiency, de novo hypertension,
de novo diabetes mellitus, dyslipidaemia, neurological complications, diarrhoea
Notes Cross-over between intervention arms: no
Sample size calculation: not reported
Sources of funding: Fujisawa GM
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: Generation of randomisation
sequence not described
Allocation concealment (selection bias) Low risk Quote from email correspondence with au-
thor (Bilbao, I) in response to the ques-
tion “How was the randomisations se-
quence generated?”: “68 closed envelopes
numbered 1 to 68 respectively, were pre-
pared before starting the trial. The en-
velopes were opened consequently when
the surgery started.”
Comment: Sealed, opaque envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: Blinding of participants and
medical staff not performed
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Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote from email correspondence with au-
thor (Bilbao, I) in response to question
“Were the outcome assessors blinded to the
patient’s treatment?”: “NO”
Quote from email correspondence with au-
thor (Bilbao, I) in response to question
“Were the pathologists confirming rejec-
tion blinded to the patient’s treatment?”:
“YES”
Comment: Blinding of pathologists per-
formed; blinding of all other outcome as-
sessors not performed
Incomplete outcome data (attrition bias) Unclear risk Quote from the publication: “Three pa-
tients were excluded after randomization
because of perioperative death (n = 2) and
positive cross-match (n = 1).”
Quote from email correspondence with au-
thor (Bilbao, I) in response to question “Of
the three patients who died after random-
ization, had any of the patients begun treat-
ment? If this is the case which group were
the two deaths part of and which was the
patient with the positive cross-match part
of?”: “One death belonged to Tacro group
and the other to the Tacro + Prednisone.
The patient with positive crossmatch be-
longed to Tacro group. The death in Tacro
group did not begin treatment because in-
traoperative problems and at the end of the
surgery received standard immunosuppres-
sion at that time (Tacro + steroids). The one
in Tacro + steroids died at 3 rd day post-
op and began treatment. The patient with
positive crossmatch began treatment for 36
hours, but then was changed to standard
triple therapy”
Comment: Three participants removed
from analysis following randomisation fol-
lowing data-dependent processes not de-
scribed in exclusion criteria. It was possible
to incorporate some of the data on mortal-
ity from these participants based on email
correspondence with the author. Other-
wise, the number of withdrawals and rea-
sons for withdrawal were not reported
Selective reporting (reporting bias) Low risk Comment: All outcomes appear to have
been reported
63Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Margarit 2005 (Continued)
Other bias Unclear risk Comment: No sample size calculation re-
ported
Free of early stopping? Low risk Comment: Study not stopped early
Free of baseline imbalance? High risk Quote from the publication: “No dif-
ferences were found between treatment
groups except for a higher incidence of graft
steatosis in TACRO + ST and of HCV-
positive patients in the TACRO group. Pri-
mary graft dysfunction secondary to is-
chaemic-reperfusion injury that could af-
fect tacrolimus metabolism and pharma-
cokinetic parameters was similar in both
groups.”
Comment: Baseline imbalance observed in
recipient HCV cirrhosis and donor graft
steatosis
Moench 2007
Methods Trial design: randomised, double-blinded, placebo-controlled, single-centre clinical trial
Mean follow-up: not reported as all patients followed up at 5 years, except deaths
Study duration: 5 years from randomisation, randomisation from February 2000 to July
2004
Language: English
Type of information: journal article
Judgement on quality: high risk
Participants Setting: Johannes Gutenberg University Mainz Hospital, Langenbeckstrasse 1, Mainz,
Germany
Allocation of participants: 110 participants, 54 allocated to Intervention A, 56 allocated
to Intervention B
Sex ratio: total: 74 (67.3%) males, 36 (32.7%) females
Intervention A: 36 (66.7%) males, 18 (33.3%) females
Intervention B: 38 (67.9%) males, 18 (32.1%) females
Mean age: total: not reported
Intervention A: 53.5 ± 8.3
Intervention B: 53.6 ± 10.4
Indication (no. (%)):
Hepatocellular carcinoma: total: 40 (36.4%), Intervention A: 19 (35.2%), Intervention
B: 21 (37.5%)
HBV cirrhosis: total: 19 (17.3%), Intervention A: 7 (13.0%), Intervention B: 12 (21.
4%)
HCV cirrhosis: total: 31 (28.2%), Intervention A: 15 (27.8%), Intervention B: 16 (28.
6%)
Alcoholic cirrhosis: total: 37 (33.6%), Intervention A: 21 (38.9%), Intervention B: 16
(28.6%)
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Primary biliary cirrhosis or primary sclerosing cholangitis: total: 8 (7.3%), Intervention
A: 5 (9.3%), Intervention B: 3 (5.4%)
Type of donor: deceased donor after brain death (DBD) or living-related donor
Inclusion criteria: orthotopic liver transplant recipients aged > 18 receiving transplant
for any indication, recipients of whole or partial liver grafts from brain dead donors as
well as living-related donors, oral informed consent
Exclusion criteria: previous organ transplants including liver retransplantation; initial,
sequential or parallel therapy with other immunosuppressive drugs besides the study
protocol; corticosteroid therapy within 6 months before transplantation; HIV infection;
pregnancy and breast feeding; allergy to or intolerance of study medication; participation
in another clinical study
Other:
Partial graft: total: 6 (5.5%), Intervention A: 3 (5.6%), Intervention B: 3 (5.4%)
Deceased donor: total: 100 (90.9%), Intervention A: 50 (92.6%), Intervention B: 50
(89.3%)
Living donor: total: 10 (9.1%), Intervention A: 4 (7.4%), Intervention B: 6 (10.7%)
Interventions Intervention A: matched placebo
Intervention B: methylprednisolone: 12 mg/day from day 15 to 60, 8 mg/day from day
61 to 180 then tapered to stop over 2 weeks
Concomitant immunosuppression:
Tacrolimus: initial dose of 0.01 mg/kg/day with target trough levels 10 to 15 ng/mL for
days 0 to 42 and 5 ng/mL to 10 ng/mL thereafter
Methylprednisolone: 1000 mg before reperfusion, 100 mg on day 1, 75 mg on day 2,
48 mg on day 3 and 4, 36 mg on day 5 and 6, 24 mg on day 7 and 8, 16 mg on days 9
to 13 and 12 mg on day 14
Outcomes Mortality, graft loss, acute rejection, time to first rejection, severity of rejection, recurrent
acute rejection, glucocorticosteroid-resistant rejection, chronic rejection, hypertension,
diabetes mellitus, infection, CMV infection, post-transplant lymphoproliferative dis-
order, hypercholesterolaemia, hypertriglyceridaemia, osteoporosis, cholesterol, triglyc-
eride, creatinine, HDL cholesterol, LDL cholesterol, fasting blood glucose, neurological
toxicity, abnormal liver function, abnormal renal function
Notes Cross-over between intervention arms: no
Sample size calculation: yes
Sources of funding: Astellas Pharma Munich, Germany
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: Generation of randomisation
sequence not described
Allocation concealment (selection bias) Low risk Quote from the publication: ”Patient care
and study conduct complied with good
clinical practice.1:1 randomization was
performed by a blinded randomization list
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generated by the Biomathematical Institute
prior to transplantation in eligible patients
(Figure 1).“
Comment: Allocation concealment not
fully described, however, the publication
describes the randomisation sequence as
”blinded“ in addition to the blinding or
participants and outcome assessors de-
scribed elsewhere
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote from the publication: ”This was a
12-month, prospective, randomized, dou-
ble-blinded, placebo-controlled investiga-
tor driven, monocenter trial comparing
early FK506 monotherapy with FK506
plus steroids.“
Quote from the publication: ”After day 14,
patients received study medication, either
placebo or methylprednisolon capsules in a
double-blinded way. Study medication was
manufactured, packed and blinded by the
PharmacyDepartment of Johannes Guten-
berg University Hospital.“
Quote from the publication: ” Patients who
experienced three ormore episodes of acute
rejection during the follow-up were ex-
cluded from the trial, unblinded and re-
ceived individualized immunosuppressive
therapy
Comment: Double-blinded trial, both par-
ticipants and medical staff blinded to treat-
ment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: Blinding of pathologists not de-
scribed
Incomplete outcome data (attrition bias) Low risk Quote from the publication: “The number
of patients completing the follow-up were
35 (66.7%) in the steroid group and36 (62.
5%) in the placebo group (p = 0.801, chi-
square). Reasons for withdrawal from the
trial were death (n = 14, 12.7%), recurrent
rejection (n = 11, 10.0%), severe adverse
events (n = 10, 9.1%) and secondary refusal
to informed consent (n = 1, 0.9%).”
Quote from the publication: “Fourteen
(12.7%) patients died during follow-up, 6
(11.1%) in the steroid group and 8 (14.
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3%) in the placebo group (p = 0.617, chi-
square). At month 6, 46 patients were still
in the steroid and the placebo group. Eight
patients were withdrawn from the steroid
group and 10 patients were withdrawn
from the placebo group during the first 6
months. Atmonth 12, 35 patients were still
in the steroid group and 36 patients were
still in the placebo group. Eleven patients
were withdrawn from the steroid group
and 10 patients were withdrawn from the
placebo groupduringmonth 6untilmonth
12.”
Comment: The numbers and reasons for
dropouts are adequately described
Selective reporting (reporting bias) Low risk Comment: All outcomes appear to be fully
reported
Other bias High risk Quote from the publication: “The study
was supported by Astellas PharmaMunich,
Germany.”
Comment: Study is industry sponsored
Free of early stopping? Low risk Comment: Study not stopped early
Free of baseline imbalance? Low risk Quote from the publication: “Patientsde-
mographicsandbaselinecharacteristics were
comparable in both groups and are demon-
strated in Table 1.”
Comment: Study free from baseline imbal-
ance
Pageaux 2004
Methods Trial design: randomised, multicentre, double-blinded, placebo-controlled clinical trial
Mean follow-up: not reported
Study duration: 1 year from randomisation, randomisation from December 1999 to
August 2001
Language: English
Type of information: journal article
Judgement on quality: high risk
Participants Setting: 7 transplantation centres in France
Allocation of participants: 174 participants, 90 allocated to Intervention A, 84 allocated
to Intervention B
Sex ratio: total: 124 (71.3%) males, 50 (28.7%) females
Intervention A: 68 (75.6%) males, 22 (24.4%) females
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Intervention B: 56 (66.7%) males, 28 (33.3%) females
Mean age: total: not reported
Intervention A: 52 ± 10.4
Intervention B: 52.7 ± 8.8
Indication (no. (%)):
Alcoholic cirrhosis: total: 84 (48.3%), Intervention A: 45 (50.0%), Intervention B: 39
(46.4%)
HCV cirrhosis: total: 26 (14.9%), Intervention A: 12 (13.3%), Intervention B: 14 (16.
7%)
HBV cirrhosis: total: 12 (6.9%), Intervention A: 8 (8.9%), Intervention B: 4 (4.8%)
Primary biliary cirrhosis: total: 11 (6.3%), Intervention A: 6 (6.7%), Intervention B: 5
(6.0%)
Hepatocellular carcinoma: total: 11 (6.3%), Intervention A: 5 (5.6%), Intervention B:
6 (7.1%)
Primary sclerosing cholangitis: total: 4 (2.3%), Intervention A: 1 (1.1%), Intervention
B: 3 (3.6%)
Other: total: 26 (14.9%), Intervention A: 13 (14.4%), Intervention B: 13 (15.5%)
Type of donor: deceased donor
Inclusion criteria: adult liver transplant recipients undergoing first cadaveric liver trans-
plant
Exclusion criteria: primary graft dysfunction, early retransplantation (before randomisa-
tion), renal insufficiency (creatinine > 200 ìmol/L), uncontrolled infection, multiorgan
failure, cardiac arrest and presence of adenocarcinoma
Interventions Intervention A: equivalent placebo
Intervention B: prednisone: started on day 8 (dose and duration not reported)
Concomitant immunosuppression:
Basiliximab: 20 mg on day 0 and day 4
Cyclosporine A: started within 24 hours of transplant aiming for trough levels of 200
ng/mL to 400 ng/mL from day 0 to 3 months and tapered to 150 ng/mL to 300 ng/mL
Methylprednisolone: 500 mg intraoperatively, 200 mg on day 1, which was tapered to
reach 20 mg on day 7
Outcomes Mortality, graft loss, acute rejection, diabetes mellitus, recurrent hepatitis C, multiorgan
failure, sepsis, intraabdominal haemorrhage, unsatisfactory therapeutic effect, hypertri-
chosis, surgical complications, renal failure, adverse events, CMV infection, CMV dis-
ease, infections, de novo malignancy, neurological complications, psychiatric complica-
tions, gastrointestinal disorders
Notes Cross-over between intervention arms: no
Sample size calculation: not reported
Sources of funding: Novartis Pharma
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: Generation of randomisation
sequence not described
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Allocation concealment (selection bias) Unclear risk Comment: Allocation concealment not de-
scribed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote from the publication: “A prospec-
tive, 1-year, comparative, double-blind,
placebo-controlled study, with informed
consent and institutional review board ap-
proval, was conducted in 15 French liver
transplantation centers.”
Comment: Double-blinded trial, both par-
ticipants and medical staff blinded to treat-
ment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: All outcome assessors including
pathologists blinded
Incomplete outcome data (attrition bias) Unclear risk Comment: Number of withdrawals and
reasons for withdrawal not reported
Selective reporting (reporting bias) Low risk Comment: All outcomes appear to be fully
reported
Other bias High risk Quote from the publication: “Supported
by a grant from Novartis Pharma.”
Comment: Study is industry sponsored
Free of early stopping? Low risk Comment: Study not stopped early
Free of baseline imbalance? Low risk Quote from the publication: “There were
no differences between the 2 groups con-
cerning clinical characteristics and indica-
tions for transplantation (Table1). Inde-
pendently of the diagnoses, 17 patients in
each group had a positive hepatitis C virus
serology.The 2 groupswere similar in terms
of Child-Turcotte-Pugh score, with a ma-
jority in stage C (40% in group 1 and 50%
in group 2). After transplantation, the cy-
closporine blood trough levels and the daily
doses of corticosteroids / placebo were sim-
ilar in the 2 groups (Table 2).”
Comment: Study is free from baseline im-
balance
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Methods Trial design: randomised, single-centre, open-label clinical trial
Mean follow-up: 2095 days ± 117
Study duration: 7 years, randomisation from June 2002 to May 2005
Language: English
Type of information: journal article
Judgement on quality: high risk
Participants Setting: Section of Transplant Surgery, University of Michigan, Michigan, USA
Allocation of participants: 100 participants, 50 allocated to Intervention A, 50 allocated
to Intervention B
Sex ratio: total: 76 (76%) males, 24 (24%) females
Intervention A: 38 (76%) males, 12 (24%) females
Intervention B: 38 (76%) males, 12 (24%) females
Mean age: total: not reported
Intervention A: 54 ± 1
Intervention B: 56 ± 1
Indication (no. (%)): (some patients reported as having multiple indications)
HCV cirrhosis: total: 54 (54%), Intervention A: 31 (62%), Intervention B: 23 (46%)
Alcoholic cirrhosis: total: 42 (42%), Intervention A: 19 (38%), Intervention B: 23 (46%)
Hepatocellular carcinoma: total: 20 (20%), Intervention A: 9 (18%), Intervention B: 11
(22%)
Primary biliary cirrhosis or primary sclerosing cholangitis: total: 6 (6%), Intervention
A: 1 (2%), Intervention B: 5 (10%)
Cryptogenic cirrhosis: total: 15 (15%), InterventionA: 8 (16%), InterventionB: 7 (14%)
Type of donor: not reported
Inclusion criteria: all consecutive, consenting participants undergoing liver transplanta-
tion at the University of Michigan between June 2002 and May 2005
Exclusion criteria: participants aged < 18 years, multiple organ recipients and participants
who required post-transplant steroid therapy for an indication other than prevention of
rejection, such as autoimmune hepatitis or inflammatory bowel disease
Other:
BMI (kg/m2): total: not reported, Intervention A: 30 ± 1, Intervention B: 29 ± 1
Pretransplant antihypertensive: total: 73 (73%), Intervention A: 36 (72%), Intervention
B: 37 (74%)
Pretransplant diabetes mellitus: total: 32 (32%), Intervention A: 20 (40%), Intervention
B: 12 (24%)
Pretransplant coronary artery disease: total: 8 (8%), Intervention A: 5 (10%), Interven-
tion B: 3 (6%)
Pretransplant haemodialysis: total: 4 (4%), Intervention A: 3 (6%), Intervention B: 1
(2%)
MELD score: total: not reported, Intervention A: 16 ± 1, Intervention B: 18 ± 1
Warm ischaemia time (minutes): total: not reported, Intervention A: 64 ± 7, Intervention
B: 54 ± 3
Cold ischaemia time (minutes): total: not reported, Intervention A: 518 ± 34, Interven-
tion B: 518 ± 24
Donor age: total: Intervention A: 38 ± 3, Intervention B: 37 ± 2
Donor sex ratio: total: 68 (68%) males, 32 (32%) females; Intervention A: 31 (62%)
males, 19 (38%) females; Intervention B: 37 (74%) males, 13 (26%) females
Donor ethnicity: total: 80 (80%) white, 20 (20%) non-white; Intervention A: 39 (78%)
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white, 11 (22%) non-white; Intervention B: 41 (82%) white, 9 (18%) non-white
Donor death from stroke: total: 50 (50%), Intervention A: 25 (50%), Intervention B:
25 (50%)
Donor CMV positive: total: 67 (67%), Intervention A: 35 (70%), Intervention B: 32
(64%)
Interventions Intervention A: no intervention
Intervention B:
Dexamethasone: 50 mg intraoperatively
Prednisone: 3- to 6-month taper (dose not reported)
Concomitant immunosuppression:
Tacrolimus: started within 24 hours aiming for trough levels of 10 ng/mL to 15 ng/mL
for days 0 to 30, 8 ng//mL to 12 ng/mL days 31 to 60, 4 ng/mL to 8 ng/mL from day
61 (tacrolimus withheld until day 4 in patients who received basiliximab induction)
MMF: dose and timings not reported
Basiliximab: intraoperatively and day 4 (dose not reported) given to 12 (24%) patients
receiving Intervention A and 13 (26%) patients receiving Intervention B
Outcomes Mortality, graft loss, acute rejection, time to first rejection, chronic rejection, recurrent
hepatitis C, primary non-function, hepatic artery thrombosis, hepatic vein or IVC steno-
sis, biliary complications, postoperative acute renal failure, postoperative chronic renal
failure, duration of high dependency stay, reoperation for bleeding, retransplantation,
infections, surgical site infection, pneumonia, urinary tract infection, septicaemia, peri-
tonitis, BMI, cholesterol, HDL, LDL, triglycerides, creatinine, diabetes mellitus, hyper-
tension
Notes Cross-over between intervention arms: no
Sample size calculation: not reported
Sources of funding: Astellas Pharma Inc.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: Generation of randomisation
sequence not described
Allocation concealment (selection bias) Low risk Quote from the publication: “Enrolledcan-
didateswererandomizedtoeither
the ‘steroids’ or ‘no-steroids’ groups using a
closed-envelope system.”
Comment: Study used “closed envelope
system”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote from the publication: “All con-
secutive, consenting candidates undergo-
ing liver transplantation at the Univer-
sity of Michigan between June 2002 and
May 2005 were enrolled into a prospec-
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tive, open-label, randomized controlled
trial (RCT) to evaluate the effects of com-
plete steroids avoidance.”
Comment: Blinding of participants and
medical staff not performed
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote from the publication: “All con-
secutive, consenting candidates undergo-
ing liver transplantation at the Univer-
sity of Michigan between June 2002 and
May 2005 were enrolled into a prospec-
tive, open-label, randomized controlled
trial (RCT) to evaluate the effects of com-
plete steroids avoidance.”
Comment: Blinding of outcome assessors
not performed
Incomplete outcome data (attrition bias) Unclear risk Comment: Number of withdrawals and
reasons for withdrawal not reported
Selective reporting (reporting bias) Low risk Comment: All outcomes appear to be fully
reported
Other bias High risk Quote from the publication: “This study
was supported by a grant from Astellas
Pharma, Inc., Deerfield, IL, USA.”
Comment: No sample size calculation re-
ported, study is industry sponsored
Free of early stopping? Low risk Comment: Study not stopped early
Free of baseline imbalance? Low risk Quote from the publication: “Donor and
recipient characteristics are summarized in
Table 1. The two groups of recipients were
well matched with respect to gender, age,
race, cause of liver failure, comorbidities,
Model of End-stage Liver Disease (MELD)
score, renal function and ischaemic times.
”
Comment: Study is free from baseline im-
balance
72Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ramirez 2013
Methods Trial design: randomised, single-centre, open-label clinical trial
Mean follow-up: 64.4 months (range: 10.6 to 79.6)
Study duration: randomisation from February 2006 and November 2007
Language: English
Type of information: journal article
Judgement on quality: high risk
Participants Setting: Division of Transplantation, Department of Surgery, Thomas Jefferson Univer-
sity, Philadelphia, USA
Allocation of participants: 40 participants, 20 allocated to Intervention A, 20 allocated
to Intervention B
Sex ratio: total: 25 (62.5%) males, 15 (37.5%) females
Intervention A: 12 (60%) males, 8 (40%) females
Intervention B: 13 (65%) males, 7 (35%) females
Mean age: total: not reported
Intervention A: 48.1 ± 4.3
Intervention B: 45.5 ± 3.5
Indication (no. (%)):
HCV cirrhosis: total: 25 (62.5%), Intervention A: 11 (55.0%), Intervention B: 14 (70.
0%)
HBV cirrhosis: total: 4 (10.0%), Intervention A: 2 (10.0%), Intervention B: 2 (10.0%)
Primary sclerosing cholangitis: total: 2 (5.0%), Intervention A: 2 (10.0%), Intervention
B: 0 (0%)
Hepatocellular carcinoma: total: 21 (52.5%), Intervention A: 10 (50.0%), Intervention
B: 11 (55.0%)
Alcoholic cirrhosis: total: 9 (22.5%), Intervention A: 3 (15.0%), Intervention B: 6 (30.
0%)
Non-alcoholic steatohepatitis: total: 1 (2.5%), Intervention A: 1 (5.0%), Intervention
B: 0 (0%)
Budd-Chiari syndrome: total: 1 (2.5%), Intervention A: 0 (0%), Intervention B: 1 (5.
0%)
Cryptogenic cirrhosis: total: 3 (7.5%), Intervention A: 2 (10.0%), Intervention B: 1 (5.
0%)
Type of donor: deceased donors
Inclusion criteria: first adult liver transplant, age 18 to 72, cold ischaemic time < 20
hours
Exclusion criteria: positive pregnancy test, previous organ transplant, multiple organ
transplant recipients, women of childbearing potential not using the prescribed contra-
ceptive methods, known sensitivity to basiliximab or class of basiliximab, participants
with severe medical condition(s) that in the view of the investigator prohibits partici-
pation in the study, and use of any other investigational agent within 30 days prior to
enrolment
Other:
Pretransplant MELD: total: not reported, Intervention A: 23.2 ± 1.5, Intervention B:
24.4 ± 2.0
Interventions Intervention A: no intervention
Intervention B: methylprednisolone: 1000 mg intraoperatively, then tapered to 50 mg
6-hourly on day 1, 40 mg 6-hourly on day 2, 30 mg 6-hourly on day 3, 20 mg 6-hourly
on day 4, 20 mg 12-hourly on day 5 and then 20 mg once daily, tapered until stop at 6
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months
Concomitant immunosuppression:
Tacrolimus: started at 0.1 mg/kg aiming for 8 ng/mL to 12 ng/mL for 1 month and
then 5 ng/mL to 8 ng/mL thereafter
Mycophenolate mofetil: 1000 mg every 12 hours via nasogastric tube until tolerating
oral medication after which 720 mg enteric-coated mycophenolate sodium twice daily
orally for 3 months
Basiliximab: 20 mg intraoperatively and on day 4
Prophylaxis:
Ganciclovir or valganciclovir: 450 mg once daily for at least 3 months
Trimethoprim sulfa: 3 times per week, dose and duration not reported
Nystatin swish and swallow: 3 times daily, dose and duration not reported
Outcomes Mortality, graft loss, acute rejection, infection, CMV infection, recurrent hepatitis C,
severity of HCV recurrence, diabetes mellitus, hypertension, weight, cholesterol, mean
arterial pressure, fasting blood glucose, ALT, AST, bilirubin
Notes Cross-over between intervention arms: no
Sample size calculation: not reported
Sources of funding: Novartis Corporation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote from the publication: “Randomiza-
tion was performed by the TJUH Investi-
gational Drug Pharmacy Service who dis-
pensed study drug based on the computer-
generated randomization schedule and the
study protocol.”
Comment: Computer-generated randomi-
sation
Allocation concealment (selection bias) Unclear risk Comment: Allocation concealment not de-
scribed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote from the publication: “Between
February 2006 and November 2007, 40
adult recipients of deceased donor primary
OLT at TJUH were enrolled into this
prospective, controlled, randomized, non-
blinded, pilot trial (Clinical Trials.gov; ID:
NCT00296244).”
Comment: Blinding of participants and
medical staff not performed
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Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote from the publication: “Between
February 2006 and November 2007, 40
adult recipients of deceased donor primary
OLT at TJUH were enrolled into this
prospective, controlled, randomized, non-
blinded, pilot trial (Clinical Trials.gov; ID:
NCT00296244).”
Comment: Blinding of outcome assessors
not performed
Incomplete outcome data (attrition bias) Low risk Quote from the publication: “Between
February 2006 and November 2007, 40
adult OLT recipients were enrolled in the
study and 20 recipients were randomized
to each group. One recipient in the CS-
free group required a retransplantation for
hepatic artery thrombosis onpost-OLTday
16. Because he expired within 10 d after re-
transplantation, follow-up data were short
and untenable, and therefore, he was ex-
cluded from the study analysis (Fig. 1).”
Comment: One withdrawal and reason for
the withdrawal adequately described
Selective reporting (reporting bias) Low risk Comment: All outcomes appear to be fully
reported
Other bias High risk Quote from the publication: “The authors
would like to acknowledge Novartis Cor-
poration for providing financial grant to
conduct the clinical trial.”
Comment: No sample size calculation re-
ported; study is industry sponsored
Free of early stopping? Low risk Comment: Study not stopped early
Free of baseline imbalance? Low risk Quote from the publication: “Donor char-
acteristics were comparable between the
two groups (Table 1). Other than a sig-
nificantly higher mean recipient age and
longer median hospital stay in CS-free (23
d) compared with CS group (15 d), recip-
ient demographics and peri-operative data
were similar between the two groups.”
Comment: Baseline imbalance is unlikely
to significantly affect outcomes
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Methods Trial design: randomised, single-centre, open-label clinical trial
Mean follow-up: 31 ± 7 months
Study duration: not reported
Language: English
Type of information: journal article
Judgement on quality: high risk
Participants Setting: IRCCS Ospedale Maggiore, Milan, Italy
Allocation of participants: 30 participants, 18 allocated to Intervention A, 12 allocated
to Intervention B
Sex ratio: total: 21 (70%) males, 9 (30%) females
Intervention A: 13 (72.2%) males, 5 (27.8%) females
Intervention B: 8 (66.7%) males, 4 (33.3%) females
Mean age: total: not reported
Intervention A: 50.4 ± 8.9
Intervention B: 49.7 ± 4.6
Indication (no. (%)):
HCV or HBV cirrhosis: total: 21 (70.0%), Intervention A: 14 (77.8%), Intervention B:
7 (58.3%)
Alcoholic cirrhosis: total: 3 (10.0%), Intervention A: 1 (5.6%), Intervention B: 2 (16.
7%)
Haemochromatosis: total: 2 (6.7%), Intervention A: 1 (5.6%), Intervention B: 1 (8.3%)
Primary biliary cirrhosis: total: 1 (3.3%), Intervention A: 1 (5.6%), Intervention B: 0
(0.0%)
Acute liver failure: total: 1 (3.3%), Intervention A: 1 (5.6%), Intervention B: 0 (0.0%)
Cryptogenic cirrhosis: total: 1 (3.3%), Intervention A: 0 (0.0%), Intervention B: 1 (8.
3%)
Polycystic liver disease: total: 1 (3.3%), Intervention A: 0 (0.0%), Intervention B: 1 (8.
3%)
Type of donor: not reported
Inclusion criteria: not reported
Exclusion criteria: not reported
Other:
Hepatocellular carcinoma: total: 14 (46.7%), Intervention A: 12 (66.7%), Intervention
B: 2 (16.7%)
Interventions Intervention A: methylprednisolone: no intervention
Intervention B: 1000 mg intraoperatively then 200 mg/day tapered to 40 mg/day at day
5, 20 mg on day 6 then tapered to stop at 3 months
Concomitant immunosuppression:
Tacrolimus: started at 0.1 mg/kg aiming for trough levels of 10 ng/mL to 15 ng/mL for
2 weeks then 8 ng/mL to 10 ng/mL thereafter
Mycophenolate mofetil: 750 mg twice daily for 1 month, 500 mg twice daily thereafter
Outcomes Mortality, surgical complications, tacrolimus levels, MMF levels, acute rejection, graft
loss, infections, diarrhoea, “peptic symptoms”, impaired renal function, leukopenia,
thrombocytopenia, anaemia, neurotoxicity, diabetes mellitus, hypertension
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Notes Cross-over between intervention arms: no
Sample size calculation: not reported
Sources of funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: Generation of randomisation
sequence not described
Allocation concealment (selection bias) Unclear risk Comment: Allocation concealment not de-
scribed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote from the publication: “To assess
the efficacy and safety or a primary im-
munosuppressive regimen with tacrolimus
(Tac) and low-dose mycophenolate mofetil
(MMF) without steroids and to determine
the exposure to mycophenolic acid (MPA)
in the early post-operative period, we per-
formed a single-center, randomized 1:1,
open-label, controlled study planned to be
60 liver transplantation patients random-
ized into 2 groups: group A, tacrolimus +
MMF (750 mg orally twice a day); and
groupB, tacrolimus +MMF(750mgorally
twice a day) + steroids.”
Comment: Blinding of participants and
medical staff not performed
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote from the publication: “To assess
the efficacy and safety or a primary im-
munosuppressive regimen with tacrolimus
(Tac) and low-dose mycophenolate mofetil
(MMF) without steroids and to determine
the exposure to mycophenolic acid (MPA)
in the early post-operative period, we per-
formed a single-center, randomized 1:1,
open-label, controlled study planned to be
60 liver transplantation patients random-
ized into 2 groups: group A, tacrolimus +
MMF (750 mg orally twice a day); and
groupB, tacrolimus +MMF(750mgorally
twice a day) + steroids.”
Comment: Blinding of outcome assessors
not performed
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Incomplete outcome data (attrition bias) Unclear risk Comment: Number of withdrawals and
reasons for withdrawal not reported
Selective reporting (reporting bias) Low risk Comment: All specified outcomes appear
to be reported
Other bias Unclear risk Comment: No sample size calculation re-
ported
Free of early stopping? High risk Quote from the publication: “Patient en-
rollment was stopped after an interim anal-
ysis by the Ethical Committee.”
Comment: Study stopped early due to data
dependent process (interim analysis)
Free of baseline imbalance? High risk Quote from the publication: “Hepatocellu-
lar carcinoma was diagnosed in 2 (16.7%)
patients in group A and in 12 (66.7%) pa-
tients in group B.”
Comment: Significantly increased rates of
pretransplant hepatocellular carcinoma in
Intervention B
Studenik 2005
Methods Trial design: randomised, single-centre clinical trial
Mean follow-up: 13 months (range: 2 to 23)
Study duration: not reported
Language: English
Type of information: abstract
Judgement on quality: unclear risk
Participants Setting: Brno, Czech Republic
Allocation of participants: 39 participants, 19 allocated to Intervention A, 20 allocated
to Intervention B
Sex ratio: total: not reported
Intervention A: not reported
Intervention B: not reported
Mean age: total: not reported
Intervention A: not reported
Intervention B: not reported
Indication (no. (%)): not reported
Type of donor: not reported
Inclusion criteria: not reported
Exclusion criteria: not reported
Other: baseline characteristics reported as comparable
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Interventions Intervention A: no intervention
Intervention B: 9-month glucocorticosteroid taper (dose, duration and type of gluco-
corticosteroid medication not reported)
Concomitant immunosuppression:
Tacrolimus: dose and duration not reported
Mycophenolate mofetil: dose and duration not reported
Hydrocortisone: 500 mg intraoperatively
Daclizumab: 1 mg/kg intraoperatively then 1 mg/kg 2 to 7 days later depending on
initial dose effect on CD25 expression on peripheral T-lymphocytes
Outcomes Mortality, graft loss, acute rejection, hypertension, diabetes mellitus, CMV infection,
leucopenia and CD25 expression on peripheral T lymphocytes
Notes Cross-over between intervention arms: no
Sample size calculation: not reported
Sources of funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: Generation of randomisation
sequence not described
Allocation concealment (selection bias) Unclear risk Comment: Allocation concealment not de-
scribed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: Blinding of participants and
medical staff not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: Blinding of outcome assessors
not described
Incomplete outcome data (attrition bias) Unclear risk Comment: Number of withdrawals and
reasons for withdrawal not reported
Selective reporting (reporting bias) Unclear risk Comment: Study protocol not available
and results only published in abstract
Other bias Unclear risk Comment: No sample size calculation re-
ported
Free of early stopping? Unclear risk Comment: Study only published in ab-
stract
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Free of baseline imbalance? Low risk Quote from the publication: “Both groups
were comparable in all observed indicators.
”
Comment: Study is reported as being free
from baseline imbalance
Tisone 1999
Methods Trial design: randomised, single-centre, open-label clinical trial
Mean follow-up: 108 ± 4 months
Study duration: 10 years from randomisation
Language: English
Type of information: journal article
Judgement on quality: high risk
Participants Setting: Ospedale S. Eugenio, Piazzale dell’Umanesimo, Rome, Italy
Allocation of participants: 45 participants, 22 allocated to Intervention A, 23 allocated
to Intervention B
Sex ratio: total: 34 (75.6%) males, 11 (24.4%) females
Intervention A: 16 (72.7%) males, 6 (26.1%) females
Intervention B: 18 (72%) males, 5 (21.7%) females
Mean age: total: not reported
Intervention A: 49.0 ± 9.8
Intervention B: 50.5 ± 6.2
Indication (no. (%)):
HCV cirrhosis: total: 15 (33.3%), Intervention A: 8 (36.4%), Intervention B: 7 (30.
4%)
HBV cirrhosis: total: 13 (28.9%), Intervention A: 7 (31.8%), Intervention B: 6 (26.1%)
Alcoholic cirrhosis: total: 6 (13.3%), Intervention A: 2 (9.1%), Intervention B: 4 (17.
4%)
Cryptogenic cirrhosis and others: total: 11 (24.4%), Intervention A: 5 (22.7%), Inter-
vention B: 6 (26.1%)
Type of donor: not reported
Inclusion criteria: adult liver transplant recipients (> 20 years of age and < 62), HBsAg-
positive participants were only considered for inclusion if repeatedlyHBV-DNAnegative
Exclusion criteria: positive HIV serology, positive for IgM anti-cytomegalovirus, HBV-
DNA-positive participants
Other:
Donor age: total: not reported, Intervention A: 38.3 ± 14, Intervention B: 35.3 ± 16
Donor sex ratio: total: 30 (66.7%) male, 15 (33.3%) female; Intervention A: 13 (59.
1%) males, 9 (39.1%) females; Intervention A: 17 (73.9%) males, 6 (26.1%) females
Cold ischaemia time (hours): total: not reported, Intervention A: 6.2+/-2.8, Intervention
B: 6.4+/-1.8
Possible selective outcome reporting: hypertension is not reported in any of the relevant
publications
Interventions Intervention A:
No intervention
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Intervention B:
Methylprednisolone: 20 mg/day (duration not reported)
Prednisone: (starting from withdrawal of methylprednisolone) 20 mg/day until day 30
then tapered “gradually” to 5 mg/day and stopped at 3 months
Concomitant immunosuppression:
Cyclosporine A: aiming for trough levels of 350 ng/mL to 450 ng/mL for “the first few
months” then 250 ng/mL to 350 ng/mL thereafter
Azathioprine: 1 to 1.5 mg/day (duration not reported)
Outcomes Mortality, graft loss, acute rejection, primary non-function, poor initial function, normal
function, chronic rejection, infection, CMV infection, recurrent hepatitis C, renal failure
(requiring dialysis), AST, bilirubin, alkaline phosphatase, GGT, creatinine, cyclosporine
serum levels, time in intensive treatment unit, time in hospital, glucose, cholesterol
Notes Cross-over between intervention arms: no
Sample size calculation: not reported
Sources of funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote from the publication: “Patients
were randomly assigned, using a com-
puter-generated list, to receive a standard
immunosuppressive therapy composed of
cyclosporine microemulsion (Neoral), in
doses to maintain trough whole-blood lev-
els (monoclonal fluorescence assay) of 350-
450ng/ml during the firstmonths and250-
350 ng/ml thereafter, and azathioprine (1-
1.5 mg/day), with (group A) or without
(group B) corticosteroids.”
Comment: Computer-generated randomi-
sation
Allocation concealment (selection bias) Unclear risk Comment: Allocation concealment not de-
scribed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote from the publication: “To address
the latter points, we conducted a prospec-
tive open-label randomized pilot study on
a consecutive series of patients undergoing
orthotopic liver transplantation (OLTx) at
our institution.”
Comment: Blinding of participants and
medical staff not performed
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Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote from the publication: “To address
the latter points, we conducted a prospec-
tive open-label randomized pilot study on
a consecutive series of patients undergoing
orthotopic liver transplantation (OLTx) at
our institution.”
Comment: Blinding of outcome assessors
not performed
Incomplete outcome data (attrition bias) Unclear risk Comment: Number of withdrawals and
reasons for withdrawal not reported
Selective reporting (reporting bias) Unclear risk Comment: Study does not report hyperten-
sion despite mentioning this as a potential
complication of glucocorticosteroid use in
both the introduction and the discussion
sections
Other bias Unclear risk Comment: No sample size calculation re-
ported
Free of early stopping? Low risk Comment: Study not stopped early
Free of baseline imbalance? Low risk Quote from the publication: “As summa-
rized in Table 1, the two groups did not dif-
fer in the demographic or clinical features
of donors and recipients, or in the duration
of cold ischemia. In particular, there were
no differences in the UNOS status or in
the hemodynamic data and the laboratory
findings related to liver and kidney func-
tion between the two groups.”
Comment: Study free from baseline imbal-
ance
Vivarelli 2007
Methods Trial design: randomised, multicentre, open-label clinical trial
Mean follow-up: 841 days (range: 130 to 1376)
Study duration: not reported
Language: English
Type of information: journal article
Judgement on quality: high risk
Participants Setting: 2 transplantation centres in Italy
Allocation of participants: 47 participants, 22 allocated to Intervention A, 25 allocated
to Intervention B
Sex ratio: total: not reported
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Intervention A: not reported
Intervention B: not reported
Mean age: total: not reported
Intervention A: 58.9 (range: 43 to 66)
Intervention B: 57.2 (range: 41 to 67)
Indication (no. (%)):
HCV cirrhosis: total: 47 (100.0%), Intervention A: 22 (100.0%), Intervention B: 25
(100.0%)
Type of donor: deceased donors
Inclusion criteria: HCV positive first-time whole liver recipients from deceased donors
Exclusion criteria: HBsAg-positive, previous transplant, partial grafts, living donors
Other:
HCV-RNA titres (Meq/mL): total: not reported, Intervention A: 0.755 (range: < 0.003
to 4.3), Intervention B: 0.765 (< 0.003 to 8.04)
MELD score: total: not reported, Intervention A: 16 (range: 8 to 25), Intervention B:
15 (range: 7 to 28)
Pretransplant diabetes mellitus: total: 11 (23.4%), Intervention A: 5 (22.7%), Interven-
tion B: 6 (24.0%)
Interventions Intervention A: prednisone: tapered from 25 mg/day to 15 mg/day from days 6 to day
30, 15 mg/day on days 31 to 45, 10 mg/day on days 46 to 60, 5 mg/day on days 61 to
75, 2.5 mg/day on days 76 to 90) and stopped at day 91
Intervention B: prednisone: 25 mg/day on day 6 tapered to 15 mg/day by day 31, 15
mg/day on days 31 to 90, 10 mg/day on days 91 to day 180, 7.5 mg/day on days 181
to 270, 5 mg/day from day 271 to the end of the first postoperative year, 2.5 mg for the
second postoperative year and stopped at the end of the second postoperative year
Concomitant immunosuppression:
Methylprednisolone: intraoperatively and on days 1 to 5 (dose not reported)
Tacrolimus: aiming for trough level of 5 ng/mL to 15 ng/mL for the first 3 months and
then 5 ng/mL to 10 ng/mL thereafter
Outcomes Mortality, graft loss, acute rejection, treatment failure, recurrent hepatitis C, HCV-
RNA levels, Scheuer fibrosis, acute rejection requiring steroids, acute rejection requiring
multiple steroids, need for antiviral treatment (anti-HCV), diabetes mellitus, tacrolimus
levels
Notes Cross-over between intervention arms: no
Sample size calculation: not reported
Sources of funding: Astellas Pharma Italia
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: Generation of randomisation
sequence not described
Allocation concealment (selection bias) Unclear risk Comment: Allocation concealment not de-
scribed
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote from the publication: “The study
was conducted at the Liver TransplantCen-
tres of Bologna and Padua, Italy, in an
open-label, not-blinded, prospective and
randomized fashion.”
Comment: Blinding of participants and
medical staff not performed
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote from the publication: “The study
was conducted at the Liver TransplantCen-
tres of Bologna and Padua, Italy, in an
open-label, not-blinded, prospective and
randomized fashion.”
Comment: Blinding of outcome assessors
not performed
Incomplete outcome data (attrition bias) Low risk Quote from the publication: “Median fol-
low-up was 841 days (130-1376); apart
from those who died or lost their graft ear-
lier, all patients had at least 2 year follow-
up.”
Comment: Missing data unlikely to affect
outcome results
Selective reporting (reporting bias) Low risk Comment: All outcomes appear to be fully
reported
Other bias High risk Quote from the publication: “The authors
declare that FG is employed by Astellas
Pharma Italia and he coordinated the Cen-
tres involved in the study and helped in
the data collection. Astellas Pharma Italia
supported the study financially and coor-
dinated the Centres involved (EPASTER
Study, investigator originated and driven).
”
Comment: No sample size calculation re-
ported; study industry sponsored
Free of early stopping? Low risk Comment: Study not stopped early
Free of baseline imbalance? Low risk Comment: Baseline characteristics are
listed in Table 1. All listed characteristics
are similar between the groups with P val-
ues > 0.05. Study is free from baseline im-
balance
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Methods Trial design: randomised, multicentre, double-blinded, placebo-controlled clinical trial
Mean follow-up: not reported
Study duration: not reported
Language: English
Type of information: abstract (abstract appears to present preliminary data for the first
182 participants randomised)
Judgement on quality: unclear risk
Participants Setting: Shanghai First People’s Hospital
Allocation of participants: target enrolment of 300 participants, current participants not
adequately reported (study ongoing)
Sex ratio: total: not reported
Intervention A: not reported
Intervention B: not reported
Mean age: total: not reported
Intervention A: not reported
Intervention B: not reported
Indication (no. (%)): (hepatocellular carcinoma primary indication for all transplants)
Hepatocellular carcinoma: total: not reported (100%), Intervention A: not reported
(100%), Intervention B: not reported (100%)
Type of donor: not reported
Inclusion criteria: liver transplant recipients with hepatocellular carcinoma
Exclusion criteria: death within 3 months of transplantation, inability to provide written
informed consent prior to study entry
Interventions Intervention A: no intervention
Intervention B: methylprednisolone 10 mg/kg intraoperatively and a further 10 mg/kg
given over 1 week
Concomitant immunosuppression:
Tacrolimus/cyclosporine A: dose not reported (NOTE: published abstract reports use of
cyclosporine A, register on clinicaltrials.gov reports use of tacrolimus)
Basiliximab: 20 mg given twice (timings not reported)
Outcomes Mortality, graft loss, acute rejection, infection, bacterial infection, de novo diabetes
mellitus, recurrent hepatitis B, hypertension, neurological complications, tumour size,
tumour differentiation, histological staging of tumour, recurrence-free survival
Notes Cross-over between intervention arms: no
Sample size calculation: not reported
Sources of funding: Shanghai Jiao Tong University School of Medicine
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: Generation of randomisation
sequence not described
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Zhong 2010 (Continued)
Allocation concealment (selection bias) Unclear risk Comment: Allocation concealment not de-
scribed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: Blinding of participants and
medical staff not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: Blinding of outcome assessors
not described
Incomplete outcome data (attrition bias) Unclear risk Comment: Number of withdrawals and
reasons for withdrawal not reported, esti-
mated enrolment not achieved and results
only published in abstract
Selective reporting (reporting bias) High risk Comment: Results only published in ab-
stract, graft survival not reported
Other bias Unclear risk Comment: No sample size calculation re-
ported
Free of early stopping? Unclear risk Comment: Study only published in ab-
stract
Free of baseline imbalance? Unclear risk Comment: Baseline characteristics not de-
scribed, presence or absence of baseline im-
balance not reported
ABO: blood group
ALT: alanine aminotransferase
AST: aspartate aminotransferase
BMI: body mass index
CMV: cytomegalovirus
GGT: gamma-glutamyl transferase
HBsAg: hepatitis B surface antigen
HBV: hepatitis B virus
HCC: hepatocellular carcinoma
HCV: hepatitis C virus
HDL: high density lipoprotein
HIV: human immunodeficiency virus
HSV: herpes simplex virus
IgM: immunoglobulin M
IVC: inferior vena cava
LDL: low density lipoprotein
MELD: model for end-stage liver disease
MMF: mycophenolate mofetil
NAFLD: non-alcoholic fatty liver disease
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RCT: randomised clinical trial
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Benitez 2010 Randomised clinical trial comparing RATG with glucocorticosteroids; no comment on glucocorticosteroid
avoidance or withdrawal possible
Boillot 2005 Randomised clinical trial comparing daclizumab with glucocorticosteroids; no comment on glucocorticos-
teroid avoidance or withdrawal possible
Cosimi 1987 Randomised clinical trial comparing muromonab CD3 with glucocorticosteroids for treatment of acute
rejection; no comment on glucocorticosteroid avoidance or withdrawal possible
Cuervas-Mons 2009 Randomised clinical trial comparing mycophenolate mofetil with glucocorticosteroids; no comment on glu-
cocorticosteroid avoidance or withdrawal possible
Day 2004 Randomised clinical trial comparing continuationof tacrolimusmonotherapywith tacrolimus discontinuation
and replacement with mycophenolate mofetil and glucocorticosteroids; no comment on glucocorticosteroid
avoidance or withdrawal possible
De Simone 2007 Randomised clinical trial comparing basiliximab with glucocorticosteroids; no comment on glucocorticos-
teroid avoidance or withdrawal possible
Filipponi 2004 Method reports study as a randomised clinical trial with ITT. Results are reported instead as a per-treatment
analysis with patients moved between arms for analysis as a result of a data-dependent process. This does
not appear to have been carried out using pre-specified criteria. Our inclusion criteria state that we are only
considering randomised clinical trials that present their data in an ITT analysis for this review. We made
attempts to contact the author to request the original data so that ITT analysis could be completed
Foroncewicz 2009 Randomised clinical trial comparing daclizumab with glucocorticosteroids; no comment on glucocorticos-
teroid avoidance or withdrawal possible
Ganschow 2007 Randomised clinical trial comparing high- and low-dose glucocorticosteroids; no comment on glucocorticos-
teroid avoidance or withdrawal possible
Hu 2013 Non-randomised clinical trial comparing multiple immunosuppression regimens
Jonas 2001 Randomised clinical trial comparing tacrolimus-based dual therapywith cyclosporine A-based quadruple ther-
apy in which glucocorticosteroid withdrawal was assessed as an outcome; no comment on glucocorticosteroid
avoidance or withdrawal possible
Junge 2005 Randomised clinical trial comparing mycophenolate mofetil with glucocorticosteroids; no comment on glu-
cocorticosteroid avoidance or withdrawal possible
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Kato 2007 Randomised clinical trial comparing daclizumab with glucocorticosteroids; no comment on glucocorticos-
teroid avoidance or withdrawal possible
Klintmalm 2011 Randomised clinical trial comparing daclizumab with glucocorticosteroids; no comment on glucocorticos-
teroid avoidance or withdrawal possible
Lupo 2008 Randomised clinical trial comparing basiliximab with glucocorticosteroids; no comment on glucocorticos-
teroid avoidance or withdrawal possible
Manousou 2009 Randomised clinical trial comparingmonotherapy of tacrolimuswith triple therapy of tacrolimus, azathioprine
and glucocorticosteroids; no comment on glucocorticosteroid avoidance or withdrawal possible
McDiarmid 1995 Randomised clinical trial comparing glucocorticosteroid continuation with glucocorticosteroid withdrawal
over 1 year post-transplant; investigation of alteration in an existing immunosuppression strategy rather than
a primary immunosuppression strategy
Nair 2006 Randomised clinical trial comparing RATG with glucocorticosteroids; no comment on glucocorticosteroid
avoidance or withdrawal possible
Nair 2008 Randomised clinical trial comparing PEG interferon alpha 2b, ribavirin and amantadine with PEG interferon
alpha 2b and ribavirin in 2 glucocorticosteroid-free arms; no comment on glucocorticosteroid avoidance or
withdrawal possible
Neumann 2012 Randomised clinical trial comparing daclizumab with glucocorticosteroids; no comment on glucocorticos-
teroid avoidance or withdrawal possible
Otero 2009 Randomised clinical trial comparing daclizumab with glucocorticosteroids; no comment on glucocorticos-
teroid avoidance or withdrawal possible
Saliba 2012 Randomised clinical trial comparing concentration-controlled mycophenolate mofetil with fixed-dose my-
cophenolate mofetil and glucocorticosteroids; differences in concomitant immunosuppression therefore no
comment on glucocorticosteroid avoidance or withdrawal possible
Spada 2006 Randomised clinical trial comparing basiliximab with glucocorticosteroids; no comment on glucocorticos-
teroid avoidance or withdrawal possible
Takada 2013 Randomised clinical trial comparing mycophenolate mofetil with glucocorticosteroids; no comment on glu-
cocorticosteroid avoidance or withdrawal possible
Teisseyre 2006 Randomised clinical trial comparing saline with methylprednisolone for prevention of ischaemia reperfusion
injury; no comment on glucocorticosteroid avoidance or withdrawal for post-transplantation immunosup-
pression possible
Turner 2006 Randomised clinical trial comparing RATG with glucocorticosteroids; no comment on glucocorticosteroid
avoidance or withdrawal possible
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Washburn 2001 Randomised clinical trial comparing daclizumab with glucocorticosteroids; no comment on glucocorticos-
teroid avoidance or withdrawal possible
ITT: intention-to-treat
Muromonab CD3: muromonab cluster of differentiation 3
PEG: pegylated
RATG: rabbit antithymocyte globulin
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D A T A A N D A N A L Y S E S
Comparison 1. Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosup-
pression
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 15 1323 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.93, 1.44]
1.1 Glucocorticosteroid
avoidance
9 758 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.84, 1.48]
1.2 Glucocorticosteroid
withdrawal
6 565 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [0.86, 1.72]
2 Graft loss including death 11 1002 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.90, 1.46]
2.1 Glucocorticosteroid
avoidance
8 671 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.77, 1.39]
2.2 Glucocorticosteroid
withdrawal
3 331 Risk Ratio (M-H, Fixed, 95% CI) 1.44 [0.93, 2.24]
3 Acute rejection 16 1347 Risk Ratio (M-H, Fixed, 95% CI) 1.33 [1.08, 1.64]
3.1 Glucocorticosteroid
avoidance
10 782 Risk Ratio (M-H, Fixed, 95% CI) 1.37 [1.04, 1.81]
3.2 Glucocorticosteroid
withdrawal
6 565 Risk Ratio (M-H, Fixed, 95% CI) 1.28 [0.93, 1.76]
4 Infection 8 778 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.73, 1.05]
4.1 Glucocorticosteroid
avoidance
6 500 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.80, 1.15]
4.2 Glucocorticosteroid
withdrawal
2 278 Risk Ratio (M-H, Fixed, 95% CI) 0.41 [0.19, 0.90]
5 Chronic rejection 9 974 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.56, 2.10]
5.1 Glucocorticosteroid
avoidance
6 586 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.32, 2.08]
5.2 Glucocorticosteroid
withdrawal
3 388 Risk Ratio (M-H, Fixed, 95% CI) 1.45 [0.55, 3.78]
6 Glucocorticosteroid-resistant
rejection
10 1020 Risk Ratio (M-H, Fixed, 95% CI) 2.14 [1.13, 4.02]
6.1 Glucocorticosteroid
avoidance
7 689 Risk Ratio (M-H, Fixed, 95% CI) 1.88 [0.89, 3.98]
6.2 Glucocorticosteroid
withdrawal
3 331 Risk Ratio (M-H, Fixed, 95% CI) 2.86 [0.86, 9.49]
7 Diabetes mellitus 12 1185 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.66, 0.99]
7.1 Glucocorticosteroid
avoidance
7 674 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.70, 1.17]
7.2 Glucocorticosteroid
withdrawal
5 511 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.50, 0.94]
8 CMV 7 786 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.48, 1.16]
8.1 Glucocorticosteroid
avoidance
5 502 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.39, 1.49]
8.2 Glucocorticosteroid
withdrawal
2 284 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.41, 1.30]
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9 HCV recurrence 10 477 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.92, 1.15]
9.1 Glucocorticosteroid
avoidance
7 274 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.84, 1.08]
9.2 Glucocorticosteroid
withdrawal
3 203 Risk Ratio (M-H, Fixed, 95% CI) 1.18 [0.96, 1.44]
10 Malignancy 3 528 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.16, 1.74]
10.1 Glucocorticosteroid
avoidance
2 354 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.13, 2.08]
10.2 Glucocorticosteroid
withdrawal
1 174 Risk Ratio (M-H, Fixed, 95% CI) 0.54 [0.05, 5.80]
11 Post-transplant
lymphoproliferative disorder
2 330 Risk Ratio (M-H, Fixed, 95% CI) 2.39 [0.36, 15.95]
11.1 Glucocorticosteroid
avoidance
1 156 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.19, 21.61]
11.2 Glucocorticosteroid
withdrawal
1 174 Risk Ratio (M-H, Fixed, 95% CI) 3.21 [0.13, 77.77]
12 Renal insufficiency 4 447 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.73, 1.19]
12.1 Glucocorticosteroid
avoidance
4 447 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.73, 1.19]
13 Creatinine 4 309 Mean Difference (IV, Fixed, 95% CI) 0.11 [0.07, 0.16]
13.1 Glucocorticosteroid
avoidance
2 145 Mean Difference (IV, Fixed, 95% CI) 0.15 [0.10, 0.20]
13.2 Glucocorticosteroid
withdrawal
2 164 Mean Difference (IV, Fixed, 95% CI) -0.06 [-0.16, 0.05]
14 Hypertension 10 1098 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.65, 0.90]
14.1 Glucocorticosteroid
avoidance
6 634 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.66, 1.00]
14.2 Glucocorticosteroid
withdrawal
4 464 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.55, 0.91]
15 Hyperlipidaemia 4 400 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.38, 1.48]
15.1 Glucocorticosteroid
avoidance
2 150 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.45, 2.52]
15.2 Glucocorticosteroid
withdrawal
2 250 Risk Ratio (M-H, Fixed, 95% CI) 0.44 [0.14, 1.41]
16 Cholesterol 6 611 Mean Difference (IV, Fixed, 95% CI) -18.49 [-22.02, -14.
96]
16.1 Glucocorticosteroid
avoidance
3 343 Mean Difference (IV, Fixed, 95% CI) -18.33 [-21.93, -14.
72]
16.2 Glucocorticosteroid
withdrawal
3 268 Mean Difference (IV, Fixed, 95% CI) -22.06 [-38.94, -5.
18]
17 Hypercholesterolaemia 2 266 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.32, 1.00]
17.1 Glucocorticosteroid
avoidance
1 156 Risk Ratio (M-H, Fixed, 95% CI) 1.2 [0.55, 2.61]
17.2 Glucocorticosteroid
withdrawal
1 110 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.08, 0.59]
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Comparison 2. Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosup-
pression (CNI subgroups)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 15 1323 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.93, 1.44]
1.1 Tacrolimus 11 802 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.92, 1.51]
1.2 Cyclosporine A 4 521 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [0.69, 1.74]
2 Graft loss including death 11 1002 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.90, 1.46]
2.1 Tacrolimus 8 585 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.85, 1.47]
2.2 Cyclosporine A 3 417 Risk Ratio (M-H, Fixed, 95% CI) 1.23 [0.72, 2.09]
3 Acute rejection 16 1347 Risk Ratio (M-H, Fixed, 95% CI) 1.33 [1.08, 1.64]
3.1 Tacrolimus 11 802 Risk Ratio (M-H, Fixed, 95% CI) 1.35 [1.02, 1.77]
3.2 Cyclosporine A 5 545 Risk Ratio (M-H, Fixed, 95% CI) 1.30 [0.94, 1.80]
4 Infection 8 778 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.73, 1.05]
4.1 Tacrolimus 4 257 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.72, 1.27]
4.2 Cyclosporine A 4 521 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.66, 1.05]
5 Chronic rejection 9 974 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.56, 2.10]
5.1 Tacrolimus 4 429 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [0.44, 2.76]
5.2 Cyclosporine A 5 545 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.41, 2.76]
6 Glucocorticosteroid-resistant
rejection
10 1020 Risk Ratio (M-H, Fixed, 95% CI) 2.14 [1.13, 4.02]
6.1 Tacrolimus 7 603 Risk Ratio (M-H, Fixed, 95% CI) 2.46 [1.01, 5.97]
6.2 Cyclosporine A 3 417 Risk Ratio (M-H, Fixed, 95% CI) 1.83 [0.74, 4.55]
7 Diabetes mellitus 12 1185 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.66, 0.99]
7.1 Tacrolimus 9 709 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.72, 1.15]
7.2 Cyclosporine A 3 476 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.41, 0.90]
8 CMV infection 7 786 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.48, 1.16]
8.1 Tacrolimus 4 369 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.46, 1.38]
8.2 Cyclosporine A 3 417 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.33, 1.40]
9 HCV recurrence 10 477 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.92, 1.15]
9.1 Tacrolimus 5 194 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.84, 1.16]
9.2 Cyclosporine A 5 283 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.92, 1.23]
10 Malignancy 3 528 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.16, 1.74]
10.1 Tacrolimus 1 156 Risk Ratio (M-H, Fixed, 95% CI) 5.0 [0.24, 102.49]
10.2 Cyclosporine A 2 372 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.04, 1.22]
11 Post-transplant
lymphoproliferative disorder
2 330 Risk Ratio (M-H, Fixed, 95% CI) 2.39 [0.36, 15.95]
11.1 Tacrolimus 1 156 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.19, 21.61]
11.2 Cyclosporine A 1 174 Risk Ratio (M-H, Fixed, 95% CI) 3.21 [0.13, 77.77]
12 Renal insufficiency 4 447 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.73, 1.19]
12.1 Tacrolimus 3 249 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.73, 1.64]
12.2 Cyclosporine A 1 198 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.63, 1.16]
13 Creatinine 4 309 Mean Difference (IV, Fixed, 95% CI) 0.11 [0.07, 0.16]
13.1 Tacrolimus 3 264 Mean Difference (IV, Fixed, 95% CI) 0.17 [0.12, 0.22]
13.2 Cyclosporine A 1 45 Mean Difference (IV, Fixed, 95% CI) -0.10 [-0.19, -0.01]
14 Hypertension 10 1098 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.65, 0.90]
14.1 Tacrolimus 7 622 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.65, 1.06]
14.2 Cyclosporine A 3 476 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.58, 0.88]
15 Hyperlipidaemia 4 400 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.38, 1.48]
15.1 Tacrolimus 3 226 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.44, 2.02]
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15.2 Cyclosporine A 1 174 Risk Ratio (M-H, Fixed, 95% CI) 0.36 [0.07, 1.72]
16 Cholesterol 6 611 Mean Difference (IV, Fixed, 95% CI) -18.49 [-22.02, -14.
96]
16.1 Tacrolimus 3 264 Mean Difference (IV, Fixed, 95% CI) -18.38 [-22.09, -14.
67]
16.2 Cyclosporine A 3 347 Mean Difference (IV, Fixed, 95% CI) -19.56 [-31.05, -8.
07]
Comparison 3. Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosup-
pression (antiproliferative subgroups)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 15 1323 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.93, 1.44]
1.1 No antiproliferative agent 8 928 Risk Ratio (M-H, Fixed, 95% CI) 1.24 [0.92, 1.66]
1.2 Mycophenolate mofetil 6 350 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.75, 1.51]
1.3 Azathioprine 1 45 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.40, 2.28]
2 Graft loss including death 11 1002 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.90, 1.46]
2.1 No antiproliferative agent 6 748 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.82, 1.52]
2.2 Mycophenolate mofetil 4 209 Risk Ratio (M-H, Fixed, 95% CI) 1.27 [0.82, 1.96]
2.3 Azathioprine 1 45 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.40, 2.28]
3 Acute rejection 16 1347 Risk Ratio (M-H, Fixed, 95% CI) 1.33 [1.08, 1.64]
3.1 No antiproliferative agent 9 952 Risk Ratio (M-H, Fixed, 95% CI) 1.23 [0.97, 1.56]
3.2 Mycophenolate mofetil 6 350 Risk Ratio (M-H, Fixed, 95% CI) 1.87 [1.15, 3.04]
3.3 Azathioprine 1 45 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.27, 3.36]
4 Infection 8 778 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.73, 1.05]
4.1 No antiproliferative agent 3 476 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.59, 1.02]
4.2 Mycophenolate mofetil 4 257 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.72, 1.27]
4.3 Azathioprine 1 45 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.75, 1.58]
5 Chronic rejection 9 974 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.56, 2.10]
5.1 No antiproliferative agent 7 829 Risk Ratio (M-H, Fixed, 95% CI) 1.35 [0.66, 2.79]
5.2 Mycophenolate mofetil 1 100 Risk Ratio (M-H, Fixed, 95% CI) 0.25 [0.03, 2.16]
5.3 Azathioprine 1 45 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Glucocorticosteroid-resistant
rejection
10 1020 Risk Ratio (M-H, Fixed, 95% CI) 2.14 [1.13, 4.02]
6.1 No antiproliferative agent 6 748 Risk Ratio (M-H, Fixed, 95% CI) 2.14 [1.13, 4.02]
6.2 Mycophenolate mofetil 3 227 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.3 Azathioprine 1 45 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Diabetes mellitus 12 1185 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.66, 0.99]
7.1 No antiproliferative agent 8 928 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.62, 1.00]
7.2 Mycophenolate mofetil 4 257 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.59, 1.25]
8 CMV infection 7 786 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.48, 1.16]
8.1 No antiproliferative agent 5 701 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.45, 1.12]
8.2 Mycophenolate mofetil 1 40 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.3 Azathioprine 1 45 Risk Ratio (M-H, Fixed, 95% CI) 1.91 [0.19, 19.63]
9 HCV recurrence 10 477 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.92, 1.15]
9.1 No antiproliferative agent 7 386 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [0.98, 1.22]
9.2 Mycophenolate mofetil 2 76 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.55, 1.22]
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9.3 Azathioprine 1 15 Risk Ratio (M-H, Fixed, 95% CI) 0.23 [0.03, 1.52]
10 Renal insufficiency 4 447 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.73, 1.19]
10.1 No antiproliferative
agent
3 417 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.72, 1.16]
10.2 Mycophenolate mofetil 1 30 Risk Ratio (M-H, Fixed, 95% CI) 3.00 [0.30, 29.52]
11 Creatinine 4 309 Mean Difference (IV, Fixed, 95% CI) 0.11 [0.07, 0.16]
11.1 No antiproliferative
agent
1 110 Mean Difference (IV, Fixed, 95% CI) -0.12 [-0.47, 0.23]
11.2 Mycophenolate mofetil 2 154 Mean Difference (IV, Fixed, 95% CI) 0.18 [0.13, 0.23]
11.3 Azathioprine 1 45 Mean Difference (IV, Fixed, 95% CI) -0.10 [-0.19, -0.01]
12 Hypertension 10 1098 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.65, 0.90]
12.1 No antiproliferative
agent
7 881 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.62, 0.88]
12.2 Mycophenolate mofetil 3 217 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.61, 1.26]
13 Hyperlipidaemia 4 400 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.38, 1.48]
13.1 No antiproliferative
agent
3 313 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.32, 1.62]
13.2 Mycophenolate mofetil 1 87 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.24, 2.85]
14 Cholesterol 6 611 Mean Difference (IV, Fixed, 95% CI) -18.49 [-22.02, -14.
96]
14.1 No antiproliferative
agent
3 412 Mean Difference (IV, Fixed, 95% CI) -8.08 [-18.99, 2.82]
14.2 Mycophenolate mofetil 2 154 Mean Difference (IV, Fixed, 95% CI) -19.84 [-23.60, -16.
08]
14.3 Azathioprine 1 45 Mean Difference (IV, Fixed, 95% CI) -11.0 [-41.10, 19.
10]
Comparison 4. Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosup-
pression (induction therapy subgroups)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 15 1323 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.93, 1.44]
1.1 No induction therapy 8 581 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [0.85, 1.50]
1.2 Basiliximab 5 599 Risk Ratio (M-H, Fixed, 95% CI) 1.24 [0.85, 1.81]
1.3 Rabbit antithymocyte
globulin
1 104 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [0.51, 2.50]
1.4 Daclizumab 1 39 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.01, 7.35]
2 Graft loss including death 11 1002 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.90, 1.46]
2.1 No induction therapy 6 451 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.73, 1.39]
2.2 Basiliximab 4 512 Risk Ratio (M-H, Fixed, 95% CI) 1.45 [0.99, 2.12]
2.3 Daclizumab 1 39 Risk Ratio (M-H, Fixed, 95% CI) 0.19 [0.01, 3.73]
3 Acute rejection 16 1347 Risk Ratio (M-H, Fixed, 95% CI) 1.33 [1.08, 1.64]
3.1 No induction therapy 8 581 Risk Ratio (M-H, Fixed, 95% CI) 1.27 [0.94, 1.71]
3.2 Basiliximab 5 599 Risk Ratio (M-H, Fixed, 95% CI) 1.47 [1.05, 2.05]
3.3 Rabbit antithymocyte
globulin
2 128 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.36, 1.67]
3.4 Daclizumab 1 39 Risk Ratio (M-H, Fixed, 95% CI) 2.22 [0.67, 7.34]
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4 Infection 8 778 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.73, 1.05]
4.1 No induction therapy 2 75 Risk Ratio (M-H, Fixed, 95% CI) 1.23 [0.86, 1.77]
4.2 Basiliximab 5 599 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.71, 1.07]
4.3 Rabbit antithymocyte
globulin
1 104 Risk Ratio (M-H, Fixed, 95% CI) 0.12 [0.02, 0.89]
5 Chronic rejection 9 974 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.56, 2.10]
5.1 No induction therapy 4 374 Risk Ratio (M-H, Fixed, 95% CI) 1.86 [0.60, 5.78]
5.2 Basiliximab 3 472 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.29, 1.89]
5.3 Rabbit antithymocyte
globulin
2 128 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.16, 6.72]
6 Glucocorticosteroid-resistant
rejection
10 1020 Risk Ratio (M-H, Fixed, 95% CI) 2.14 [1.13, 4.02]
6.1 No induction therapy 5 421 Risk Ratio (M-H, Fixed, 95% CI) 2.46 [1.01, 5.97]
6.2 Basiliximab 5 599 Risk Ratio (M-H, Fixed, 95% CI) 1.83 [0.74, 4.55]
7 Diabetes mellitus 12 1185 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.66, 0.99]
7.1 No induction therapy 6 482 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.69, 1.24]
7.2 Basiliximab 5 599 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.60, 1.06]
7.3 Rabbit antithymocyte
globulin
1 104 Risk Ratio (M-H, Fixed, 95% CI) 0.23 [0.07, 0.77]
8 CMV infection 7 786 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.48, 1.16]
8.1 No induction therapy 4 374 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.50, 1.44]
8.2 Basiliximab 3 412 Risk Ratio (M-H, Fixed, 95% CI) 0.60 [0.27, 1.30]
9 HCV recurrence 10 477 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.92, 1.15]
9.1 No induction therapy 4 133 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.84, 1.18]
9.2 Basiliximab 4 273 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.90, 1.18]
9.3 Rabbit antithymocyte
globulin
2 71 Risk Ratio (M-H, Fixed, 95% CI) 1.31 [0.55, 3.11]
10 Malignancy 3 528 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.16, 1.74]
10.1 No induction therapy 1 156 Risk Ratio (M-H, Fixed, 95% CI) 5.0 [0.24, 102.49]
10.2 Basiliximab 2 372 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.04, 1.22]
11 Post-transplant
lymphoproliferative disorder
2 330 Risk Ratio (M-H, Fixed, 95% CI) 2.39 [0.36, 15.95]
11.1 No induction therapy 1 156 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.19, 21.61]
11.2 Basiliximab 1 174 Risk Ratio (M-H, Fixed, 95% CI) 3.21 [0.13, 77.77]
12 Renal insufficiency 4 447 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.73, 1.19]
12.1 No induction therapy 3 249 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.73, 1.64]
12.2 Basiliximab 1 198 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.63, 1.16]
13 Creatinine 4 309 Mean Difference (IV, Fixed, 95% CI) 0.11 [0.07, 0.16]
13.1 No induction therapy 3 209 Mean Difference (IV, Fixed, 95% CI) -0.08 [-0.15, -0.01]
13.2 Basiliximab 1 100 Mean Difference (IV, Fixed, 95% CI) 0.25 [0.19, 0.31]
14 Hypertension 10 1098 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.65, 0.90]
14.1 No induction therapy 5 435 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.57, 1.08]
14.2 Basiliximab 4 559 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.72, 1.05]
14.3 Rabbit antithymocyte
globulin
1 104 Risk Ratio (M-H, Fixed, 95% CI) 0.30 [0.16, 0.57]
15 Hyperlipidaemia 4 400 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.38, 1.48]
15.1 No induction therapy 2 139 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.38, 2.72]
15.2 Basiliximab 2 261 Risk Ratio (M-H, Fixed, 95% CI) 0.57 [0.22, 1.49]
16 Cholesterol 6 611 Mean Difference (IV, Fixed, 95% CI) -18.49 [-22.02, -14.
96]
16.1 No induction therapy 2 99 Mean Difference (IV, Fixed, 95% CI) -51.27 [-76.48, -26.
06]
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16.2 Basiliximab 3 408 Mean Difference (IV, Fixed, 95% CI) -17.10 [-20.69, -13.
51]
16.3 Rabbit antithymocyte
globulin
1 104 Mean Difference (IV, Fixed, 95% CI) -70.0 [-100.17, -39.
83]
Comparison 5. Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosup-
pression (co-interventions subgroups)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 15 1323 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.93, 1.44]
1.1 Monotherapy 5 452 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [0.90, 1.83]
1.2 Dual therapy 6 605 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.68, 1.42]
1.3 Triple therapy 4 266 Risk Ratio (M-H, Fixed, 95% CI) 1.23 [0.79, 1.90]
2 Graft loss including death 11 1002 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.90, 1.46]
2.1 Monotherapy 4 376 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.73, 1.48]
2.2 Dual therapy 4 447 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.69, 1.93]
2.3 Triple therapy 3 179 Risk Ratio (M-H, Fixed, 95% CI) 1.35 [0.86, 2.11]
3 Acute rejection 16 1347 Risk Ratio (M-H, Fixed, 95% CI) 1.33 [1.08, 1.64]
3.1 Monotherapy 5 452 Risk Ratio (M-H, Fixed, 95% CI) 1.14 [0.81, 1.59]
3.2 Dual therapy 7 629 Risk Ratio (M-H, Fixed, 95% CI) 1.44 [1.07, 1.95]
3.3 Triple therapy 4 266 Risk Ratio (M-H, Fixed, 95% CI) 1.56 [0.84, 2.88]
4 Infection 8 778 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.73, 1.05]
4.1 Dual therapy 5 551 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.70, 1.09]
4.2 Triple therapy 3 227 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.65, 1.20]
5 Chronic rejection 9 974 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.56, 2.10]
5.1 Monotherapy 3 329 Risk Ratio (M-H, Fixed, 95% CI) 1.86 [0.60, 5.78]
5.2 Dual therapy 5 545 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.41, 2.76]
5.3 Triple therapy 1 100 Risk Ratio (M-H, Fixed, 95% CI) 0.25 [0.03, 2.16]
6 Glucocorticosteroid-resistant
rejection
10 1020 Risk Ratio (M-H, Fixed, 95% CI) 2.14 [1.13, 4.02]
6.1 Monotherapy 4 376 Risk Ratio (M-H, Fixed, 95% CI) 2.46 [1.01, 5.97]
6.2 Dual therapy 3 417 Risk Ratio (M-H, Fixed, 95% CI) 1.83 [0.74, 4.55]
6.3 Triple therapy 3 227 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Diabetes mellitus 12 1185 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.66, 0.99]
7.1 Monotherapy 5 452 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.70, 1.28]
7.2 Dual therapy 4 506 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.41, 0.89]
7.3 Triple therapy 3 227 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.61, 1.31]
8 CMV infection 7 786 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.48, 1.16]
8.1 Monotherapy 3 329 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.46, 1.38]
8.2 Dual therapy 3 417 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.33, 1.40]
8.3 Triple therapy 1 40 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 HCV recurrence 10 477 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.92, 1.15]
9.1 Monotherapy 3 118 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.91, 1.25]
9.2 Dual therapy 5 283 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.92, 1.23]
9.3 Triple therapy 2 76 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.55, 1.22]
10 Malignancy 3 528 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.16, 1.74]
10.1 Monotherapy 1 156 Risk Ratio (M-H, Fixed, 95% CI) 5.0 [0.24, 102.49]
10.2 Dual therapy 2 372 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.04, 1.22]
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11 Post-transplant
lymphoproliferative disorder
2 330 Risk Ratio (M-H, Fixed, 95% CI) 2.39 [0.36, 15.95]
11.1 Monotherapy 1 156 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.19, 21.61]
11.2 Dual therapy 1 174 Risk Ratio (M-H, Fixed, 95% CI) 3.21 [0.13, 77.77]
12 Renal insufficiency 4 447 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.73, 1.19]
12.1 Monotherapy 2 219 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.68, 1.56]
12.2 Dual therapy 2 228 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.66, 1.20]
13 Creatinine 4 309 Mean Difference (IV, Fixed, 95% CI) 0.11 [0.07, 0.16]
13.1 Monotherapy 1 110 Mean Difference (IV, Fixed, 95% CI) -0.12 [-0.47, 0.23]
13.2 Dual therapy 2 99 Mean Difference (IV, Fixed, 95% CI) -0.08 [-0.15, -0.01]
13.3 Triple therapy 1 100 Mean Difference (IV, Fixed, 95% CI) 0.25 [0.19, 0.31]
14 Hypertension 10 1098 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.65, 0.90]
14.1 Monotherapy 4 405 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.57, 1.10]
14.2 Dual therapy 4 506 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.57, 0.88]
14.3 Triple therapy 2 187 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.63, 1.32]
15 Hyperlipidaemia 4 400 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.38, 1.48]
15.1 Monotherapy 2 139 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.38, 2.72]
15.2 Dual therapy 1 174 Risk Ratio (M-H, Fixed, 95% CI) 0.36 [0.07, 1.72]
15.3 Triple therapy 1 87 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.24, 2.85]
16 Cholesterol 6 611 Mean Difference (IV, Fixed, 95% CI) -18.49 [-22.02, -14.
96]
16.1 Monotherapy 1 110 Mean Difference (IV, Fixed, 95% CI) 35.0 [12.31, 57.69]
16.2 Dual therapy 4 401 Mean Difference (IV, Fixed, 95% CI) -26.94 [-38.10, -15.
79]
16.3 Triple therapy 1 100 Mean Difference (IV, Fixed, 95% CI) -19.0 [-22.77, -15.
23]
Comparison 6. Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosup-
pression (treatment duration subgroups)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 14 1149 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.87, 1.36]
1.1 2 to 3 months
glucocorticosteroid
7 655 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.70, 1.41]
1.2 > 3 to 6 months
glucocorticosteroids
3 250 Risk Ratio (M-H, Fixed, 95% CI) 1.48 [1.00, 2.18]
1.3 > 6 months
glucocorticosteroids
4 244 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.55, 1.33]
2 Graft loss including death 10 828 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.83, 1.37]
2.1 2 to 3 months
glucocorticosteroid
5 492 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.59, 1.29]
2.2 > 3 to 6 months
glucocorticosteroids
3 250 Risk Ratio (M-H, Fixed, 95% CI) 1.44 [1.01, 2.04]
2.3 > 6 months
glucocorticosteroids
2 86 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.25, 1.47]
3 Acute rejection 15 1173 Risk Ratio (M-H, Fixed, 95% CI) 1.28 [1.01, 1.62]
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3.1 2 to 3 months
glucocorticosteroid
8 679 Risk Ratio (M-H, Fixed, 95% CI) 1.30 [0.97, 1.75]
3.2 > 3 to 6 months
glucocorticosteroids
3 250 Risk Ratio (M-H, Fixed, 95% CI) 1.33 [0.83, 2.15]
3.3 > 6 months
glucocorticosteroids
4 244 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.54, 2.12]
4 Infection 7 604 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.75, 1.08]
4.1 2 to 3 months
glucocorticosteroid
4 360 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.71, 1.11]
4.2 > 3 to 6 months
glucocorticosteroids
2 140 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.81, 1.54]
4.3 > 6 months
glucocorticosteroids
1 104 Risk Ratio (M-H, Fixed, 95% CI) 0.12 [0.02, 0.89]
5 Chronic rejection 8 800 Risk Ratio (M-H, Fixed, 95% CI) 1.27 [0.59, 2.71]
5.1 2 to 3 months
glucocorticosteroid
5 486 Risk Ratio (M-H, Fixed, 95% CI) 1.23 [0.41, 3.73]
5.2 > 3 to 6 months
glucocorticosteroids
2 210 Risk Ratio (M-H, Fixed, 95% CI) 1.64 [0.51, 5.24]
5.3 > 6 months
glucocorticosteroids
1 104 Risk Ratio (M-H, Fixed, 95% CI) 0.31 [0.01, 7.42]
6 Glucocorticosteroid-resistant
rejection
9 846 Risk Ratio (M-H, Fixed, 95% CI) 1.93 [0.93, 4.01]
6.1 2 to 3 months
glucocorticosteroid
5 549 Risk Ratio (M-H, Fixed, 95% CI) 1.88 [0.89, 3.98]
6.2 > 3 to 6 months
glucocorticosteroids
3 250 Risk Ratio (M-H, Fixed, 95% CI) 2.89 [0.12, 69.55]
6.3 > 6 months
glucocorticosteroids
1 47 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Diabetes mellitus 11 1011 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.67, 1.03]
7.1 2 to 3 months
glucocorticosteroid
6 610 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.54, 1.01]
7.2 > 3 to 6 months
glucocorticosteroids
3 250 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [0.81, 1.66]
7.3 > 6 months
glucocorticosteroids
2 151 Risk Ratio (M-H, Fixed, 95% CI) 0.63 [0.39, 1.03]
8 CMV infection 6 612 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.48, 1.18]
8.1 2 to 3 months
glucocorticosteroid
4 462 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.39, 1.49]
8.2 > 3 to 6 months
glucocorticosteroids
2 150 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.42, 1.35]
9 HCV recurrence 9 369 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.89, 1.15]
9.1 2 to 3 months
glucocorticosteroid
5 198 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.88, 1.12]
9.2 > 3 to 6 months
glucocorticosteroids
2 76 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.55, 1.22]
9.3 > 6 months
glucocorticosteroids
2 95 Risk Ratio (M-H, Fixed, 95% CI) 1.37 [0.89, 2.09]
10 Creatinine 4 309 Mean Difference (IV, Fixed, 95% CI) 0.11 [0.07, 0.16]
10.1 > 6 months
glucocorticosteroids
1 45 Mean Difference (IV, Fixed, 95% CI) -0.10 [-0.19, -0.01]
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10.2 2 to 3 months
glucocorticosteroid
2 210 Mean Difference (IV, Fixed, 95% CI) 0.24 [0.18, 0.30]
10.3 > 3 to 6 months
glucocorticosteroids
1 54 Mean Difference (IV, Fixed, 95% CI) -0.05 [-0.16, 0.06]
11 Hypertension 9 924 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.63, 0.89]
11.1 2 to 3 months
glucocorticosteroid
6 610 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.57, 0.92]
11.2 > 3 to 6 months
glucocorticosteroids
2 210 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.80, 1.40]
11.3 > 6 months
glucocorticosteroids
1 104 Risk Ratio (M-H, Fixed, 95% CI) 0.30 [0.16, 0.57]
12 Cholesterol 6 611 Mean Difference (IV, Fixed, 95% CI) -18.49 [-22.02, -14.
96]
12.1 2 to 3 months
glucocorticosteroid
2 243 Mean Difference (IV, Fixed, 95% CI) -11.00 [-23.43, 1.
43]
12.2 > 3 to 6 months
glucocorticosteroids
2 210 Mean Difference (IV, Fixed, 95% CI) -17.55 [-21.27, -13.
83]
12.3 > 6 months
glucocorticosteroids
2 158 Mean Difference (IV, Fixed, 95% CI) -92.75 [-118.01, -
67.50]
13 Hypercholesterolaemia 2 266 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.32, 1.00]
13.1 2 to 3 months
glucocorticosteroid
1 156 Risk Ratio (M-H, Fixed, 95% CI) 1.2 [0.55, 2.61]
13.2 > 3 to 6 months
glucocorticosteroids
1 110 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.08, 0.59]
Comparison 7. Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosup-
pression (pre-2000 and post-2000 subgroups)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 15 1323 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.93, 1.44]
1.1 Pre-2000 4 386 Risk Ratio (M-H, Fixed, 95% CI) 1.36 [0.90, 2.06]
1.2 Post-2000 11 937 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.83, 1.40]
2 Graft loss including death 11 1002 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.90, 1.46]
2.1 Pre-2000 3 282 Risk Ratio (M-H, Fixed, 95% CI) 1.25 [0.65, 2.40]
2.2 Post-2000 8 720 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [0.87, 1.47]
3 Acute rejection 16 1347 Risk Ratio (M-H, Fixed, 95% CI) 1.33 [1.08, 1.64]
3.1 Pre-2000 5 410 Risk Ratio (M-H, Fixed, 95% CI) 1.26 [0.91, 1.75]
3.2 Post-2000 11 937 Risk Ratio (M-H, Fixed, 95% CI) 1.37 [1.05, 1.80]
4 Infection 8 778 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.73, 1.05]
4.1 Pre-2000 3 323 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.48, 1.04]
4.2 Post-2000 5 455 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.77, 1.15]
5 Chronic rejection 9 974 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.56, 2.10]
5.1 Pre-2000 5 410 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.25, 2.31]
5.2 Post-2000 4 564 Risk Ratio (M-H, Fixed, 95% CI) 1.32 [0.57, 3.03]
6 Glucocorticosteroid-resistant
rejection
10 1020 Risk Ratio (M-H, Fixed, 95% CI) 2.14 [1.13, 4.02]
6.1 Pre-2000 3 282 Risk Ratio (M-H, Fixed, 95% CI) 2.17 [0.84, 5.57]
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6.2 Post-2000 7 738 Risk Ratio (M-H, Fixed, 95% CI) 2.11 [0.90, 4.96]
7 Diabetes mellitus 12 1185 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.66, 0.99]
7.1 Pre-2000 3 341 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.36, 0.88]
7.2 Post-2000 9 844 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.72, 1.13]
8 CMV infection 7 786 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.48, 1.16]
8.1 Pre-2000 3 282 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.20, 3.21]
8.2 Post-2000 4 504 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.46, 1.17]
9 HCV recurrence 10 477 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.92, 1.15]
9.1 Pre-2000 5 229 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.84, 1.22]
9.2 Post-2000 5 248 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.92, 1.19]
10 Malignancy 3 528 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.16, 1.74]
10.1 Pre-2000 1 174 Risk Ratio (M-H, Fixed, 95% CI) 0.54 [0.05, 5.80]
10.2 Post-2000 2 354 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.13, 2.08]
11 Post-transplant
lymphoproliferative disorder
2 330 Risk Ratio (M-H, Fixed, 95% CI) 2.39 [0.36, 15.95]
11.1 Pre-2000 1 174 Risk Ratio (M-H, Fixed, 95% CI) 3.21 [0.13, 77.77]
11.2 Post-2000 1 156 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.19, 21.61]
12 Renal insufficiency 4 447 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.73, 1.19]
12.1 Pre-2000 1 63 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [0.85, 1.96]
12.2 Post-2000 3 384 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.62, 1.12]
13 Creatinine 4 309 Mean Difference (IV, Fixed, 95% CI) 0.11 [0.07, 0.16]
13.1 Pre-2000 1 45 Mean Difference (IV, Fixed, 95% CI) -0.10 [-0.19, -0.01]
13.2 Post-2000 3 264 Mean Difference (IV, Fixed, 95% CI) 0.17 [0.12, 0.22]
14 Hypertension 10 1098 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.65, 0.90]
14.1 Pre-2000 3 341 Risk Ratio (M-H, Fixed, 95% CI) 0.57 [0.40, 0.79]
14.2 Post-2000 7 757 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.72, 1.03]
15 Hyperlipidaemia 4 400 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.38, 1.48]
15.1 Pre-2000 2 237 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.30, 1.91]
15.2 Post-2000 2 163 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.27, 2.01]
16 Cholesterol 6 611 Mean Difference (IV, Fixed, 95% CI) -18.49 [-22.02, -14.
96]
16.1 Pre-2000 2 149 Mean Difference (IV, Fixed, 95% CI) -40.42 [-61.73, -19.
11]
16.2 Post-2000 4 462 Mean Difference (IV, Fixed, 95% CI) -17.87 [-21.45, -14.
29]
Comparison 8. Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosup-
pression (best-worst analysis)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 16 1347 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.80, 1.22]
1.1 Glucocorticosteroid
avoidance
10 782 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.87, 1.52]
1.2 Glucocorticosteroid
withdrawal
6 565 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.60, 1.12]
2 Graft loss including death 11 1002 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.78, 1.24]
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2.1 Glucocorticosteroid
avoidance
8 671 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.77, 1.39]
2.2 Glucocorticosteroid
withdrawal
3 331 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.61, 1.33]
3 Acute rejection 16 1347 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.85, 1.26]
3.1 Glucocorticosteroid
avoidance
10 782 Risk Ratio (M-H, Fixed, 95% CI) 1.37 [1.04, 1.81]
3.2 Glucocorticosteroid
withdrawal
6 565 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.59, 1.02]
4 Infection 8 778 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.67, 0.96]
4.1 Glucocorticosteroid
avoidance
6 500 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.80, 1.15]
4.2 Glucocorticosteroid
withdrawal
2 278 Risk Ratio (M-H, Fixed, 95% CI) 0.24 [0.12, 0.50]
5 Chronic rejection 9 974 Risk Ratio (M-H, Fixed, 95% CI) 0.59 [0.33, 1.05]
5.1 Glucocorticosteroid
avoidance
6 586 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.32, 2.08]
5.2 Glucocorticosteroid
withdrawal
3 388 Risk Ratio (M-H, Fixed, 95% CI) 0.48 [0.23, 1.02]
6 Glucocorticosteroid-resistant
rejection
10 1020 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.61, 1.65]
6.1 Glucocorticosteroid
avoidance
7 689 Risk Ratio (M-H, Fixed, 95% CI) 1.88 [0.89, 3.98]
6.2 Glucocorticosteroid
withdrawal
3 331 Risk Ratio (M-H, Fixed, 95% CI) 0.55 [0.27, 1.13]
7 Diabetes mellitus 12 1185 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.58, 0.86]
7.1 Glucocorticosteroid
avoidance
7 674 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.70, 1.17]
7.2 Glucocorticosteroid
withdrawal
5 511 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.39, 0.70]
8 CMV infection 7 786 Risk Ratio (M-H, Fixed, 95% CI) 0.57 [0.37, 0.87]
8.1 Glucocorticosteroid
avoidance
5 502 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.39, 1.49]
8.2 Glucocorticosteroid
withdrawal
2 284 Risk Ratio (M-H, Fixed, 95% CI) 0.46 [0.27, 0.81]
9 Malignancy 3 528 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.07, 0.61]
9.1 Glucocorticosteroid
avoidance
2 354 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.13, 2.08]
9.2 Glucocorticosteroid
withdrawal
1 174 Risk Ratio (M-H, Fixed, 95% CI) 0.08 [0.01, 0.57]
10 Post-transplant
lymphoproliferative disorder
2 330 Risk Ratio (M-H, Fixed, 95% CI) 0.24 [0.07, 0.85]
10.1 Glucocorticosteroid
avoidance
1 156 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.19, 21.61]
10.2 Glucocorticosteroid
withdrawal
1 174 Risk Ratio (M-H, Fixed, 95% CI) 0.09 [0.01, 0.67]
11 Hypertension 10 1098 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.60, 0.82]
11.1 Glucocorticosteroid
avoidance
6 634 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.66, 1.00]
11.2 Glucocorticosteroid
withdrawal
4 464 Risk Ratio (M-H, Fixed, 95% CI) 0.59 [0.47, 0.76]
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12 Hyperlipidaemia 4 400 Risk Ratio (M-H, Fixed, 95% CI) 0.40 [0.21, 0.73]
12.1 Glucocorticosteroid
avoidance
2 150 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.45, 2.52]
12.2 Glucocorticosteroid
withdrawal
2 250 Risk Ratio (M-H, Fixed, 95% CI) 0.16 [0.06, 0.45]
Comparison 9. Glucocorticosteroid avoidance or withdrawal versus glucocorticosteroid-containing immunosup-
pression (worst-best analysis)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 16 1347 Risk Ratio (M-H, Fixed, 95% CI) 1.35 [1.10, 1.67]
1.1 Glucocorticosteroid
avoidance
10 782 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [0.86, 1.49]
1.2 Glucocorticosteroid
withdrawal
6 565 Risk Ratio (M-H, Fixed, 95% CI) 1.71 [1.23, 2.38]
2 Graft loss including death 11 1002 Risk Ratio (M-H, Fixed, 95% CI) 1.38 [1.08, 1.74]
2.1 Glucocorticosteroid
avoidance
8 671 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.78, 1.41]
2.2 Glucocorticosteroid
withdrawal
3 331 Risk Ratio (M-H, Fixed, 95% CI) 2.24 [1.47, 3.41]
3 Acute rejection 16 1347 Risk Ratio (M-H, Fixed, 95% CI) 1.53 [1.25, 1.88]
3.1 Glucocorticosteroid
avoidance
10 782 Risk Ratio (M-H, Fixed, 95% CI) 1.38 [1.05, 1.83]
3.2 Glucocorticosteroid
withdrawal
6 565 Risk Ratio (M-H, Fixed, 95% CI) 1.73 [1.29, 2.31]
4 Infection 8 778 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.87, 1.23]
4.1 Glucocorticosteroid
avoidance
6 500 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.80, 1.15]
4.2 Glucocorticosteroid
withdrawal
2 278 Risk Ratio (M-H, Fixed, 95% CI) 1.50 [0.89, 2.50]
5 Chronic rejection 9 974 Risk Ratio (M-H, Fixed, 95% CI) 2.45 [1.40, 4.31]
5.1 Glucocorticosteroid
avoidance
6 586 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.32, 2.08]
5.2 Glucocorticosteroid
withdrawal
3 388 Risk Ratio (M-H, Fixed, 95% CI) 4.87 [2.16, 11.01]
6 Glucocorticosteroid-resistant
rejection
10 1020 Risk Ratio (M-H, Fixed, 95% CI) 3.71 [2.07, 6.66]
6.1 Glucocorticosteroid
avoidance
7 689 Risk Ratio (M-H, Fixed, 95% CI) 1.99 [0.95, 4.17]
6.2 Glucocorticosteroid
withdrawal
3 331 Risk Ratio (M-H, Fixed, 95% CI) 8.63 [2.95, 25.28]
7 Diabetes mellitus 12 1185 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.79, 1.15]
7.1 Glucocorticosteroid
avoidance
7 674 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.71, 1.19]
7.2 Glucocorticosteroid
withdrawal
5 511 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.76, 1.32]
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8 CMV infection 7 786 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [0.87, 1.90]
8.1 Glucocorticosteroid
avoidance
5 502 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.41, 1.59]
8.2 Glucocorticosteroid
withdrawal
2 284 Risk Ratio (M-H, Fixed, 95% CI) 1.70 [1.04, 2.78]
9 Malignancy 3 528 Risk Ratio (M-H, Fixed, 95% CI) 3.05 [1.38, 6.73]
9.1 Glucocorticosteroid
avoidance
2 354 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.13, 2.08]
9.2 Glucocorticosteroid
withdrawal
1 174 Risk Ratio (M-H, Fixed, 95% CI) 10.71 [2.58, 44.45]
10 Post-transplant
lymphoproliferative disorder
2 330 Risk Ratio (M-H, Fixed, 95% CI) 15.64 [3.08, 79.56]
10.1 Glucocorticosteroid
avoidance
1 156 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.19, 21.61]
10.2 Glucocorticosteroid
withdrawal
1 174 Risk Ratio (M-H, Fixed, 95% CI) 43.89 [2.70, 714.49]
11 Renal insufficiency 4 447 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.75, 1.21]
11.1 Glucocorticosteroid
avoidance
4 447 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.75, 1.21]
12 Hypertension 10 1098 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.75, 1.02]
12.1 Glucocorticosteroid
avoidance
6 634 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.67, 1.01]
12.2 Glucocorticosteroid
withdrawal
4 464 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.75, 1.18]
13 Hyperlipidaemia 4 400 Risk Ratio (M-H, Fixed, 95% CI) 1.92 [1.12, 3.28]
13.1 Glucocorticosteroid
avoidance
2 150 Risk Ratio (M-H, Fixed, 95% CI) 1.18 [0.51, 2.73]
13.2 Glucocorticosteroid
withdrawal
2 250 Risk Ratio (M-H, Fixed, 95% CI) 2.64 [1.28, 5.44]
WH A T ’ S N E W
Last assessed as up-to-date: 4 April 2018.
Date Event Description
16 November 2017 New search has been performed Searches performed until May 2017. One new trial
added, but data could only be incorporated into qual-
itative analysis
8 November 2017 New citation required but conclusions have not
changed
Background updated. New references added. Searches
re-executed. Long-term follow-up of one previously
included trial now incorporated to meta-analysis.
Three furthermeta-analyses addressing same or similar
review question identified and incorporated to review
discussion
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
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